



ctos[®]

Bringing together the
world's sarcoma specialists[®]

2018 Annual Meeting

Final
Program

November 14 - 17, 2018

Rome Cavalieri Hotel • Rome, Italy



David Thomas, FRACP, PhD
2018 CTOS President

Paolo Dei Tos, MD and Andrew Wagner, MD, PhD
Program Co-Chairs



November 14 - 17, 2018
Rome Cavalieri Hotel • Rome, Italy



2018 Annual Meeting Program At-a-Glance

Wednesday, 14 November, 2018

12:00 pm - 6:00 pm	Registration and Poster Set Up	<i>Salon de Cavalieri 1 & Gallery</i>
6:00 pm - 8:00 pm	Welcome Reception	<i>San Pietro Gallery</i>

Thursday, 15 November, 2018

6:00 am - 7:00 pm	Registration	<i>Salon de Cavalieri 1 & Gallery</i>
7:00 am - 8:00 am	Coffee and Posters	<i>Salon de Cavalieri 1 & Gallery</i>
7:00 am - 11:00 am	TARPSWG Semiannual Meeting	<i>Ellisse Room</i>
8:00 am - 5:30 pm	4th International Sarcoma Nurse and Allied Professionals Meeting (iSNAP) - "Collaboration in Sarcoma Care - Realizing Better Outcomes"	<i>Caravaggio Room</i>
9:00 am - 11:00 am	SARC PROGRAM	<i>Salon del Cavalieri 2,3,4</i>
10:30 am - 11:00 am	Morning Coffee Break	<i>Salon de Cavalieri 1 & Gallery</i>
11:15 am - 11:30 am	OPENING REMARKS	<i>Salon del Cavalieri 2,3,4</i>
11:30 am - 1:00 pm	SESSION 1 – Sarcoma of the Year: Intimal Sarcoma	<i>Salon del Cavalieri 2,3,4</i>
1:00 pm - 2:00 pm	Lunch	<i>Belle Arti & Garden Lobby</i>
2:00 pm - 3:30 pm	SESSION 2 – Soft Tissue Sarcoma: Chemotherapy	<i>Salon del Cavalieri 2,3,4</i>
3:30 pm - 4:00 pm	Afternoon Coffee Break	<i>Salon de Cavalieri 1 & Gallery</i>
4:00 pm - 6:00 pm	SESSION 3 – GIST	<i>Salon del Cavalieri 2,3,4</i>
6:00 pm - 7:00 pm	Poster Viewing Reception	<i>Salon de Cavalieri 1 & Gallery</i>

Friday, 16 November, 2018

6:00 am - 6:00 pm	Registration	Salon de Cavalieri 1 & Gallery
7:00 am - 8:00 am	Coffee and Posters	Salon de Cavalieri 1 & Gallery
7:00 am - 8:00 am	Executive Committee Meeting	San Giovanni
8:00 am - 10:00 am	SESSION 4 – Soft Tissue Sarcoma: Targeted Therapy	Salon del Cavalieri 2,3,4
10:00 am - 10:30 am	Morning Coffee Break	Salon de Cavalieri 1 & Gallery
10:30 am - 11:00 am	Presentation of Young Investigator Awards	Salon del Cavalieri 2,3,4
11:00 am - 12:00 pm	HERMAN SUIT LECTURE – Cristina Antonescu	Salon del Cavalieri 2,3,4
12:00 pm - 1:30 pm	Lunch	Belle Arti & Garden Lobby
12:00 pm - 1:30 pm	Board of Directors Meeting	San Giovanni
1:30 pm - 3:30 pm	SESSION 5 – Benign and Intermediate Grade Bone/Soft Tissue Lesions	Salon del Cavalieri 2,3,4
3:30 pm - 4:00 pm	Afternoon Coffee Break	Salon de Cavalieri 1 & Gallery
4:00 pm - 6:00 pm	SESSION 6 – Ewing Sarcoma	Salon del Cavalieri 2,3,4
7:00 pm - 10:00 pm	Gala – Reception and Dinner at the beautiful Villa Miani next door to the Cavalieri Hotel. Cocktail Attire	Villa Miani

Saturday, 17 November, 2018

6:30 am - 5:30 pm	Registration	Salon de Cavalieri 1 & Gallery
7:00 am - 8:00 am	Coffee and Posters	Salon de Cavalieri 1 & Gallery
8:00 am - 9:00 am	Poster Discussion	Salon del Cavalieri 2,3,4
9:00 am - 10:30 am	SESSION 7 – Osteosarcoma/Chondrosarcoma/Chordoma	Salon del Cavalieri 2,3,4
10:30 am - 11:00 am	Morning Coffee Break	Salon de Cavalieri 1 & Gallery
11:00 am - 12:00 pm	NINA AXELRAD LECTURE – Jean-Yves Blay	Salon del Cavalieri 2,3,4
12:00 pm - 1:00 pm	Lunch	Belle Arti & Garden Lobby
1:00 pm - 1:30 pm	Liddy Shriver Early Career Research Award	Salon del Cavalieri 2,3,4
1:30 pm - 3:30 pm	SESSION 8 – Soft Tissue Sarcoma: Biology	Salon del Cavalieri 2,3,4
3:30 pm - 4:00 pm	Afternoon Coffee Break	Salon de Cavalieri 1 & Gallery
4:00 pm - 5:30 pm	SESSION 9 – Soft Tissue Sarcoma: Local Therapy	Salon del Cavalieri 2,3,4
5:30 pm - 6:00 pm	CTOS Business Meeting	Salon del Cavalieri 2,3,4
6:00 pm	ADJOURN	



TARPSWG Semiannual Meeting

Thursday, November 15th
07.00 to 11.00 am

Cavalieri Hotel, Rome
Ellisse Room

Agenda

- | | |
|-------------|--|
| 07.00-07.15 | Welcome introduction
(A. Gronchi) |
| 07.15-08.00 | RESAR project – an update on site activation, recruitment status and plans
(M. Fiore M. Fairweather and D. Strauss) |
| 08.00-08.20 | Report from the REC committee on 2017-2018 activities and status of ongoing projects
(C. Nessim) |
| 08.20-08.45 | The STREXIT project
(C. Swallow) |
| 08.45-09.30 | STRASS 2 study
(W. Van Houdt) |
| 09.30-09.45 | Recurrent RPS series: secondary manuscripts after the nomogram
(CP Raut) |
| 09.45-10.00 | RT in primary retroperitoneal Liposarcoma: a propensity matched substudy from the original 1007 series
(R. Haas) |
| 10.00-10.15 | Chemotherapy in primary RPS; a propensity matched substudy from the original 1007 series
(C. Honoré) |
| 10.15-11.00 | TARPSWG governance and formalization: present perspective and future directions
(all) |
| 11.00 | Start of CTOS official program |
| 8.30 | TARPSWG dinner |



ctos[®]

Connective Tissue Oncology Society

2018 Annual Meeting

November 14 - 17, 2018

Rome Cavalieri Hotel • Rome, Italy



Wednesday, 14 November, 2018

12:00 pm - 6:00 pm	Registration
6:00 pm - 8:00 pm	Welcome Reception

Salon de Cavalieri 1 & Gallery

San Pietro Gallery

Thursday, 15 November, 2018

6:00 am - 7:00 pm	Registration
7:00 am - 8:00 am	Coffee and Posters
7:00 am - 11:00 am	TARPSWG Semiannual Meeting
8:00 am - 5:30 pm	4th International Sarcoma Nurse and Allied Professionals Meeting (iSNAP) - "Collaboration in Sarcoma Care - Realizing Better Outcomes"

Salon de Cavalieri 1 & Gallery

Salon de Cavalieri 1 & Gallery

Ellisse Room

Caravaggio Room

9:00 am - 11:00 am

– SARC PROGRAM –

Salon del Cavalieri 2,3,4

Chawla/Rosenfeld Developmental Therapeutics Symposium

Emerging and Novel Biologically Targeted Approaches for Sarcoma Patients

Introduction

Elizabeth Lawlor, MD, PhD

Robert Maki, MD, PhD

Enhancing Activity of B7-H3 CAR T Cells for Pediatric Sarcomas

Robbie Majzner, MD

Discussion / Q & A

Translating PARP Inhibition as a Therapeutic Target into Benefit for Patients with Sarcoma

Sandra Strauss, MD, PhD

Discussion / Q & A

Epigenetic Changes following the Loss of PRC2 in MPNST: Emerging Therapeutic Opportunities

Keila Torres, MD, PhD

Discussion / Q & A

2019 Career Development Update

Elizabeth Lawlor, MD, PhD



SARC
collaborating to cure sarcoma

10:30 am - 11:00 am

Morning Coffee Break

Salon de Cavalieri 1 & Gallery

Sarcoma of the Year: Intimal Sarcoma

Moderators: **Olivier Mir** and **Elizabeth Baldini**

Biology and Pathology of Intimal Sarcoma – A. Paolo dei Tos

Paper 001

3042623

SYSTEMIC TREATMENTS IN MDM2 + INTIMAL SARCOMA: A MULTICENTRE EXPERIENCE WITH ANTHRACYCLINE, GEMCITABINE AND PAZOPANIB WITHIN THE WORLD SARCOMA NETWORK (WSN)

Anna Maria Frezza¹; Tarek Assi²; Luigi Mariani³; Armelle Dufresne⁴; Siontis Brittany⁵; Kan Yonemori⁶; Emi Noguchi⁶; Eytan Ben-Amy⁷; Mrinal Gounder⁸; Robin Jones⁹; Pawel Teterycz¹⁰; Florence Duffaud¹²; Maria Abbondanza Pantaleo¹¹; Vinod Ravi¹³; Bruno Vincenzi¹⁴; Giacomo Giulio Baldi¹⁵; Alexander Fedenko¹⁶; Hans Gelderblom¹⁷; Robert Maki¹⁸; Jean-Yves Blay⁴; Axel Le Cesne²; Scott Schuetze⁵; Paolo Casali¹; Katherine Thornton⁷; Silvia Stacchiotti¹

¹Medical Oncology 2, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; ²Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France; ³Unit of Clinical Epidemiology and Trial Organization, IRCCS Fondazione Istituto Nazionale Tumori, Milano, Milan, Italy; ⁴Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France; ⁵Department of Medicine, University of Michigan, Ann Arbor, MI, USA; ⁶Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan; ⁷Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ⁸Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁹Sarcoma Unit, Royal Marsden NHS Foundation Trust/ Institute of Cancer Research, London, United Kingdom; ¹⁰Maria Sklodowska-Curie Institute-Oncology Center, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland; ¹¹Sant'Orsola Malpighi Hospital, Department of Specialized, Experimental and Diagnostic Medicine, Bologna, Italy; ¹²Department of Oncology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France; ¹³Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Huston, TX, USA; ¹⁴Medical Oncology, University Campus Bio-Medico, Rome, Italy; ¹⁵Medical Oncology, Nuovo Ospedale "S.Stefano", Prato, Italy; ¹⁶Medical Oncology, N.N. Blokhin Russian Cancer Research, Moscow, Russian Federation; ¹⁷Medical Oncology, Leiden University Medical Centre, Leiden, Netherlands; ¹⁸Medical Oncology, Northwell Health and Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

Paper 002

3026957

PRIMARY MALIGNANT SARCOMAS OF THE HEART AND GREAT VESSELS: A RETROSPECTIVE ANALYSIS OF PRESENTATION, MANAGEMENT AND OUTCOMES

Luke Smith¹; Han Hsi Wong²; Marius Berman³; Dochka Davidson²; Gail Horan²; David Jenkins³; Helen Hatcher²

¹School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; ²Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; ³Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom

Paper 003

3042337

CLINICAL "REAL WORLD" NEXT GENERATION SEQUENCING REVEALS UNIQUE ABERRATIONS IN INTIMAL SARCOMA

Jason Roszik; Anthony P. Conley; Roman Groisberg; Vinod Ravi; Roberto Carmagnani Pestana; Shiraj Sen; Vivek Subbiah

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Paper 004 3042847
OUTCOMES OF MULTIMODALITY TREATMENT WITH INDUCTION CHEMOTHERAPY, MAXIMAL RESECTION, AND PROTON BASED RADIATION THERAPY FOR CARDIAC AND PULMONARY VESSEL SARCOMAS
Yen-Lin E. Chen¹; Rouyu Miao¹; Edwin Choy²; Gregory M. Cote²; Thomas F. DeLaney¹
¹Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA

Discussion – Robert Maki

1:00 pm - 2:00 pm

Lunch

Belle Arti & Garden Lobby

2:00 pm - 3:30 pm

– SESSION 2 –

Salon del Cavaliere 2,3,4

Soft Tissue Sarcoma: Chemotherapy

Moderators: **Wei-Wu (Tom) Chen** and **Claudia Valverde**

Paper 005 3042630
THE IMPACT OF CHEMOTHERAPY ON SURVIVAL OF PATIENTS WITH EXTREMITY AND TRUNK WALL SOFT TISSUE SARCOMA: REVISITING THE RESULTS OF THE EORTC-STBSG 62931 RANDOMISED TRIAL USING SARculator, A VALIDATED NOMOGRAM-BASED RISK ASSESSMENT TOOL
Sandro Pasquali¹; Sara Pizzamiglio²; Nathan Touati²; Saskia Litiere²; Sandrine Marreaud²; Bernd Kasper³; Hans Gelderblom⁴; Silvia Stacchiotti¹; Ian Judson⁵; Angelo P. Dei Tos⁶; Paolo Verderio¹; Paolo Casali¹; Penella J. Wolf⁷; Alessandro Gronchi¹
¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; ²European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; ³University of Heidelberg, Heidelberg, Germany; ⁴Leiden University Medical Centre, Leiden, Netherlands; ⁵The Royal NHS Foundation Trust, London, United Kingdom; ⁶Treviso General Hospital, Treviso, Italy; ⁷University of Sheffield, Sheffield, United Kingdom

Paper 006 3042737
PROPENSITY SCORE MATCHING ANALYSIS OF DOXORUBICIN PLUS DACARBAZINE, DOXORUBICIN PLUS IFOSFAMIDE OR DOXORUBICIN ALONE AS FIRST-LINE TREATMENT FOR ADVANCED, METASTATIC OR UNRESECTABLE LEIOMYOSARCOMA: A RETROSPECTIVE STUDY FROM THE EORTC SOFT TISSUE AND BONE SARCOMA GROUP
Lorenzo D'Ambrosio¹; Nathan Touati²; Jean-Yves Blay³; Tiziana Venesio⁴; Ronan Flippot¹⁷; Anna M. Czarnecka⁵; Sophie Piperno-Neumann⁶; Javier Martín-Broto⁷; Roberta Sanfilippo⁸; Daniela Katz⁹; Florence Duffaud¹⁰; Bruno Vincenzi¹¹; Bernd Kasper¹²; Daniel P. Stark¹³; Filomena Mazzeo¹⁴; Armin Tuchscherer¹⁵; Saskia Litiere²; Ward Sents²; Silvia Stacchiotti⁸; Hans Gelderblom¹⁶; Alessandro Gronchi⁸
¹Department of Oncology, University of Torino, Torino, Italy; ²European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; ³University Claude Bernard Lyon I, Centre Leon Bernard, Lyon, France; ⁴Medical Oncology - Sarcoma Unit, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy; ⁵Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland; ⁶Medical Oncology, Institute Curie, Paris, France; ⁷Medical Oncology, Virgen del Rocio University Hospital, Institute of Biomedicine Research (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain; ⁸Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁹Assaf Harofeh Medical Center, Zrifin, Israel; ¹⁰Service d'Oncologie Médicale Chu la Timone, Marseille, France; ¹¹University Campus Bio-Medico of Rome, Roma, Italy; ¹²Sarcoma Unit, University of Heidelberg, Mannheim University Medical Center, ITM - Interdisciplinary Tumor Center Mannheim, Mannheim, Germany; ¹³St James's Institute of Oncology, Leeds, United Kingdom; ¹⁴Clinique Universitaire Saint-Luc, Institut Roi Albert II, Brussels, Belgium; ¹⁵University Hospital Cologne, Köln, Germany; ¹⁶Leiden University Medical Center, Leiden, Netherlands; ¹⁷Gustave Roussy Cancer Center, Villejuif, France

- Paper 007 3042520
PHASE 1B STUDY OF OLARATUMAB PLUS DOXORUBICIN AND IFOSFAMIDE IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA: INITIAL RESULTS
Sebastian Bauer¹; Neeta Somaiah²; Silvia Stacchiotti³; Peter Reichardt⁴; Hector Soto Parra⁵; Rainer Hamacher¹; Andrew Lithio⁶; Gary Mo⁶; Samuel Ramage⁶; Jonathan Trent⁷
¹West German Cancer Center, University of Duisburg-Essen, Essen, Germany; ²MD Anderson Cancer Center, University of Texas, Houston, TX, USA; ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁴Helios Klinikum Berlin-Buch, Berlin, Germany; ⁵Department of Medical Oncology, Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele, Catania, Italy; ⁶Eli Lilly and Company, Indianapolis, IN, USA; ⁷Miller School of Medicine/Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
- Paper 008 3042717
ANTHRACYCLINE-BASED VERSUS GEMCITABINE-BASED ADJUVANT CHEMOTHERAPY IN FIGO STAGE 1 UTERINE LEIOMYOSARCOMA
Roberta Sanfilippo¹; Rosanna Mancari²; Sara Manglaviti¹; Giorgio Bogani¹; Domenica Lorusso¹; Elena Fumagalli¹; Rossella Bertulli¹; Angelo Paolo Dei Tos³; Paola Collini¹; Francesco Raspagliesi¹; Nicoletta Colombo²; Paolo Casali¹
¹Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; ²Gynaecology department, IEO, Milan, Italy; ³General Hospital Treviso, Treviso, Italy
- Paper 009 3042702
EUROPEAN PHASE I/II TRASTS TRIAL OF TRABECTEDIN PLUS RADIOTHERAPY IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA (STS): A COLLABORATIVE SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) SARCOMA GROUPS STUDY
Javier Martín-Broto¹; Antonio Lopez-Pousa²; Nadia Hindi¹; Josefina Cruz³; Javier Peinado¹; Carlo Morosi⁴; Josep Isern Verdun²; Maria Carmen Dolado⁵; Rosa Maria Alvarez Alvarez⁵; Ana Alvarez González⁵; Tiziana Venesio⁶; Marco Gatti⁶; Pablo Luna Fra⁷; Ignacio Alastuey⁷; Jean-Yves Blay⁸; Marie-Pierre Sunyach⁸; Inmaculada Rincon¹⁰; Alessandro Gronchi⁴; Jesus Romero⁹
¹Institute of Biomedicine Research (IBIS)- University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain; ²Hospital Sant Pau, Barcelona, Spain; ³University Hospital of Canary Islands, Santa Cruz De Tenerife, Spain; ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁵University Hospital Gregorio Marañón, Madrid, Spain; ⁶Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy; ⁷University Hospital Son Espases, Palma de Mallorca, Spain; ⁸Centre Léon Bérard, Lyon, France; ⁹Hospital Puerta de Hierro, Madrid, Spain; ¹⁰University Hospital Virgen del Rocío, Seville, Spain

Discussion – Florence Duffaud

3:30 pm - 4:00 pm

Afternoon Coffee Break

Salon de Cavalieri 1 & Gallery

4:00 pm - 6:00 pm

– SESSION 3 –

Salon del Cavalieri 2,3,4

GIST

Moderators: **Richard Riedel** and **Sebastian Bauer**

- Paper 010 3042567
MULTICENTRIC RETROSPECTIVE ANALYSIS OF PATIENTS WITH KIT EXON 9 MUTATED GIST
Almudena Callejo Goena¹; Sara Faouzi²; Olivier Bouche³; Thomas Chevalier⁴; Nicolas Isambert⁵; Florence Duffaud⁴; Olivier Collard⁶; Nicolas Penel⁷; Olivier Mir²; Philippe Terrier³; Jean-Yves Blay⁹; Axel Le Cesne²
¹Medical Oncology, Cruces University Hospital, Barakaldo, Bizkaia, Spain; ²Medical Oncology, Gustave Roussy Institute, Villejuif, France; ³Digestive Oncology, Chu Robert Debre, Reims, France; ⁴Medical Oncology, Chu La Timone and Aix Marseille University (Amu), Marseille, France; ⁵Department of Early Clinical Trials, Centre Georges-François Leclerc, Dijon, France; ⁶Medical Oncology, Institut De Cancerologie De La Loire – Lucien Neuwirth, La Loire, France; ⁷Medical Oncology, Oscar Lambret Center, Lille, France; ⁸Department Of Pathology, Gustave Roussy Institute, Villejuif, France; ⁹Medical Oncology, Centre Leon Berard, Lyon, France

- Paper 011 3041313
A WEB-BASED SURVEY OF PERCEIVED COGNITIVE IMPAIRMENTS AND OTHER PATIENT-REPORTED OUTCOMES IN GIST PATIENTS
Robert Ferguson¹; Jessica Manculich²; Hsuan Chang²; Beth Snitz³; Dana Bovbjerg⁴; **Anette Duensing**⁵
¹Biobehavioral Oncology Program, UPMC Hillman Cancer Center, Dept. of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; ²Biobehavioral Oncology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; ³Dept. of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; ⁴Biobehavioral Oncology Program, UPMC Hillman Cancer Center, Dept. of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; ⁵Cancer Therapeutics Program, UPMC Hillman Cancer Center, Dept. of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- Paper 012 3027631
AVAPRITINIB IS HIGHLY ACTIVE AND WELL-TOLERATED IN PATIENTS (PTS) WITH ADVANCED GIST DRIVEN BY DIVERSE VARIETY OF ONCOGENIC MUTATIONS IN KIT AND PDGFRA
Michael Heinrich¹; Margaret von Mehren²; Robin L. Jones³; Sebastian Bauer⁴; Yoon-Koo Kang⁵; Patrick Schöffski⁶; Ferry Eskens⁷; Cesar Serrano⁸; Philippe Cassier⁹; Olivier Mir¹⁰; William D. Tap¹¹; Piotr Rutkowski¹²; Jonathan Trent¹³; Shreyaskumar Patel¹⁴; Sant P. Chawla¹⁵; Teresa Zhou¹⁶; Tamiaka Lauz¹⁶; Oleg Schmidt-Kittler¹⁶; Khalid K. Mamlouk¹⁶; Beni B. Wolf¹⁶; Suzanne George¹⁷
¹OHSU Knight Cancer Institute, Portland, OR, USA; ²Fox Chase Cancer Centre, Philadelphia, PA, USA; ³Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; ⁴University of Duisburg-Essen, Essen, Germany; ⁵Asan Medical Centre, Seoul, Korea (the Republic of); ⁶University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; ⁷Erasmus MC Cancer Institute, Rotterdam, Netherlands; ⁸Vall d' Hebron Institute of Oncology, Barcelona, Spain; ⁹Centre Léon Bérard, Lyon, France; ¹⁰Institut Gustave Roussy; Edouard Vaillant Villejuif, Villejuif, France; ¹¹Memorial Sloan Kettering Cancer Centre, New York, NY, USA; ¹²Maria Skłodowska-Curie Institute - Oncology Center, Warszawa, Poland; ¹³Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA; ¹⁴MD Anderson Cancer Center, Houston, TX, USA; ¹⁵Sarcoma Oncology Centre, Santa Monica, CA, USA; ¹⁶Blueprint Medicines Corporation, Cambridge, MA, USA; ¹⁷Dana Farber Cancer Institute, Boston, MA, USA
- Paper 013 3033840
INITIAL RESULTS OF PHASE 1 STUDY OF DCC-2618, A BROAD-SPECTRUM KIT AND PDGFRINHIBITOR, IN PATIENTS (PTS) WITH GASTROINTESTINAL STROMAL TUMOR (GIST) BY NUMBER OF PRIOR REGIMENS
Suzanne George³; Michael Heinrich¹⁰; Ping Chi⁴; Albiruni Razak⁵; Margaret von Mehren⁶; Michael Gordon⁷; Kristen Ganjoo²; Neeta Somaiah⁸; Jonathan Trent¹¹; Julie Wolf⁹; Rodrigo Ruiz-Soto¹; Oliver Rosen¹; Filip Janku⁸
¹Deciphera, Waltham, MA, USA; ²Stanford University, Palo Alto, CA, USA; ³Dana-Farber Cancer Institute, Boston, MA, USA; ⁴MSKCC, New York, NY, USA; ⁵Princess Margaret Cancer Centre, Toronto, ON, Canada; ⁶Fox Chase Cancer Center, Philadelphia, PA, USA; ⁷Pinnacle Oncology Hematology, Scottsdale, AZ, USA; ⁸MDACC, Houston, TX, USA; ⁹Biostats Consultants, Denver, CO, USA; ¹⁰OHSU, Portland, OR, USA; ¹¹University Miami, Miami, FL, USA
- Discussion – Victor Villalobos
- Paper 014 3041747
NON-INVASIVE DETECTION OF CTDNA REVEALS INTRATUMOR HETEROGENEITY AND IS ASSOCIATED WITH TUMOR BURDEN IN GASTROINTESTINAL STROMAL TUMOR
Boye Kjetil¹; Heidi Namløs²; Skyler J. Mishkin³; Tale Barøy²; Susanne Lorenz⁴; Bodil Bjerkehagen⁵; Eva Stratford²; Else Munthe²; Brian A. Kudlow³; Ola Myklebost²; Leonardo A. Meza-Zepeda²
¹Department of Oncology, Oslo University Hospital, Oslo, Norway; ²Department of Tumor Biology, Oslo University Hospital, Oslo, Norway; ³Archer DX, Inc., Boulder, CO, USA; ⁴Genomics Core Facility, Oslo University Hospital, Oslo, Norway; ⁵Department of Pathology, Oslo University Hospital, Oslo, Norway

- Paper 015 3042824
UTILITY OF CIRCULATING TUMOR DNA (CTDNA) IN THE MANAGEMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST): ANALYSIS OF 184 PATIENTS
*Junaid Arshad¹; Breelyn A. Wilky¹; Ali Roberts²; Becky Nagy²; **Jonathan Trent¹***
¹Sarcoma Medical Oncology, Sylvester Comprehensive Cancer Center, Miami, FL, USA;
²Guardant Health, Redwood City, CA, USA
- Paper 016 3030004
CLINICAL VALUE OF CT-DNA IN LOCALIZED AND ADVANCED GIST: CROSS-VALIDATION OF AMPLICON-BASED NGS WITH DD-PCR IN MATCHED TISSUE AND PLASMA SAMPLES
Cesar Serrano¹; Ana Vivancos⁵; Antonio Lopez-Pousa¹²; Judit Matito⁵; Francesco M. Mancuso⁵; Claudia Valverde¹¹; Sergi Quiroga⁶; Stefania Landolfi²; Sandra Castro⁷; Cristina Dopazo⁷; Ana Sebio¹²; Anna C. Virgili Manrique¹²; Maria M Menso⁸; Javier Martín-Broto⁹; Alfonso Garcia-Valverde¹⁰; Jordi Rosell¹⁰; Jonathan A. Fletcher³; Suzanne George⁴; Joan Carles¹¹; Joaquín Arribas¹⁰
¹Preclinical Research Program and Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO); Vall d'Hebron University Hospital, Barcelona, Barcelona, Spain; ²Pathology, Vall d'Hebron University Hospital, Barcelona, Spain; ³Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA; ⁴Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ⁵Genomic Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; ⁶Radiology, Vall d'Hebron University Hospital, Barcelona, Spain; ⁷Surgical Oncology Division, Vall d'Hebron University Hospital, Barcelona, Spain; ⁸Radiology, Sant Pau Hospital, Barcelona, Spain; ⁹Medical Oncology, Virgen del Rocío Hospital, Sevilla, Spain; ¹⁰Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; ¹¹Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; ¹²Medical Oncology, Sant Pau Hospital, Barcelona, Spain

Discussion – Bartosz Chmielowski

6:00 pm - 7:00 pm

Poster Viewing Reception

Salon de Cavalieri 1 & Gallery

Friday, 16 November, 2018

6:00 am - 6:00 pm	Registration	Salon de Cavalieri 1 & Gallery
7:00 am - 8:00 am	Coffee and Posters	Salon de Cavalieri 1 & Gallery
7:00 am - 8:00 am	Executive Committee Meeting	San Giovanni

8:00 am - 10:00 am

– SESSION 4 –

Salon del Cavalieri 2,3,4

Soft Tissue Sarcoma: Targeted Therapy

Moderators: **Thierry Alcindor** and **Robin Jones**

- Paper 017 3016595
PROSPECTIVE TRIAL OF CRIZOTINIB (C) IN PATIENTS (PTS) WITH ADVANCED, INOPERABLE INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMFT) WITH AND WITHOUT ALK ALTERATIONS: EORTC PHASE II STUDY 90101 "CREATE"
Patrick Schöffski¹; Jozef Sufliarsky²; Hans Gelderblom³; Jean-Yves Blay⁷; Sandra Strauss⁸; Silvia Stacchiotti⁹; Piotr Rutkowski¹⁰; Lars Lindner¹¹; Michael Leahy¹²; Antoine Italiano¹³; Maria Debiec-Rychter¹⁴; Raf Sciot⁴; Sandrine Marreaud⁵; Axelle Nzokirantevye⁵; Agnieszka Wozniak⁶
¹General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; ²National Cancer Institute, Bratislava, Slovakia; ³Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands; ⁴Department of Pathology, University Hospitals Leuven, Leuven, Belgium; ⁵European Organisation for Research and Treatment of Cancer, Brussels, Belgium; ⁶Department of Oncology, KU Leuven, Laboratory of Experimental Oncology, Leuven, Belgium; ⁷Université Cl. Bernard Lyon 1, Centre Léon Bérard, Lyon, France; ⁸Department of Oncology, University College London Hospitals NHS Trust, London, United Kingdom; ⁹Sarcoma Unit, Cancer Medical Department, Fondazione IRCC Istituto Nazionale Tumori, Milan, Italy; ¹⁰Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Institute-Oncology Center, Warsaw, Poland; ¹¹Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; ¹²The Christie NHS Foundation Trust, Manchester, United Kingdom; ¹³Institut Bergonié, Bordeaux, France; ¹⁴Department of Human Genetics, University Hospitals Leuven, Leuven, Belgium
- Paper 018 3006132
ACTIVITY AND SAFETY OF CRIZOTINIB IN PATIENTS WITH ADVANCED CLEAR CELL SARCOMA (CCSA) WITH MET ALTERATIONS. EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER PHASE 2 TRIAL 90101 "CREATE"
Patrick Schöffski¹; **Agnieszka Wozniak**²; Silvia Stacchiotti³; Piotr Rutkowski⁴; Jean-Yves Blay⁵; Lars Lindner⁸; Sandra Strauss⁹; Alan Anthoney¹²; Florence Duffaud¹⁴; Stephan Richter¹³; Raf Sciot⁶; Debiec-Rychter Maria¹⁰; Sandrine Marreaud⁷; Laurence Collette⁷; Sebastian Bauer¹¹
¹General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; ²Department of Oncology, KULeuven, Laboratory of Experimental Oncology, Leuven, Belgium; ³Sarcoma Unit, Cancer Medical Department, Fondazione IRCC Istituto Nazionale Tumori, Milan, Italy; ⁴Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; ⁵Université Claude Bernard Lyon Institute, Centre Léon Bérard, Lyon, France; ⁶Department of Pathology, University Hospitals Leuven, Leuven, Belgium; ⁷European Organisation for Research and Treatment of Cancer, Brussels, Belgium; ⁸Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; ⁹Department of Oncology, University College London Hospitals NHS Trust, London, United Kingdom; ¹⁰Department of Human Genetics, University Hospitals Leuven, Leuven, Belgium; ¹¹Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Germany; ¹²Leeds Institute of Cancer & Pathology, University of Leeds, Leeds, United Kingdom; ¹³University Cancer Center/Medical Dept, University Hospital Carl Gustav Carus, Dresden, Germany; ¹⁴Medical oncology Unit, La Timone University Hospital, Marseille, France

- Paper 019 3025592
MILADEMETAN, AN ORAL MDM2 INHIBITOR, IN WELL-DIFFERENTIATED/DE-DIFFERENTIATED LIPOSARCOMA: RESULTS FROM A PHASE 1 STUDY IN PATIENTS WITH SOLID TUMORS AND LYMPHOMAS
Mrinal Gounder¹; Todd M. Bauer²; Gary K. Schwartz³; Amy M. Weise⁴; Patricia LoRusso⁵; Prasanna Kumar⁶; Shuquan Chen⁶; Jeanne Mendell⁶; Jarema Kochan⁶; Oleg Zernovak⁶; David S. Hong⁷
¹Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA; ²Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, USA; ³Columbia University Medical Center, New York, NY, USA; ⁴Karmanos Cancer Institute, Detroit, MI, USA; ⁵Smilow Cancer Hospital at Yale-New Haven, New Haven, CT, USA; ⁶Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; ⁷The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Paper 020 3042882
PHASE 2 STUDY OF THE CDK4 INHIBITOR ABEMACICLIB IN DEDIFFERENTIATED LIPOSARCOMA
Mark A. Dickson¹; Sandra D'Angelo¹; Mrinal Gounder¹; Mary L. Keohan¹; Ciara M. Kelly¹; Ping Chi¹; Cristina Antonsecu⁴; Jonathan Landa²; Li-Xuan Qin⁵; Andrew Koff⁶; Aimee M. Crago³; Sam Singer³; William D. Tap¹
¹Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Radiology, Memorial Sloan Kettering, New York, NY, USA; ³Surgery, Memorial Sloan Kettering, New York, NY, USA; ⁴Pathology, Memorial Sloan Kettering, New York, NY, USA; ⁵Biostatistics, Memorial Sloan Kettering, New York, NY, USA; ⁶Molecular Biology, Sloan Kettering Institute, New York, NY, USA
- Discussion – Javier Martin-Broto
- Paper 021 3042818
PHASE II STUDY OF ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA
Geraldine O'Sullivan Coyne¹; Elad Sharon²; Nancy Moore¹; Robert Meehan³; Naoko Takebe¹; Lamin Juwara⁴; Laurence Rubinstein²; William Read⁵; Richard F. Riedel⁷; Priscilla Merriam⁸; James Hu⁶; Melissa Burgess⁹; James Doroshov¹; Alice Chen¹
¹Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA; ²Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, USA; ³Moderna Therapeutics, Cambridge, MA, USA; ⁴National Cancer Institute, Bethesda, MD, USA; ⁵Emory Cancer Center, Atlanta, GA, USA; ⁶University of Southern California, Los Angeles, CA, USA; ⁷Duke University School of Medicine, Durham, NC, USA; ⁸Dana Farber Cancer Institute, Boston, MD, USA; ⁹UPMC Hillman Cancer Center, Pittsburgh, PA, USA
- Paper 022 3033993
EZH2 INHIBITOR TAZEMETOSTAT (TAZ) INTERIM DATA IN ADULTS AND PEDIATRIC PATIENTS WITH INI1-NEGATIVE SOFT-TISSUE SARCOMAS (STS) INCLUDING EPITHELIOID SARCOMA (ES) (NCT02601950, NCT02601937)
Mrinal Gounder¹; Patrick Schöffski²; Silvia Stacchiotti³; Victor Villalobos⁴; Rashmi Chugh⁵; Mark Agulnik⁶; Steven Attia⁷; Tom Wei-Wu Chen⁸; Gupta Abha⁹; Thierry Jahan¹⁰; Robin Jones²²; Antoine Italiano¹¹; Jean-Yves Blay¹²; Gregory M. Cote¹³; George Demetri¹⁴; Elizabeth Loggers¹⁵; Ravin Ratan¹⁶; Maryam Fouladi¹⁷; Margaret Macy¹⁸; Guy Makin¹⁹; Alicia Clawson²⁰; Scott Daigle²⁰; Chelsea Mencio²⁰; Inbal Sapir²⁰; Franck Bourdeaut²¹
¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; ³Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; ⁴University of Colorado, Denver, CO, USA; ⁵Michigan Medicine Comprehensive Cancer Center, Ann Arbor, MI, USA; ⁶Northwestern Memorial Hospital, Chicago, IL, USA; ⁷Mayo Clinic in Florida, Jacksonville, FL, USA; ⁸National Taiwan University Hospital, Taipei City, Japan; ⁹Princess Margaret Hospital, Toronto, ON, Canada; ¹⁰University of California, San Francisco, CA, USA; ¹¹Institut Bergonie, Bordeaux, France; ¹²Centre Léon Bérard, Lyon, France; ¹³Massachusetts General Hospital, Boston, MA, USA; ¹⁴Dana Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, MA, USA; ¹⁵Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ¹⁶MD Anderson Cancer Center, Houston, TX, USA; ¹⁷Cincinnati Children's Hospital, Cincinnati, OH, USA; ¹⁸Children's Hospital Colorado, Aurora, CO, USA; ¹⁹University of Manchester, Manchester, United Kingdom; ²⁰Epizyme, Cambridge, MA, USA; ²¹Curie Institute, Paris, France; ²²The Royal Marsden Hospital and Institute for Cancer Research, London, United Kingdom

Paper 023

3029169

ACTIVITY OF LAROTRECTINIB IN SARCOMA PATIENTS WITH TRK FUSION CANCER

Noah Federman¹; Daniel Orbach²; Shivaani Kummar³; Alexander Drilon⁴; Ulrik Lassen⁵; Birgit Georger⁶; Cornelis M. van Tillburg⁷; Theodore W. Laetsch⁸; Steven DuBois⁹; Ramamoorthy Nagasubramanian¹⁰; Neerav Shukla⁴; Michela Casanova¹¹; Soledad Gallego¹²; Stefan Bielack¹³; Atrayee Basu-Mallick¹⁴; Mohamad Farid¹⁵; Jyoti Patel¹⁶; Vicki Keedy¹⁷; Scott Cruickshank¹⁸; Nora C. Ku¹⁸; Michael C. Cox¹⁸; Alberto Pappo¹⁹; George Demetri²⁰; Douglas Hawkins²¹

¹Departments of Pediatrics and Orthopaedics, Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA, USA; ²SIREDO Oncology Center, Institut Curie, PSL University, Paris, France; ³Stanford Cancer Center, Palo Alto, CA, USA; ⁴Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁵Rigshospitalet, Copenhagen, Denmark; ⁶Gustave Roussy Cancer Center, Villejuif, France; ⁷Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany; ⁸University of Texas Southwestern Medical Center/Children's Health, Dallas, TX, USA; ⁹Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA; ¹⁰Nemours Children's Hospital, Orlando, FL, USA; ¹¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; ¹²Hospital Universitario Vall d'Hebron, Barcelona, Spain; ¹³Olgahospital, Klinikum Stuttgart, Stuttgart, Germany; ¹⁴Thomas Jefferson University, Philadelphia, PA, USA; ¹⁵National Cancer Centre, Singapore, Singapore; ¹⁶University of Chicago, Chicago, IL, USA; ¹⁷Vanderbilt University School of Medicine, Nashville, TN, USA; ¹⁸Loxo Oncology Inc., South San Francisco, CA, USA; ¹⁹St Jude Children's Research Hospital, Memphis, TN, USA; ²⁰Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; ²¹Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Discussion – Neeta Somaiah

10:00 am - 10:30 am

Morning Coffee Break

Salon de Cavalieri 1 & Gallery

10:30 am - 11:00 am

Presentation of Young Investigator Awards

Salon del Cavalieri 2,3,4

Paper 036

3035962

SLFN11 IS A SIGNIFICANT DETERMINANT OF PARP INHIBITOR SENSITIVITY IN PEDIATRIC SARCOMAS

Jessica Gartrell; Marcia M. Mellado-Largarde; Jia Xie; Brandon Bianski; Kaley Blankenship; Michael Clay; Armita Bahrami; Sara Federico; Christopher L. Tinkle; Elizabeth Stewart; Anang Shelat
St. Jude Children's Research Hospital, Memphis, TN, USA

Paper 021

3042818

PHASE II STUDY OF ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA

Geraldine O'Sullivan Coyne¹; Elad Sharon²; Nancy Moore¹; Robert Meehan³; Naoko Takebe¹; Lamin Juwara⁴; Laurence Rubinstein²; William Read⁵; Richard F. Riedel⁷; Priscilla Merriam⁸; James Hu⁶; Melissa Burgess⁹; James Doroshow¹; Alice Chen¹

¹Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA; ²Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, USA; ³Moderna Therapeutics, Cambridge, MA, USA; ⁴National Cancer Institute, Bethesda, MD, USA; ⁵Emory Cancer Center, Atlanta, GA, USA; ⁶University of Southern California, Los Angeles, CA, USA; ⁷Duke University School of Medicine, Durham, NC, USA; ⁸Dana Farber Cancer Institute, Boston, MD, USA; ⁹UPMC Hillman Cancer Center, Pittsburgh, PA, USA

11:00 am - 12:00 pm

– HERMAN SUIT LECTURE –

Salon del Cavaliere 2,3,4

How Molecular Discoveries Changed our Morphology-Based Profession
Cristina Antonescu

(Memorial Sloan Kettering Cancer Center, New York, NY)

12:00 pm - 1:30 pm

Lunch

Belle Arti & Garden Lobby

12:00 pm - 1:30 pm

Board of Directors Meeting

San Giovanni

1:30 pm - 3:30 pm

– SESSION 5 –

Salon del Cavaliere 2,3,4

Benign and Intermediate Grade Bone/Soft Tissue Lesions

Moderators: **William Tseng** and **Katherine Thornton**

Paper 024

3042858

RISK FACTORS IN TENOSYNOVIAL GIANT CELL TUMOURS OF LARGE JOINTS, EVALUATED IN 30 INTERNATIONAL SARCOMA CENTERS

Monique Mastboom; Emanuela Palmerini; Floortje Verspoor; Anja Rueten-Budde; Silvia Stacchiotti; Eric Staals; Gerard Schaap; Paul Jutte; Will Aston; Andreas Leithner; Dietmar Dammerer; Akihiko Takeuchi; Quirina Thio; Xiaohui Niu; Jay Wunder; Michiel A. van de Sande
Orthopaedics oncology, Leiden University Medical Center, Amsterdam, Noord Holland, Netherlands

Paper 025

3038487

POSITIVE ASSOCIATION BETWEEN TUMOR RESPONSE AND PATIENT-REPORTED OUTCOMES IN PHASE 3 ENLIVEN STUDY OF PEXIDARTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT)

Heather L. Gelhorn¹; Charles Peterfy²; Xin Ye³; **Rebecca M. Speck**¹; Emanuela Palmerini⁴; Silvia Stacchiotti⁵; Jayesh Desai⁶; Andrew Wagner⁷; Thierry Alcindor⁸; Kristen Ganjoo⁹; Javier Martín-Broto¹⁰; Christopher Ryan¹¹; Qiang Wang³; Dale Shuster³; William D. Tap¹²; Hans Gelderblom¹³
¹Evidera, Bethesda, MD, USA; ²Spire Sciences, Inc., Boca Raton, FL, USA; ³Daiichi Sankyo, Inc., Basking Ridge, NJ, USA; ⁴Istituto Ortopedico Rizzoli, Bologna, Italy; ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁶Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ⁷Dana-Farber Cancer Institute, Boston, MA, USA; ⁸McGill University, Montreal, QC, Canada; ⁹Stanford Cancer Institute, Stanford, CA, USA; ¹⁰Hospital Universitario Virgen del Rocío, Seville, Spain; ¹¹Oregon Health & Science University, Portland, OR, USA; ¹²Memorial Sloan Kettering Cancer Institute, New York, NY, USA; ¹³Leiden University Medical Center, Leiden, Netherlands

Paper 026

3042414

PRIMARY VASCULAR TUMORS OF BONE: AN ANALYSIS OF 427 PATIENTS

Marta Sbaraglia¹; Alberto Righi²; Marco Gambarotti²; Dino Gibertoni³; Stefania Benini²; Piero Picci²; Angelo Paolo Dei Tos¹
¹University of Padua, Treviso, Italy; ²Pathology, IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy; ³Biomedical and Neuromotor Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy

Paper 027 3042427
PHASE II TRIAL OF PAZOPANIB IN ADVANCED EXTRASKELETAL MYXOID CHONDROSARCOMA. A COLLABORATIVE SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) SARCOMA GROUPS STUDY
Silvia Stacchiotti¹; Stefano Ferrari²; Antonio Redondo³; Emanuela Palmerini²; Nadia Hindi⁴; Maria A. Vaz⁵; Anna Maria Frezza¹; Antonio Gutierrez⁶; Antonio Lopez-Pousa¹⁶; Tiziana Venesio⁷; Antoine Italiano⁸; Sarah N. Dumont⁹; Jean-Yves Blay¹⁰; Nicolas Penel¹¹; Daniel Bernabeu¹²; Enrique De Alava¹³; Dominique Ranchere-Vince¹⁰; Gian Paolo Dagrada¹; Paola Collini¹; Josefina Cruz¹⁴; Javier Martín-Broto¹⁵
¹Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ²Cancer Medicine, Istituto Ortopedico Rizzoli, Bologna, Italy; ³Cancer Medicine, La Paz Institute for Health Research, Madrid, Spain; ⁴University Hospital Virgen del Rocío, Sevilla, Spain; ⁵Hospital Universitario Ramón y Cajal, Cajal, Spain; ⁶Hospital Universitari Son Espases, Palma, Spain; ⁷Cancer Medicine, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy; ⁸Institut Bergonie, Bordeaux, France; ⁹Cancer Medicine, Goustave Roussy, Villejuif, France; ¹⁰Centre Léon Bérard, Lyon, France; ¹¹Centre Oscar Lambret, Lille, France; ¹²Radiology, University Hospital La Paz, Madrid, France; ¹³Institute of Biomedicine of Sevilla, Sevilla, Spain; ¹⁴University Hospital of Canarias, Tenerife, Spain; ¹⁶Sant Pau Hospital, Barcelona, Spain

Discussion – Paolo Casali

Paper 028 3042598
LONGITUDINAL DISTRESS ASSESSMENT AND RESPONSE TOOL (DART) SCREENING IN ADULTS WITH AGGRESSIVE FIBROMATOSIS: HIGH PREVALENCE OF PERSISTENT EMOTIONAL DISTRESS
Abha Gupta¹; Nicole Byers¹; Sally Burtenshaw²; Katrina Ingle²; Carol Swallow²; Savtaj Brar²; Anthony M. Griffin²; Peter Ferguson²; Jay Wunder²; Albiruni Razak¹; Rebecca Gladdy²; Roberta Klein³; Madeline Li³
¹Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada; ²Surgery, Mount Sinai Hospital, Toronto, ON, Canada; ³Psychiatry, Princess Margaret Cancer Center, Toronto, ON, Canada

Paper 029 3042617
CAN WAIT AND SEE BE THE STANDARD OF CARE FOR INITIAL APPROACH TO PRIMARY SPORADIC DESMOID TUMORS? PRELIMINARY DATA FROM AN ITALIAN SARCOMA GROUP PROSPECTIVE STUDY
Chiara Colombo¹; Marco Fiore¹; Tiziana Venesio²; Erica Palesandro²; Paola Boccone²; Lorenzo D'Ambrosio²; Alba Bianco¹; Paola Collini¹; Elena Palassini¹; Silvia Stacchiotti¹; Angelo Paolo Dei Tos³; Paolo Casali¹; Federica Perrone¹; Alessandro Gronchi¹
¹Fondazione IRCCS Istituto Tumori Milano, Milan, Italy; ²IRCCS Istituto Candiolo, Torino, Italy; ³Ospedale di Treviso, Treviso, Italy

Paper 030 3042719
INCORPORATION OF CTNNB1 MUTATION STATUS INTO A PRE-OPERATIVE DESMOID LOCAL RECURRENCE NOMOGRAM IMPROVES PREDICTIVE VALUE
Iris Wei¹; Anthony Villano¹; Andrea Knezevic²; Bhumika Jadeja¹; Li-Xuan Qin²; Meera Hameed³; Sam Singer¹; **Aimee M. Crago**¹
¹Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Discussion – Bernd Kasper

3:30 pm - 4:00 pm

Afternoon Coffee Break

Salon de Cavalieri 1 & Gallery

Ewing Sarcoma

Moderators: **Abha Gupta** and **Piero Picci**

- Paper 031 3027408
EASY-TO-USE PRACTICAL CLINICAL TOOL FOR SURVIVAL ESTIMATION IN EWING SARCOMA AT DIAGNOSIS AND AFTER SURGERY
Sarah E. Bosma¹; Carlo Lancia²; Anja J. Rüten-Budde²; Andreas Ranft³; Hans Gelderblom⁴; Marta Fiocco²; Michiel A. van de Sande¹; Sander Dijkstra¹; Uta Dirksen³
¹Orthopedics, Leiden University Medical Center, Leiden, Netherlands; ²Mathematical Institute, Leiden University, Leiden, Netherlands; ³Pediatrics III, University Hospital Essen, University Duisburg-Essen, Sarcoma Center, West German Cancer Center, Essen, Germany; ⁴Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
- Paper 032 3042243
RETROSPECTIVE ANALYSIS OF USE OF WHOLE LUNG IRRADIATION FOR PATIENTS WITH NEWLY DIAGNOSED EWING SARCOMA AND PULMONARY METASTASES
Hadeel Halalshah¹; Sue Kaste²; Matthew J. Krasin³; April Sykes⁴; Natasha Sahr⁴; Sheri Spunt⁵; Sara Federico¹; Alberto Pappo¹; **Michael W. Bishop**¹
¹Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA; ²Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, USA; ³Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA; ⁴Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA; ⁵Pediatrics - Hematology/Oncology, Lucile Packard Children's Hospital Stanford, Palo Alto, CA, USA
- Paper 033 3042780
WHOLE-LUNG IRRADIATION AFTER HIGH-DOSE BUSULFAN/MELPHALAN CONDITIONING THERAPY IN EWING SARCOMA WITH LUNG METASTASES: A MULTICENTRIC STUDY
Massimo E. Abate¹; Letizia Ronchi²; Barbara Diletto¹⁴; Lorenza Gandola¹⁴; Nadia Puma¹⁵; Angela Tamburini³; Maurizio Mascarin⁴; Elisa Coassin⁴; Arcangelo Prete⁵; Sebastian Asaftei⁶; Carla Manzitti⁷; Luca Coccoli⁸; Mariella Capasso⁹; Tiziana Venesio¹³; Emilia Pecori¹⁴; Marta Pierobon¹⁶; Anna Paioli¹; Elisa Carretta¹⁰; Giovanni Piero Frezza¹¹; Alessio Giuseppe Morganti²; Stefano Ferrari¹; Piero Picci¹²; Alessandra Longhi¹; Silvia Cammelli²; Roberto Luksch¹⁵
¹Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy; ²Radiotherapy, Sant'Orsola Hospital, Bologna, Italy; ³Pediatric Oncoematology, Hospital Meyer, Firenze, Italy; ⁴Radiotherapy, CRO Aviano, Aviano, Italy; ⁵Pediatric Oncoematology, Sant'Orsola Hospital, Bologna, Italy; ⁶Pediatric Oncoematology, OIRM Sant'ANNA, Torino, Italy; ⁷Pediatric Oncology, Gaslini Hospital, Genova, Italy; ⁸Pediatric Oncoematology, AOUP Pisa, Pisa, Italy; ⁹Pediatric Oncology, AORN Santobono-Pausillipon, Napoli, Italy; ¹⁰Statistics, Istituto Ortopedico Rizzoli, Bologna, Italy; ¹¹Radiotherapy, AUSL Bologna, Bologna, Italy; ¹²Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy; ¹³Medical Oncology, Istituto Candiolo, Torino, Italy; ¹⁴Radiotherapy, Fondazione IRCCS ISTITUTO NAZIONALE TUMORI, Milano, Italy; ¹⁵Pediatric Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy; ¹⁶Pediatric Oncoematology, Azienda Ospedaliera di Padova, Padova, Italy
- Discussion – Rick Haas
- Paper 034 3042627
THE WNT-DEPENDENT SECRETOME ALTERS TUMOR: TUMOR MICROENVIRONMENT CROSSTALK TO PROMOTE INVASION AND ANGIOGENESIS IN EWING SARCOMA
Allegra Hawkins; Elisabeth Pedersen; Sonja Konzen; Colin Sperring; Sydney Treichel; **Elizabeth Lawlor**
University of Michigan, Ann Arbor, MI, USA

- Paper 035 3042245
A PHASE I STUDY OF THE POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITOR, NIRAPARIB (NIR), IN COMBINAITON WITH IRINOTECAN (IRN) IN PATIENTS WITH ADVANCED EWING SARCOMA: RESULTS OF SARCO25 ARM 2
Sandra J. Strauss¹; Karla V Ballman²; Kam Zaki¹; Lee Helman³; Brigitte Widemann⁴; Douglas Hawkins⁵; Leo Mascarenhas³; J.W Glod⁴; Jay Ji⁶; Ziping Zhang⁶; Birgit Geoerger⁷; Jeremy Whelan¹; Denise Reinke⁸; Shreyaskumar Patel⁹; Rashmi Chugh¹⁰
¹University College London Hospitals NHS Trust, London, United Kingdom; ²Weill Cornell Medicine, New York, NY, USA; ³Children's Center for Cancer and Blood Diseases, Los Angeles, CA, USA; ⁴National Cancer Institute Centre for Cancer Research, Bethesda, MD, USA; ⁵Seattle Children's Hospital, Seattle, OR, USA; ⁶National Clinical Target Validation Laboratory, Bethesda, MD, USA; ⁷Institut Gustave Roussy, Paris, France; ⁸SARC, Ann Arbor, MI, USA; ⁹MD Anderson, Houston, TX, USA; ¹⁰University of Michigan, Ann Arbor, MI, USA
- Paper 036 3035962
SLFN11 IS A SIGNIFICANT DETERMINANT OF PARP INHIBITOR SENSITIVITY IN PEDIATRIC SARCOMAS
Jessica Gartrell; Marcia M. Mellado-Largarde; Jia Xie; Brandon Bianski; Kaley Blankenship; Michael Clay; Armita Bahrami; Sara Federico; Christopher L. Tinkle; Elizabeth Stewart; Anang Shelat
St. Jude Children's Research Hospital, Memphis, TN, USA
- Paper 037 3027426
INNOVATIVE TARGETED THERAPY FOR EWING SARCOMA
Shunya Ohmura¹; Martin F. Orth¹; Aruna Marchetto¹; Stefanie Stein¹; Julia S. Gerke¹; Giuseppina Sannino¹; Julian Musa¹; Fabienne Wehweck¹; Maximilian M. Knott¹; Jing Li¹; Tilman Hölting¹; Laura Romero-Pérez¹; Florencia Cidre-Aranaz¹; Horacio Bach²; Wolfgang Hartmann³; Uta Dirksen⁴; Thomas Kirchner⁵; Thomas G. Grünewald⁶
¹Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany; ²Department of Medicine, Division of Infectious Diseases, University of British Columbia, Vancouver, BC, Canada; ³Gerhard-Domagk Institute of Pathology, University Hospital of Muenster, Muenster, Germany; ⁴Division of Hematology and Oncology, Department of Pediatrics III, West German Cancer Centre, University Hospital Essen, Essen, Germany; ⁵Institute of Pathology, Faculty of Medicine, LMU Munich, German Cancer Research Center (DKFZ), Heidelberg, German Cancer Consortium (DKTK), partner site Munich, Munich, Germany; ⁶Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, German Cancer Research Center (DKFZ), Heidelberg, German Cancer Consortium (DKTK), partner site Munich, Munich, Germany

Discussion – Stephen Lessnick

7:00 pm - 10:00 pm

**Gala – Reception and Dinner at the beautiful Villa Miani
next door to the Cavalieri Hotel. Cocktail Attire**

Villa Miani

Saturday, 17 November, 2018

6:30 am - 5:30 pm	Registration	Salon de Cavalieri 1 & Gallery
7:00 am - 8:00 am	Coffee and Posters	Salon de Cavalieri 1 & Gallery

8:00 am - 9:00 am	– POSTER DISCUSSION –	Salon del Cavalieri 2,3,4
	Abstracts within Poster Abstract Section	

Circulating Tumor DNA – Brian Crompton

- Poster 127 3042631
PILOT STUDY EVALUATING THE CONCORDANCE OF CIRCULATING TUMOR DNA ALTERATIONS WITH TUMOR-BASED SEQUENCING IN SOFT TISSUE SARCOMA
Bryce Demoret¹; Sherri Z. Millis²; Gabriel Tinoco¹; David Liebner¹; **James L. Chen**¹
¹The Ohio State University, Columbus, OH, USA; ²Foundation Medicine, Cambridge, MA, USA
- Poster 128 3042674
CIRCSARC; NON-INVASIVE MONITORING OF SARCOMAS PATIENTS BY CIRCULATING TUMOUR DNA IN PLASMA
Heidi M. Namløs¹; Seyed Hossein Moosavi¹; Bodil Bjerkehagen²; Olga Zaikova³; Susanne Lorenz⁴; Lars Aasheim⁴; Eivind Hovig¹; Nina L. Jebsen⁵; Ola Myklebost⁶; Boye Kjetil⁷; **Leonardo A. Meza-Zepeda**¹
¹Department of Tumor Biology, Oslo University Hospital, Oslo, Norway; ²Department of Pathology, Oslo University Hospital, Oslo, Norway; ³Department of Surgery, Oslo University Hospital, Oslo, Norway; ⁴Department of Core Facilities, Oslo University Hospital, Oslo, Norway; ⁵Department of Oncology, Haukeland University Hospital, Bergen, Norway; ⁶Department of Clinical Science, University of Bergen, Bergen, Norway; ⁷Department of Oncology, Oslo University Hospital, Oslo, Norway
- Poster 129 3042933
ULTRA-SENSITIVE DETECTION OF TRANSLOCATIONS IN THE CELL-FREE DNA OF PEDIATRIC SARCOMA PATIENTS
Avanthi T. Shah¹; Tej Azad²; Jake Chabon³; Stan Leung¹; Aviv Spillinger¹; Heng-Yi Liu¹; Marcus Breese¹; Maximilian Diehn³; Ash A. Alizadeh³; Alejandro Sweet-Cordero¹
¹Pediatrics, UCSF, San Francisco, CA, USA; ²Stanford University School of Medicine, Stanford, CA, USA; ³Stanford Cancer Institute, Stanford, CA, USA
- Poster 130 3043078
NONINVASIVE MOLECULAR PROFILING AND RESPONSE MONITORING BY CELL-FREE DNA ANALYSIS IN OSTEOSARCOMA
Emily Slotkin¹; Julie Yang²; Dana Tsui²
¹Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Poster 132 3042854
TREATMENT MONITORING IN PATIENTS WITH PEDIATRIC SARCOMAS USING CIRCULATING TUMOR DNA ANALYSIS: A FEASIBILITY STUDY
Jun Zhao¹; Braden McDonald²; Tania Contente-Cuomo²; Ahuva Odenheimer²; Michelina de la Maza¹; Pooja Hingorani¹; Muhammed Murtaza²
¹Pediatric Hematology/Oncology, Phoenix Children's Hospital, Phoenix, AZ, USA; ²Center for Non-invasive Diagnostics, Translational Genomics Research Institute, Phoenix, AZ, USA

Geonomics – Roberta Maestro

- Poster 182 3042599
DISCOVERY AND CHARACTERIZATION OF RECURRENT, TARGETABLE ALK FUSIONS IN LEIOMYOSARCOMA
Lara E. Davis¹; Kevin Nusser¹; Joanna Przybyl²; Janet Pittsenbarger¹; Nicolle Hofmann¹; Sushama Varma²; Sujay Vennam²; Maria Debiec-Rychter³; Matt van de Rijn²; Monika Davare¹
¹Oregon Health & Science University, Portland, OR, USA; ²Stanford University, Stanford, CA, USA; ³KU Leuven, Leuven, Belgium
- Poster 183 3014793
GENOME INFORMED THERAPY FOR OSTEOSARCOMA
Leanne Sayles¹; Marcus Breese¹; Amanda Koehne¹; Stan Leung¹; Avanthi T. Shah¹; Sheri Spunt²; Steven DuBois⁴; Douglas Hawkins³; **Alejandro Sweet-Cordero**¹
¹Pediatrics, University of California San Francisco, San Francisco, CA, USA; ²Pediatrics, Stanford University, San Francisco, CA, USA; ³Pediatrics, University of Washington, Seattle, WA, USA; ⁴Pediatrics, Dana Farber Cancer Institute, Boston, MA, USA
- Poster 185 3042669
COMPREHENSIVE GENOMIC PROFILING OF SYNOVIAL SARCOMAS IDENTIFIES GENOMICALLY DEFINED SUBGROUPS WITH CHARACTERISTIC ALTERATION PATTERNS
Sherri Z. Millis¹; Peter Vorenkamp³; Petra Vorenkamp³; Jeffrey Ross¹; Siraj Ali¹; Sally Trabucco¹; James L. Chen²
¹Foundation Medicine, Inc., Phoenix, AZ, USA; ²The Ohio State University, Columbus, OH, USA; ³Live For Others Foundation, Laguna Beach, CA, USA
- Poster 186 3042566
THE FUSION LANDSCAPE AND ACTIONABLE ALTERATIONS OF SARCOMA REVEALED BY “REAL WORLD” GENOMIC SEQUENCING
Jason Roszik¹; Anthony P. Conley¹; Roman Groisberg¹; Roberto Carmagnani Pestana¹; Shiraj Sen¹; Vivek Subbiah¹
¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Poster 188 3042711
UTILITY OF FOUNDATIONONE HEME PROFILING IN SARCOMA: INSTITUTIONAL EXPERIENCE AND CLINICAL OUTCOMES
Adrienne Victor¹; Deepak Sahasrabudhe¹; Megan Baumgart¹
¹Medical Oncology, University of Rochester, Rochester, NY, USA

Immunotherapy – Sandra D'Angelo

- Poster 216 3014823
NEOADJUVANT THERAPY INDUCES A POTENT INFLAMMATORY AND CORRESPONDING REGULATORY RESPONSE WITHIN THE SARCOMA IMMUNE MICROENVIRONMENT
Teresa Kim¹; Matthew Spraker³; Y. David Seo¹; Kimberly Smythe²; Robert Pierce²; Taylor Hain²; Edward Y. Kim³; Gabrielle Kane³; Isaac Jenkins⁵; Qianchuan (Chad) He⁴; Seth Pollack²
¹Surgery, University of Washington, Seattle, WA, USA; ²Clinical Research Division, Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ³Radiation Oncology, University of Washington, Seattle, WA, USA; ⁴Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ⁵Clinical Biostatistics, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

- Poster 229 3042851
RESPONSE TO SUBSEQUENT THERAPY IN NY-ESO-1 POSITIVE SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY
Sant P. Chawla¹; Seth Pollack²; Matthew Block⁷; Mihaela Druta³; Khanh Do⁴; John C. Morris⁵; Joseph W. Kim⁶; Chet Bohac⁸; Hailing Lu⁹; Sacha Gnjatic¹⁰; Robin L. Jones¹¹; P. Hwu¹²; Neeta Somaiah¹³
¹Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; ²Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; ³Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; ⁴Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; ⁵Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; ⁶Medical Oncology, Yale University, New Haven, CT, USA; ⁷Medical Oncology, Mayo clinic, Rochester, MN, USA; ⁸Clinical Development, Immune Design, South San Francisco, CA, USA; ⁹Science, Immune Design, Seattle, WA, USA; ¹⁰Immunology, Mt. Sinai, New York City, NY, USA; ¹¹Medical Oncology, Royal Marsden, London, United Kingdom; ¹²Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ¹³Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA
- Poster 230 3042145
IMMUNE RESPONSE, SAFETY, AND OVERALL SURVIVAL OF NY-ESO-1+ SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY
Sant P. Chawla¹; **Seth Pollack**²; Matthew Block¹¹; Mihaela Druta³; Khanh Do⁴; John C. Morris⁵; Joseph W. Kim⁶; Chet Bohac⁷; Hailing Lu⁷; Sacha Gnjatic⁸; R. L. Jones⁹; P. Hwu¹⁰; Neeta Somaiah¹⁰
¹Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; ²Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; ³Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; ⁴Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; ⁵Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; ⁶Medical Oncology, Yale University, New Haven, CT, USA; ⁷Science, Immune Design, Seattle, WA, USA; ⁸Immunology, Mt. Sinai, New York City, NY, USA; ⁹Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; ¹⁰Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ¹¹Medical Oncology, Mayo Clinic, Rochester, MN, USA
- Poster 238 3042673
ACTIVITY OF TREMELIMUMAB AND DURVALUMAB IN ADVANCED SARCOMAS: PRELIMINARY RESULTS OF A SIGNAL-SEEKING PHASE 2 TRIAL
Maya Kansara¹; Subotheni Thavaneswaran¹; John Grady¹; Mark Cowley¹; Audrey Silvestri¹; Mandy L. Ballinger¹; Elektra Hajdu¹; Emily Collignon¹; Lucille Sebastian²; Katrin Sjoquist²; Wendy Hague²; Amy Prawira¹; Anthony Joshua¹; Charles Bailey³; Ulf Schmitz³; Trevor Pugh⁴; Torsten O. Nielsen⁵; Amanda R. Dancsok⁵; Chee Lee²; John Simes³; David M. Thomas¹
¹Cancer Genomic Medicine, Garvan Institute, Sydney, NSW, Australia; ²NHMRC Clinical Trials Centre, Sydney, NSW, Australia; ³Gene and Stem Cell Therapy Program, Centenary Institute, Sydney, NSW, Australia; ⁴Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; ⁵Vancouver Coastal Health Research Institute and Faculty of Medicine, Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada
- Poster 240 3042810
INTERFERON GAMMA MAKES "COLD" SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA "HOT": RESULTS OF A PHASE 0 TRIAL
Shihong Zhang¹; Venu Pillarisetty²; Lee D. Cranmer¹; Stanley Riddell¹; R. L. Jones³; **Seth Pollack**¹
¹Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ²Surgery, University of Washington, Seattle, WA, USA; ³Royal Marsden Hospital, London, United Kingdom

Vascular Tumors – Silvia Stacchiotti

- Poster 002 3042315
PITFALLS IN ANGIOSARCOMA DIAGNOSIS: LESSONS LEARNED FROM CENTRAL REVIEW OF 657 DUTCH CASES
Marije Weidema¹; Melissa Hillebrandt-Roeffen¹; Ingrid Desar¹; Yvonne Versleijen-Jonkers¹; Winette van der Graaf¹; Uta Flucke²
¹Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands; ²Pathology, Radboud University Medical Center, Nijmegen, Netherlands
- Poster 005 3037976
THE ANGIOSARCOMA PROJECT: GENERATING THE GENOMIC LANDSCAPE OF A RARE SARCOMA THROUGH A NATIONWIDE PATIENT-DRIVEN INITIATIVE
Michael Dunphy¹; Esha Jain¹; Elana Anastasio¹; Mary McGillicuddy¹; Rachel Stoddard¹; Beena Thomas¹; Sara Balch¹; Kristin Anderka²; Katie Larkin²; Niall Lennon²; Yen-Lin E. Chen³; Andrew Zimmer⁴; Esme O. Baker⁴; Simone Maiwald⁴; Jen Lapan⁴; Jason L. Hornick⁵; Chandrajit Raut⁵; George Demetri⁶; Eric S. Lander⁷; Todd Golub¹; Nikhil Wagle⁶; **Corrie Painter**¹
¹Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; ²Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA; ³Massachusetts General Hospital, Boston, MA, USA; ⁴Data Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA; ⁵Brigham and Women's Hospital, Boston, MA, USA; ⁶Dana-Farber Cancer Institute, Cambridge, MA, USA; ⁷Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Poster 006 3042503
A RETROSPECTIVE REVIEW OF PATIENTS WITH ANGIOSARCOMA TREATED IN BRITISH COLUMBIA
Alannah Smrke¹; Jeremy Hamm¹; Anand Karvat¹; Christine Simmons¹; Amirtha Srikanthan¹
¹BC Cancer , Vancouver, BC, Canada
- Poster 008 3042562
NEOADJUVANT CHEMOTHERAPY ASSOCIATED WITH ENHANCED LOCAL CONTROL IN RADIATION-INDUCED ANGIOSARCOMA OF BREAST AND CHEST
Audrey Michot¹; Marie Karanian²; Maryck Lae¹¹; Romuald Wernert³; Marie-Pierre Sunyach⁴; Dimitri Tzanis⁵; Jean-Marie Guilloit⁶; Maria Rios⁷; Antoine Giraud⁸; François Le Loarer⁹; Jean-Yves Blay¹⁰; Eberhard Stoeckle¹
¹Surgery, Institut Bergonié, Bordeaux, France; ²Pathology, Leon Berard, Lyon, France; ³Surgery, Institut de Cancerologie de l'Ouest, Angers, France; ⁴Radiotherapy, Centre Leon Berard, Lyon, France; ⁵Surgery, Institut Curie, Paris, France; ⁶Surgery, Centre Francois Baclesse, Caen, France; ⁷Medical Oncology, Institut de Cancerologie de Lorraine, Nancy, France; ⁸Epidemiology and Clinical Research Unit, Institut Bergonié, Bordeaux, France; ⁹Pathology, Institut Bergonié, Bordeaux, France; ¹⁰Medical Oncology, Centre Leon Berard, Lyon, France; ¹¹Pathology, Institut Curie, Paris, France

Osteosarcoma/Chondrosarcoma/Chordoma

Moderators: **Vicki Keedy** and **Kirsten Sundby Hall**

- Paper 038 3042790
STRESS MEDIATED TRANSLATIONAL CONTROL OF CHILDHOOD BONE SARCOMA METASTASIS
 Amal M. EL-Naggar¹; Syam Somasekharan²; Hongwei Cheng²; Gian Luca Negri³; Didier Surdez⁴; Olivier Delattre⁴; **Poul H. Sorensen**¹
¹Molecular Oncology, BC Cancer & University of British Columbia, Vancouver, BC, Canada; ²Vancouver Prostate Centre, Vancouver, BC, Canada; ³Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada; ⁴Centre de recherche de l'Institut Curie, Paris, France
- Paper 039 3035462
PROSPECTIVE PHASE II STUDY OF SCANNED BEAM PROTON THERAPY FOR SPINE SARCOMAS
David J. Konieczkowski¹; Yen-Lin E. Chen¹; Karen De Amorim Bernstein¹; Beow Yeap²; Matthew DiMaria³; Wenquin Jiang²; Nannette Thomas¹; Suzanne L. McGovern⁴; John T. Mullen⁵; Joseph H. Schwab⁶; Francis Hornicek⁷; Thomas F. DeLaney¹
¹Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA; ³Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA, USA; ⁴Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA; ⁵Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁶Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA; ⁷Department of Orthopedic Surgery, University of California Los Angeles, Los Angeles, MA, USA
- Paper 040 2993960
APATINIB FOR ADVANCED OSTEOSARCOMA AFTER FAILURE OF STANDARD MULTIMODAL THERAPY: AN OPEN LABEL PHASE 2 CLINICAL TRIAL(NCT02711007)
Lu Xie; Jie Xu; Xin Sun; Xiaodong Tang; Taiqiang Yan; Rongli Yang; Wei Guo
 Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China
- Paper 041 3042511
SARC024: REGORAFENIB IN PATIENTS WITH REFRACTORY OSTEOSARCOMA
Lara E. Davis¹; Christopher Ryan¹; John Crowley²; Kristen Ganjoo³; Elizabeth Loggers⁴; Sant P. Chawla⁵; Mark Agulnik⁶; Michael B. Livingston⁷; Damon Reed⁸; Vicki Keedy⁹; Daniel A. Rushing¹⁰; Scott Okuno¹¹; Denise Reinke¹²; Richard F. Riedel¹³; Steven Attia¹⁴; Leo Mascarenhas¹⁵; Robert Makj¹⁶
¹Oregon Health and Science University, Portland, OR, USA; ²Cancer Research and Biostatistics, Seattle, WA, USA; ³Stanford Cancer Institute, Stanford, CA, USA; ⁴Seattle Cancer Care Alliance, Seattle, WA, USA; ⁵Sarcoma Oncology Research Center, Santa Monica, CA, USA; ⁶Northwestern University Feinberg School of Medicine, Chicago, IL, USA; ⁷Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; ⁸H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; ⁹Vanderbilt University Medical Center, Nashville, TN, USA; ¹⁰Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA; ¹¹Mayo Clinic, Rochester, MN, USA; ¹²SARC, Ann Arbor, MI, USA; ¹³Duke University Medical Center, Durham, NC, USA; ¹⁴Mayo Clinic, Jacksonville, FL, USA; ¹⁵Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Univ. of Southern California, Los Angeles, CA, USA; ¹⁶Monter Cancer Center, Northwell Health and Cold Spring Harbor Laboratory, Lake Success, NY, USA

Paper 042 3042857
CABOZANTINIB IN PATIENTS WITH ADVANCED OSTEOSARCOMAS AND EWING SARCOMAS: A FRENCH SARCOMA GROUP (FSG)/ US NATIONAL CANCER INSTITUTE PHASE II COLLABORATIVE STUDY
Antoine Italiano¹; Nicolas Penel²; Emmanuelle Bompas³; Sophie Piperno-Neumann⁴; Marina Pulido¹; Natacha Entz-Werle⁵; Axel Le Cesne⁶; Christine Chevreau⁷; Florence Duffaud⁸; Isabelle Ray-Coquard⁹; Maud Toulmonde¹; Carine Bellera¹; Jean-Yves Blay⁹
¹Institut Bergonié, Bordeaux, France; ²Centre Oscar Lambret, Lille, France; ³Institut Cancerologie de l'Ouest, Nantes, France; ⁴Institut Curie, Paris, France; ⁵CHU de Strasbourg, Strasbourg, France; ⁶Institut Gustave Roussy, Villejuif, France; ⁷Oncopole Toulouse, Toulouse, France; ⁸APHM Marseille, Marseille, France; ⁹Centre Leon Berard, Lyon, France

Discussion – Katherine Janeway

10:30 am - 11:00 am **Morning Coffee Break** Salon de Cavalieri 1 & Gallery

11:00 am - 12:00 pm – NINA AXELRAD LECTURE – Salon del Cavalieri 2,3,4
Academic Clinical Trials in Sarcomas at the Time of Genomic Revolution
Jean-Yves Blay
(Centre Léon BERARD Lyon, France)

12:00 pm - 1:00 pm **Lunch** Belle Arti & Garden Lobby

1:00 pm - 1:30 pm Salon del Cavalieri 2,3,4
Liddy Shriver Early Career Research Award
Cigall Kadoch

1:30 pm - 3:30 pm – SESSION 8 – Salon del Cavalieri 2,3,4
Soft Tissue Sarcoma: Biology
Moderators: **Torsten Nielsen** and **Poul Sorensen**

Paper 043 3042288
WHOLE GENOME SEQUENCING OF 1,111 SARCOMA PROBANDS REVEALS POT-1 AS A SARCOMA PREDISPOSITION GENE
Mandy L. Ballinger¹; Mark Pinese¹; Emma Rath¹; Paul James²; Ajay Puri³; Nicolas Isambert⁴; Martin Tattersall⁵; Beatrice Seddon⁶; Ian Judson⁷; Winette van der Graaf⁷; Nicolas Penel⁸; Axel Lecesne⁹; Coonoor Chandrasekar¹⁰; Jean-Emmanuel Kurtz¹¹; Joshua Schiffman¹²; R. Lor Randall¹²; Florence Duffaud¹³; Jin-Hee Ahn¹⁴; Rory Rickard¹⁵; Jean-Yves Blay¹⁶; Isabelle Ray-Coquard¹⁶; David M. Thomas¹
¹Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia; ²Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ³Tata Memorial Hospital, Mumbai, India; ⁴Centre Georges Francois Leclerc, Dijon, France; ⁵University of Sydney, Sydney, New South Wales, Australia; ⁶University College Hospital, London, United Kingdom; ⁷The Royal Marsden NHS Foundation Trust, London, United Kingdom; ⁸Centre Oscar Lambret, Lille, France; ⁹Institut Gustav Roussy, Villejuif, France; ¹⁰Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom; ¹¹Hopitaux Universitaires de Strasbourg, Strasbourg, France; ¹²Huntsman Cancer Institute, Salt Lake City, UT, USA; ¹³La Timone University Hospital, Marseille, France; ¹⁴Asan Medical Centre, Seoul, Korea (the Republic of); ¹⁵Derriford Hospital, Plymouth, United Kingdom; ¹⁶Centre Leon Berard, Lyon, France

- Paper 044 3042786
SEQCOMPLEX UNRAVELLING OMICS LANDSCAPE AND TARGETING ONCOGENIC PATHWAYS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS - AN INTEGRATED APPROACH
Maud Toulmonde¹; Damien Geneste¹; Stephanie Verbeke¹; Julien Adam²; Fabiola Cecchi³; Banafshe Larijani⁴; Francois Bertucci⁶; Florent Petitprez⁵; Audrey Laroche¹; Carlo Lucchesi¹; Antoine Italiano¹; Todd Hembrough³
¹Institut Bergonié, Bordeaux, France; ²Gustave Roussy, Villejuif, France; ³Nantomics, Rockville, MD, USA; ⁴Fastbase Solutions Ltd, Plentzia, Spain; ⁵UMRS 1138 - Centre de Recherche des Cordeliers, Paris, France; ⁶Institut Paoli Calmettes, Marseille, France
- Paper 045 3010210
RATIONALES FOR TARGETING/CO-TARGETING LEIOMYOSARCOMA PATHWAYS: BIOLOGIC PROFILES IN 712 UTERINE OR SOFT-TISSUE LMS
Inga-Marie Schaefer¹; Elizabeth G. Demicco²; Magdalena Matusiak³; Sebastian Bauer⁴; Frédéric Chibon⁵; Davis Ingram⁶; Jason L. Hornick¹; Wei-Lien Wang⁶; Alexander J. Lazar⁶; Matt van de Rijn³; Jonathan A. Fletcher¹
¹Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ²Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; ³Department of Pathology, Stanford University Medical Center, Stanford, CA, USA; ⁴Department of Medical Oncology, West German Cancer Center, Essen, Germany; ⁵Centre de Recherches en Cancérologie de Toulouse, Toulouse, France; ⁶Departments of Pathology & Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Paper 046 3042897
CHROMATIN STATE TRANSITIONS ASSOCIATED WITH PRC2 FUNCTIONAL LOSS DRIVE A DE-DIFFERENTIATED PHENOTYPE IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Veena Kochat¹; Ayush Raman²; Sharon Landers¹; Christopher Terranova²; Chia-Chin Wu²; Xizeng Mao²; Davis Ingram³; Zachary Mulder¹; Michelle Yeagley¹; Hannah Beird²; Angela Bhalla¹; John Slopis⁴; Ian McCutcheon⁵; Jianhua Zhang²; Phillip Futreal²; Wei-Lien Wang³; Alexander J. Lazar³; Kunal Rai²; Kiela E. Torres¹
¹Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ²Genomic Medicine Department, MD Anderson Cancer Center, Houston, TX, USA; ³Pathology, MD Anderson Cancer Center, Houston, TX, USA; ⁴NeuroOncology Department, MD Anderson Cancer Center, Houston, TX, USA; ⁵NeuroSurgery Department, MD Anderson Cancer Center, Houston, TX, USA
- Paper 047 3042069
TWIST BRIDGES P53 AND MDM2 AND REDUCES THE EFFICACY OF MDM2 INHIBITORS
Sara Piccinin¹; Elena Doriguzzi Breatta¹; Sara Lombardi¹; Mattia Lombardi¹; Flavia Pivetta¹; Michela Armellin¹; Camillo Rosano²; **Roberta Maestro**¹
¹CRO Aviano, Aviano, Italy; ²San Martino National Cancer Institute, Genova, Italy

Discussion – Judith Bovee

3:30 pm - 4:00 pm

Afternoon Coffee Break

Salon de Cavalieri 1 & Gallery

Soft Tissue Sarcoma: Local Therapy

Moderators: **Kenneth Cardona** and **Alessandro Gronchi**

- Paper 048 3042386
LONG-TERM COMPARISON OF LOCAL RECURRENCE AFTER CONVENTIONAL AND INTENSITY-MODULATED RADIATION THERAPY FOR PRIMARY SOFT TISSUE SARCOMAS OF THE EXTREMITY
Joanna C. Yang¹; Michael Folkert²; Aimee M. Crago³; Sam S. Yoon³; Sam Singer³; Kaled Alektiar¹
¹Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA; ³Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Paper 049 3028760
CAN WE CURE PATIENTS WITH ABDOMINAL DESMOPLASTIC SMALL ROUND CELL TUMOR? RESULTS OF A RETROSPECTIVE MULTICENTRIC STUDY ON 100 PATIENTS
Charles Honoré¹; Jean-Baptiste Delhorme²; Elise Nassif³; Gwenael Ferron⁴; Emmanuelle Bompas⁵; Olivier Glehen⁶; Antoine Italiano⁷; Francois Bertucci⁸; Daniel Orbach⁹; Axel Le Cesne³; Jean-Yves Blay¹⁰; Christine Chevreau¹¹; Olivier Mir³
¹Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; ²General and Digestive Surgery, Strasbourg University Hospital, Strasbourg, France; ³Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; ⁴Surgery, Claudius Régaud Institute, Toulouse, France; ⁵Medical Oncology, West Cancer Institute, Nantes, France; ⁶Surgical Oncology, South Lyon University Hospital, Lyon, France; ⁷Medical Oncology, Bergonié Institute, Bordeaux, France; ⁸Medical Oncology, Paoli-Calmettes Institute, Marseilles, France; ⁹SIREDO, Institut Curie, Paris, France; ¹⁰Medical Oncology, Centre Léon Bérard, Lyon, France; ¹¹Medical Oncology, Claudius Régaud Institute, Toulouse, France
- Paper 050 3027816
ENHANCED RECOVERY AFTER SURGERY (ERAS) IN PATIENTS UNDERGOING SURGERY FOR SOFT TISSUE SARCOMA (STS): EARLY RESULTS OF A PROSPECTIVE QUALITY IMPROVEMENT PROTOCOL
Heather Lyu¹; Lily V. Saadat¹; Elizabeth H. Baldini²; Jiping Wang¹; Matthias Stopfkuchen-Evans¹; Ronald Bleday¹; Monica Bertagnolli¹; Chandrajit Raut¹
¹Brigham and Women's Hospital, Boston, MA, USA; ²Dana Farber Cancer Institute, Boston, MA, USA
- Paper 051 3042593
DEVELOPMENT OF A DYNAMIC PROGNOSTIC NOMOGRAM TO PREDICT OVERALL SURVIVAL DURING FOLLOW-UP IN PRIMARY EXTREMITY SOFT TISSUE SARCOMA PATIENTS TREATED WITH SURGERY
Dario Callegaro¹; Rosalba Miceli²; Sylvie Bonvalot³; Peter Ferguson⁴; Dirk Strauss⁵; Antonin Levy⁶; Anthony M. Griffin⁴; Andrew J. Hayes⁵; Silvia Stacchiotti⁷; Cécile Le Péchoux⁶; Myles J. Smith⁵; Marco Fiore¹; Angelo Paolo Dei Tos⁸; Henry Smith⁵; Charles Catton⁹; Paolo Casali¹⁰; Jay Wunder⁴; Alessandro Gronchi¹
¹Surgery, Istituto Nazionale Tumori, Milan, Italy; ²Clinical Epidemiology and Trial Organisation, Istituto Nazionale Tumori, Milan, Italy; ³Surgery, Institut Curie, PSL Research University, Paris, France; ⁴Surgery, Mount Sinai and Princess Margaret Hospitals, University of Toronto, Toronto, ON, Canada; ⁵Surgery, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; ⁶Radiation Oncology, Gustave Roussy Cancer Campus, Paris Sud University, Villejuif, France; ⁷Cancer Medicine, Istituto Nazionale Tumori, Milan, Italy; ⁸Pathology, General Hospital of Treviso, Treviso, Italy; ⁹Radiation Oncology, Mount Sinai and Princess Margaret Hospitals, University of Toronto, Toronto, ON, Canada; ¹⁰Oncology and Hemato-Oncology, Istituto Nazionale Tumori, University of Milan, Milan, Italy

Paper 052

3042509

**THE IMPACT OF UNPLANNED EXCISIONS OF SOFT TISSUE SARCOMAS:
A MULTI-INSTITUTIONAL PROPENSITY SCORE ANALYSIS FROM THE US-SARCOMA
COLLABORATIVE**

Mohammad Zaidi¹; Cecilia G. Ethun¹; Yuan Liu²; Thuy B. Tran³; George Poultsides³;
Valerie P. Grignol⁴; J. H. Howard⁴; Meena Bedi⁵; Harveshp Mogal⁶; Jennifer Tseng⁷; Kevin K. Roggin⁷;
Konstantinos Chouliaras⁸; Konstantinos Votanopoulos⁸; Darren Cullinan⁹; Ryan C. Fields⁹;
Shervin Oskouei¹; Nickolas Reimer¹; David Monson¹; Kenneth Cardona¹
¹Surgery, Emory University, Atlanta, GA, USA; ²Biostatistics and Bioinformatics, Emory University,
Atlanta, GA, USA; ³Surgery, Stanford University, Atlanta, GA, USA; ⁴Surgery, The Ohio State University,
Columbus, OH, USA; ⁵Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA;
⁶Surgery, Medical College of Wisconsin, Milwaukee, WI, USA; ⁷Surgery, University of Chicago Medicine,
Chicago, IL, USA; ⁸Surgery, Wake Forest University, Winston-Salem, NC, USA; ⁹Surgery, Washington
University School of Medicine, St. Louis, MO, USA

Discussion – Rebecca Gladdy

5:30 pm - 6:00 pm

CTOS Business Meeting

Salon del Cavaliere 2,3,4

POSTER PRESENTATIONS LISTING

Poster 001 3027672

MULTICENTER, OPEN-LABEL PHASE II STUDY OF DAILY ORAL REGORAFENIB FOR CHEMOTHERAPY-REFRACTORY, METASTATIC AND LOCALLY ADVANCED ANGIOSARCOMA

Mark Agulnik¹; **Brian Van Tine**²; **Steven Attia**³; **Alfred Rademaker**¹; **Mohammed Milhem**⁴; **Steven Robinson**⁵; **Scott Okuno**⁵
¹Hematology/ Oncology, Northwestern University, Chicago, IL, USA; ²Washington University, St. Louis, MO, USA;
³Mayo, Jacksonville, FL, USA; ⁴University of Iowa, Iowa City, IA, USA; ⁵Mayo, Rochester, MN, USA

Poster 002 3042315

PITFALLS IN ANGIOSARCOMA DIAGNOSIS: LESSONS LEARNED FROM CENTRAL REVIEW OF 657 DUTCH CASES

Marije Weidema¹; **Melissa Hillebrandt-Roeffen**¹; **Ingrid Desar**¹; **Yvonne Versleijen-Jonkers**¹; **Winette van der Graaf**¹; **Uta Flucke**²
¹Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands; ²Pathology, Radboud University Medical Center, Nijmegen, Netherlands

Poster 003 3042833

LOCALIZED RADIATION-ASSOCIATED ANGIOSARCOMA OF THE BREAST: A MONO-INSTITUTIONAL CASE SERIES

Elena Palassini¹; **Silvia Stacchiotti**¹; **Claudia Sangalli**¹; **Alessandro Gronchi**¹; **Carlo Morosi**¹; **Paola Collini**¹; **Salvatore Provenzano**¹; **Rossella Bertulli**¹; **Giacomo Giulio Baldi**¹; **Marta Barisella**¹; **Massimiliano Gennaro**¹; **Paolo Casali**¹
¹IRCCS Fondazione Istituto Nazionale dei Tumori, Milano, Italy

Poster 004 3000082

TRAMETINIB INDUCES RESPONSE IN REFRACTORY HRAS G13D-MUTATED ANGIOSARCOMA OF SCALP

Benjamin Powers¹; **Stacie Fogelberg**¹; **Tiffany Verhulst**¹; **Andrew Huskey**²; **Kaylee Drenker**²
¹Medical Oncology, U of Kansas Cancer Center, Overland Park, KS, USA; ²Pharmacology, U of Kansas Cancer Center, Kansas City, KS, USA

Poster 005 3037976

THE ANGIOSARCOMA PROJECT: GENERATING THE GENOMIC LANDSCAPE OF A RARE SARCOMA THROUGH A NATIONWIDE PATIENT-DRIVEN INITIATIVE

Michael Dunphy¹; **Esha Jain**¹; **Elana Anastasio**¹; **Mary McGillicuddy**¹; **Rachel Stoddard**¹; **Beena Thomas**¹; **Sara Balch**¹; **Kristin Anderka**²; **Katie Larkin**²; **Niall Lennon**²; **Yen-Lin E. Chen**³; **Andrew Zimmer**⁴; **Esme O. Baker**⁴; **Simone Maiwald**⁴; **Jen Lapan**⁴; **Jason L. Hornick**⁵; **Chandrajit Raut**⁵; **George Demetri**⁶; **Eric S. Lander**⁷; **Todd Golub**¹; **Nikhil Wagle**⁶; **Corrie Painter**¹
¹Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; ²Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA; ³Massachusetts General Hospital, Boston, MA, USA; ⁴Data Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA; ⁵Brigham and Women's Hospital, Boston, MA, USA; ⁶Dana-Farber Cancer Institute, Cambridge, MA, USA; ⁷Broad Institute of MIT and Harvard, Cambridge, MA, USA

Poster 006 3042503

A RETROSPECTIVE REVIEW OF PATIENTS WITH ANGIOSARCOMA TREATED IN BRITISH COLUMBIA

Alannah Smrke¹; **Jeremy Hamm**¹; **Anand Karvat**¹; **Christine Simmons**¹; **Amirtha Srikanthan**¹
¹BC Cancer, Vancouver, BC, Canada

Poster 007 3042537

DETECTION OF ENDOGLIN-EXPRESSING CTCS IN PATIENTS ENROLLED IN AN ADAPTIVE ENRICHMENT PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS)

Ravi Vinod²; Andrew Brohl³; Robin Jones⁴; Sant P. Chawla⁵; Kristen Ganjoo¹⁴; Steven Attia¹⁰; Atrayee Basu-Mallick⁹; Darren Davis⁶; Mario Cervantes⁶; Wen Liu⁶; Lilian Liu¹; Charles Theuer¹; Steven Robinson¹¹; Nicolas Penel¹²; Silvia Stacchiotti¹³; William D. Tap⁷; Robert Makj⁸

¹TRACON Pharma, San Diego, CA, USA; ²University of Texas M. D. Anderson Cancer Center, Houston, TX, USA; ³Moffitt Cancer Center, Tampa, FL, USA; ⁴Royal Marsden/ Institute of Cancer Research, London, United Kingdom; ⁵Sarcoma Oncology Center, Santa Monica, CA, USA; ⁶ApoCell, Houston, TX, USA; ⁷Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁸Northwell Health, Lake Success, NY, USA; ⁹Thomas Jefferson University, Philadelphia, PA, USA; ¹⁰Mayo Clinic, Jacksonville, FL, USA; ¹¹Mayo Clinic, Rochester, MN, USA; ¹²Centre Oscar Lambret, Lille, France; ¹³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ¹⁴Stanford University, Stanford, CA, USA

Poster 008 3042562

NEOADJUVANT CHEMOTHERAPY ASSOCIATED WITH ENHANCED LOCAL CONTROL IN RADIATION-INDUCED ANGIOSARCOMA OF BREAST AND CHEST

Audrey Michot¹; Marie Karanian²; Maryck Lae¹¹; Romuald Wernert³; Marie-Pierre Sunyach⁴; Dimitri Tzanis⁵; Jean-Marie Guilloit⁶; Maria Rios⁷; Antoine Giraud⁸; François Le Loarer⁹; Jean-Yves Blay¹⁰; Eberhard Stoeckle¹

¹Surgery, Institut Bergonié, Bordeaux, France; ²Pathology, Leon Berard, Lyon, France; ³Surgery, Institut de Cancerologie de l'Ouest, Angers, France; ⁴Radiotherapy, Centre Leon Berard, Lyon, France; ⁵Surgery, Institut Curie, Paris, France; ⁶Surgery, Centre Francois Baclesse, Caen, France; ⁷Medical Oncology, Institut de Cancerologie de Lorraine, Nancy, France; ⁸Epidemiology and Clinical Research Unit, Institut Bergonié, Bordeaux, France; ⁹Pathology, Institut Bergonié, Bordeaux, France; ¹⁰Medical Oncology, Centre Leon Berard, Lyon, France; ¹¹Pathology, Institut Curie, Paris, France

Poster 009 3015887

ASSOCIATION OF BETA-BLOCKER USE WITH CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED ANGIOSARCOMA

Andrew Johns³; James L. Chen¹; David Liebner¹; Lai Wei²; Gabriel Tinoco¹

¹Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA; ²Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, USA; ³Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA

Poster 010 3016619

ACTIVITY AND SAFETY OF CRIZOTINIB IN PATIENTS WITH ADVANCED, METASTATIC ALVEOLAR SOFT PART SARCOMA (ASPS) WITH REARRANGEMENT OF TFE³EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC) PHASE 2 TRIAL 90101 "CREATE"

Patrick Schöffski¹; Agnieszka Wozniak²; Bernd Kasper⁴; Steinar Aamdal³; Michael Leahy⁶; Piotr Rutkowski⁷; Sebastian Bauer¹²; Hans Gelderblom⁸; Antoine Italiano⁵; Lars Lindner⁹; Ivo Hennig¹⁵; Sandra Strauss¹⁰; Branko Zakotnik¹⁴; Alan Anthoney¹³; Silvia Stacchiotti¹¹

¹General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; ²Department of Oncology, KU Leuven, Laboratory of Experimental Oncology, Leuven, Belgium; ³Department of Oncology, Oslo University Hospital, Oslo, Norway; ⁴Mannheim University Medical Center, Mannheim, Germany; ⁵Institut Bergonié, Bordeaux, France; ⁶The Christie NHS Foundation Trust, Manchester, United Kingdom; ⁷Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland; ⁸Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands; ⁹Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; ¹⁰Department of Oncology, University College London Hospitals NHS Trust, London, United Kingdom; ¹¹Sarcoma Unit, Cancer Medical Department, Fondazione IRCC Istituto Nazionale Tumori, Milan, Italy; ¹²Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Germany; ¹³Leeds Institute of Cancer & Pathology, University of Leeds, Leeds, United Kingdom; ¹⁴Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; ¹⁵City Campus, Dept of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

Poster 011 3042589

TREATMENT PATTERNS OF ALVEOLAR SOFT PART SARCOMA PATIENTS AND RESPONSE TO MULTIPLE EXPERIMENTAL THERAPIES

Roman Groisberg¹; Jason Roszik⁶; Shiraj Sen⁴; Anthony P. Conley²; Alexander J. Lazar²; David S. Hong³; Aung Naing³; Cynthia E. Herzog⁵; Neeta Somaiah²; Maria A. Zarzour²; Shreyaskumar Patel²; Vivek Subbiah³

¹Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; ²Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ³Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX, USA; ⁴Sarah Cannon Research Institute, Denver, CO, USA; ⁵Pediatrics, MD Anderson Cancer Center, Houston, TX, USA; ⁶Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

Poster 012 3042597

CLINICAL CHARACTERISTICS OF ALVEOLAR SOFT PART SARCOMA PATIENTS WITH BRAIN METASTASIS

Tonita Bates¹; Akash Mitra²; John A. Livingston¹; Alexander J. Lazar³; Andrew J. Bishop⁴; B. Ashleigh Guadagnolo⁴; Ravin Ratan¹; Vinod Ravi¹; Neeta Somaiah¹; Maria A. Zarzour¹; Daniela A. Camacopa¹; Dejka M. Araujo¹; Robert Benjamin¹; Shreyaskumar Patel¹; Anthony P. Conley¹

¹Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; ³Pathology, MD Anderson Cancer Center, Houston, TX, USA; ⁴Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA

Poster 013 3019420

EXPANDING THE HISTONE MUTATION LANDSCAPE IN SARCOMA

Benjamin A. Nacev²; Sandra D'Angelo²; Mark A. Dickson²; Ping Chi²; Cristina Antonsecu²; Sam Singer²; C. David Allis¹; William D. Tap²

¹The Rockefeller University, New York, NY, USA; ²Memorial Sloan Kettering Cancer Center, New York, NY, USA

Poster 014 3042534

DEVELOPMENT OF A PLASMA MICRORNA BIOMARKER FOR PEDIATRIC OSTEOSARCOMA

Wendy Allen-Rhoades¹; Meng Liu¹; Lyazat Kurenbekova¹; Chad Creighton²; Jason T. Yustein¹

¹Pediatrics, Baylor College of Medicine, Houston, TX, USA; ²Medicine, Baylor College of Medicine, Houston, TX, USA

Poster 015 3042930

SHIFTING THE PARADIGM IN PRECLINICAL CANCER MODELING: A MOUSE-DOG-HUMAN PERSONALIZED MEDICINE PIPELINE TO IDENTIFY NOVEL THERAPEUTICS FOR OSTEOSARCOMA

Sneha Rao¹; Erdem Altunel²; Wayne Glover²; Suzanne Bartholf DeWitt³; Laura Selmic⁴; Cindy Eward⁵; Julia Visgauss³; Brian Brigman³; William Eward³; David Hsu²; Jason Somarelli²

¹School of Medicine, Duke University, Durham, NC, USA; ²Medicine, Duke University, Durham, NC, USA; ³Orthopaedic Surgery, Duke University, Durham, NC, USA; ⁴Veterinary Medicine, University of Illinois at Urbana-Champaign, Champaign, IL, USA; ⁵Triangle Veterinary Referral Hospital, Holly Springs, NC, USA

Poster 016 3025705

XENOSARC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA (STS) – AND UPDATE ON A PRECLINICAL PLATFORM FOR EARLY DRUG TESTING

Agnieszka Wozniak¹; Jasmien Cornillie¹; Yemarshet K. Gebreyohannes¹; Yannick Wang¹; Jasmien Wellens¹; Ulla Vanleeuw¹; Daphne Hompes²; Marguerite Stas²; Friedl Sinnaeve³; Hazem Wafa²; Maria Debiec-Rychter⁴; Raf Sciot⁵; Patrick Schöffski⁶

¹Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium; ²Department of Surgical Oncology, UZ Leuven, Leuven, Belgium; ³Department of Orthopedic Surgery, UZ Leuven, Leuven, Belgium; ⁴Department of Human Genetics, KU Leuven, Leuven, Belgium; ⁵Department of Pathology, UZ Leuven, Leuven, Belgium; ⁶Department of General Medical Oncology, UZ Leuven, Leuven, Belgium

Poster 017 3029268

BMP-2 SIGNALLING INFLUENCES TUMOUR BIOLOGY IN PRE-CLINICAL MODELS OF OSTEOSARCOMA

Joseph K. Kendal¹; Arvind K. Singla²; Asmaa Affan³; Kurt Hildebrand³; Doha Itani⁴; Michael J. Monument¹

¹Department of Surgery, Section of Orthopaedic Surgery, University of Calgary, Calgary, AB, Canada; ²Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; ³McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, AB, Canada; ⁴Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada

Poster 018 3036616

PHENOTYPIC CHARACTERIZATION OF IGFR2R KNOCKOUT IN HUMAN OSTEOSARCOMA CELLS

Edmond O'Donnell¹; Brian Batko¹; Yoav Zvi¹; Jonathan Gill²; Micheal Roth²; Richard Gorlick²; Rui Yang¹; Bang Hoang¹; David Geller¹

¹Orthopaedic Oncology, Albert Einstein College of Medicine, Bronx, NY, USA; ²Department of Pediatrics, MD Anderson, Houston, TX, USA

Poster 019 3041727

THE ODC1/POLYAMINES/C-MYC AXIS PROMOTES OSTEOSARCOMA TUMORGENESIS BY REGULATING GLUTAMINOLYSIS

Hongsheng Wang¹; Ling Ren²; Shan Huang²; Zhengdong Cai¹; **Yingqi Hua¹**; Amy K. LeBlanc²

¹Shanghai General Hospital, Shanghai, China; ²National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Poster 020 3042199

THE TYPE OF NR4A3 FUSION PARTNER DICTATES AN AXON GUIDANCE SWITCH IN EXTRASKELETAL MYXOID CHONDROSARCOMAS

Monica Brenca¹; Silvia Stacchiotti²; Kelly Fassetta¹; Maurizio Polano¹; Dominga Racanelli¹; Milijana Janjusevic¹; Marta Sbaraglia³; Sabrina Rossi³; Silvia Brich²; Gian Paolo Dagrada²; Chiara Colombo²; Chiara Castelli²; Alessandro Gronchi²; Annalisa Astolfi⁵; Valentina Indio⁵; Maria Abbondanza Pantaleo⁵; Piero Picci⁴; Paolo Casali²; Angelo P. Dei Tos³; Silvana Pilotti²; Roberta Maestro¹

¹CRO National Cancer Institute, Aviano, Italy; ²National Cancer Institute of Milan, Milano, Italy; ³Treviso General Hospital, Treviso, Treviso, Italy; ⁴Istituto Ortopedico Rizzoli, Bologna, Italy; ⁵University of Bologna, Bologna, Italy

Poster 021 3042292

THE MECHANISMS OF ZOLEDRONIC ACID-INDUCED AUTOPHAGY ON OSTEOSARCOMA CELLS

Chang-Bae Kong¹; EunHo Kim¹

¹Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Korea (the Republic of)

Poster 022 3042653

ATRX MUTATIONS INCREASE TUMORIGENICITY IN OSTEOSARCOMA

Suzanne Bartholf DeWitt¹; Jason Somarelli²; So Young Kim²; Vidya Seshadri²; Robert Floyd²; David Kerr²; Randall T. Kreulen²; Willa Chen²; Gireesh B. Reddy²; Sneha Rao²; Rachael Thomas³; Brian Brigman²; Matthew Breen³; Benjamin Alman²; William Eward²

¹Pathology, Duke University, Durham, NC, USA; ²Duke University, Durham, NC, USA; ³NC State University, College of Veterinary Medicine, Raleigh, NC, USA

Poster 023 3042613

DOXORUBICIN, GEMCITABINE, IFOSFAMIDE, AND THE EZH2 INHIBITOR EPZ-011989 IN EPITHELIOID SARCOMA: A COMPARISON OF DIFFERENT REGIMENS IN A PATIENT-DERIVED XENOGRAFT

Nadia Zaffaroni¹; Anna Maria Frezza¹; Valentina Zuco¹; Alessandro Gronchi¹; Chiara Colombo¹; Sandro Pasquali¹; Paolo Casali¹; Marta Barisella¹; Angelo Paolo Dei Tos²; Paola Collini¹; Maria Abbondanza Pantaleo³; Annalisa Astolfi³; Valentina Indio³; Monica Tortoreto¹; Silvia Stacchiotti¹

¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; ²General Hospital of Treviso, Treviso, Italy; ³Interdepartmental Centre of Cancer Research "Giorgio Prodi", University of Bologna, Bologna, Italy

Poster 024 3042633

REACTIVATION OF WILD TYPE P53 BY MDM2 INHIBITION IN SYNOVIAL SARCOMAS

Jennifer Wilson¹; Toshihiko Nishisho³; Aimee Laporte³; Neal M. Poulin³; Torsten O. Nielsen³; Kevin B. Jones²; **Bertha Brodin¹**

¹Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; ²Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; ³Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada

Poster 025 3026307

MACHINE LEARNING ANALYSIS OF GENE EXPRESSION DATA REVEALS NOVEL DIAGNOSTIC AND PROGNOSTIC BIOMARKERS AND IDENTIFIES THERAPEUTIC TARGETS FOR SOFT TISSUE SARCOMAS

David G. van IJzendoorn¹; Karoly Szuhai³; Inge Briaire-de Bruijn¹; Marie Kostine¹; Marieke Kuijjer²; Judith V. Bovee¹
¹Department of Pathology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands; ²Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; ³Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands

Poster 026 3042679

THE DEVELOPMENT AND CHARACTERIZATION OF A HUMANIZED XENOGRFT MURINE MODEL FOR OSTEOSARCOMA

Brian Batko¹; Yoav Zvi¹; Edmond O'Donnell¹; Kenji Sato¹; Xiu-Quan Du¹; Micheal Roth²; Jonathan Gill²; Richard Gorlick²; Alexander J. Lazar³; Rui Yang¹; Bang Hoang¹; David Geller¹
¹Department of Orthopedic Surgery, Montefiore Medical Center, Bronx, NY, USA; ²Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA; ³Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Poster 027 3042837

COMBINATION OF CISPLATIN AND HIV PROTEASE INHIBITOR NELFINAVIR SHOWS SYNERGISTIC EFFECTS AGAINST THE GROWTH OF HUMAN OSTEOSARCOMA CELLS

Michelina de la Maza¹; Aparna R. Sertil²; Anthony Diaz²; Anuj Shah²; Dustin Daniel²; Saravana Kumar²; Alexa Trensche²
¹CCBD, Phoenix Childrens Hospital, Phoenix, AZ, USA; ²University of Arizona, Phoenix, AZ, USA

Poster 028 3042736

PROGNOSTIC IMPACT OF THE FGFR EXPRESSION IN LIPOSARCOMA ROLE OF FGFR AND MDM2 DUAL TARGETING

Bérengère Dadone-Montaudie¹; Audrey Laroche-Clary²; Aline Mongis¹; Vanessa Chaire²; Ilaria Di Mauro⁵; Renaud Schiappa³; Emmanuel Chamorey³; Jean-François Michiels⁴; Florence Pedetour⁶; Antoine Italiano⁶; **Laurence Bianchini**¹
¹Laboratory of solid tumor genetics, Université Côte d'Azur CNRS IRCAN, Nice, France; ²INSERM U1218 Institut Bergonié, Université de Bordeaux, Bordeaux, France; ³Biostatistics, Centre Antoine Lacassagne, Nice, France; ⁴Pathology, Nice University Hospital, Nice, France; ⁵Laboratory of solid tumor genetics, Nice University Hospital IRCAN, Nice, France; ⁶Department of medical oncology INSERM 1218; Institut Bergonié, Bordeaux, France

Poster 029 3042825

DISCOVERY SCREEN OF SMALL MOLECULE INHIBITORS OF THE PAX3-FOXO1 FUSION PROTEIN NOMINATES THERAPEUTIC COMBINATION STRATEGIES

John Shern¹; Berkley Gryder¹; Robert Hawley¹; Carly Sayers¹; Girma Woldenmichael¹; Javed Khan¹
¹National Cancer Institute, Bethesda, MD, USA

Poster 030 3042839

HIGH-THROUGHPUT DRUG SCREENING OF PATIENT-DERIVED SARCOMA TUMOR ORGANIDS FOR PERSONALIZED THERAPY

Jane Yanagawa²; Noah Federman³; Matthew Mapua¹; Jenny Hong¹; Benjamin J. DiPardo⁴; James S. Tomlinson⁵; Arun S. Singh¹; Anusha Kalbas⁶; Francis Hornicek⁷; Sarah Dry⁸; Scott Nelson⁸; Fritz C. Eilber⁶; Nicholas N. Bernthal⁹; Robert Damoiseaux¹⁰; **Alice Soragni**¹
¹Division of Hematology-Oncology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; ²Division of Thoracic Surgery, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; ³Department of Pediatrics and Department of Orthopaedics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; ⁴Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; ⁵Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, CA, USA; ⁶Department of Radiation Oncology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; ⁷Department of Orthopaedics, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; ⁸Department of Pathology, Department of Medicine, UCLA, Los Angeles, CA, USA; ⁹Division of Orthopaedic Oncology, Department of Orthopaedics, UCLA, Los Angeles, CA, USA; ¹⁰Department of Molecular and Medicinal Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA

Poster 031 3042840

TARGETING ACTIVATING TRANSCRIPTION FACTOR 6 ALPHA (ATF6 A): A NOVEL APPROACH FOR THE TREATMENT OF PEDIATRIC OSTEOSARCOMA

Aparna R. Sertil¹; Pooja Hingorani²; Justin Montoya³; Daniel Wai³; David Azorsa³

¹Basic Medical Sciences, University of Arizona, Phoenix, AZ, USA; ²Hematology and Oncology, Phoenix Childrens Hospital, Phoenix, AZ, USA; ³Child Health, University of Arizona, Phoenix, AZ, USA

Poster 032 3042902

ELUCIDATING THE ROLE OF THE EPHRIN TYPE-A RECEPTOR (EPHA2) AS THERAPEUTIC TARGET IN OSTEOSARCOMA USING PATIENT-DERIVED TUMOR XENOGRAPTS

Nino Rainusso¹; Meng Liu¹; Jason T. Yustein¹

¹Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA

Poster 033 3042984

PATIENT-DERIVED SARCOMA MODELS - FIRST RESULTS FROM THE SARQMA STUDY

Manuela Gaebler¹; Alessandra Silvestri²; Peter Reichardt¹; Guido Gambarà³; Johannes Haybaeck⁴; Philipp Stroebel⁵; Maya Niethard⁶; Markus Templin⁷; Christian R. Regenbrecht²

¹Department of Oncology and Palliative Care, Helios Klinikum Berlin-Buch GmbH, Berlin, Germany; ²CPO - Cellular Phenomics & Oncology, Berlin, Germany; ³German Consortium for Translational Research (DKTK), Deutsches Krebsforschungszentrum (DKFZ), Berlin, Germany; ⁴Department for Pathology, University Hospital Magdeburg, Magdeburg, Germany; ⁵Department for Pathology, University Hospital Göttingen, Göttingen, Germany; ⁶Department for Tumor Orthopedics, Helios Klinikum Berlin-Buch GmbH, Berlin, Germany; ⁷Department for Proteom Analyses, NMI, Reutlingen, Germany

Poster 034 3042827

CLEAR CELL SARCOMA OF THE KIDNEY SHOWS ELEVATED LEVELS OF THE ONCOMETABOLITE AND EPIGENETIC MODIFIER L-2-HYDROXYGLUTARATE

Kelsi R. Willis¹; Rebecca R. Collins¹; Richard L. Boriack²; **Dinesh Rakheja¹**

¹Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA; ²Pathology and Laboratory Medicine, Children's Health, Dallas, TX, USA

Poster 035 3025487

ANTI-TUMOR EFFECTS OF TAS-115 ON MURINE OSTEOSARCOMA CELL LINE(LM8) WITH HIGH METASTATIC POTENTIAL TO THE LUNG

Naohiro Yasuda¹; Sho Nakai¹; Takaaki Nakai²; Yoshinori Imura³; Hironari Tamiya³; Takaaki Tanaka³; Hidetatsu Outani¹; Satoshi Takenaka¹; Kenichiro Hamada¹; Akira Myouji¹; Hideki Yoshikawa¹; Norifumi Naka³

¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Suita, Japan; ²Orthopaedic Surgery, Kawachi General Hospital, Osaka, Japan; ³Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka, Japan

Poster 036 3026960

MESENCHYMAL STROMAL CELLS ENHANCE METASTASIS FORMATION IN OSTEOSARCOMA

Sofia Avnet¹; Silvia Lemma¹; Giulia Grisendi²; Massimo Dominici²; Dominique Heymann³; Nicola Baldini¹

¹Rizzoli Orthopaedic Institute, Bologna, Italy; ²Division of Oncology, Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy; ³Institut de Cancérologie de l'Ouest, University of Nantes, Nantes, France

Poster 037 3027348

TNIK IS A NOVEL MOLECULAR TARGET FOR OSTEOSARCOMA TREATMENT AND CONTROLS OSTEOSARCOMA CELL FATE

Toru Hirozane¹; Mari Masuda²; Naoko Goto²; Teppei Sugano³; Naofumi Asano¹; Eisuke Kobayashi⁴; Akira Kawai⁴; Keisuke Horiuchi⁵; Morio Matsumoto¹; Masaya Nakamura¹; Masaaki Sawa⁶; Hideo Morioka⁷; Robert Nakayama¹; Tesshi Yamada²

¹Department of Orthopedic Surgery, Keio University School of Medicine, Tokyo, Japan; ²Lab of Collaborative Research, National Cancer Center Research Institute, Tokyo, Japan; ³Department of Pulmonary Medicine and Oncology, Nippon Medical School Hospital, Tokyo, Japan; ⁴Division of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan; ⁵Department of Orthopedic Surgery, National Defense Medical College, Tokyo, Japan; ⁶Carna Biosciences, Inc., Kobe, Japan; ⁷Department of Orthopedic Surgery, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Poster 038 3028039

IRE1 α -XBP1 INHIBITORS EXERTS ANTITUMOR ACTIVITY IN OSTEOSARCOMAS

Taisei Kurihara¹; Yoshiyuki Suehara¹; Takuo Hayashi¹; Keisuke Akaike¹; Taketo Okubo¹; Youngji Kim¹; Kazuo Kaneko¹; Tsuyoshi Saito¹

¹Juntendo University, Tokyo, Japan

Poster 039 3036627

ESTABLISHMENT OF PATIENT-DERIVED XENOGRAFT MODELS OF MUSCULOSKELETAL SARCOMA SERIALLY EVALUATED WITH COMPREHENSIVE GENE EXPRESSION PROFILING

Michiyuki Hakozaki¹; Yuu Dobashi²; Hitoshi Yamada¹; Takahiro Tajino³; Yoichi Kaneuchi¹; Junichi Imai²; Kiyooki Katahira²; Shin-ichi Konno¹; Shinya Watanabe²

¹Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan;

²Medical-Industrial Translational Research Center, Fukushima Global Medical Science Center, Fukushima Medical

University, Fukushima, Japan; ³Division of Orthopaedic Surgery, Southern Tohoku Fukushima Hospital, Fukushima, Japan

Poster 040 3037703

IMAGING THE INTERACTION OF OSTEOSARCOMA CELLS WITH HOST STROMAL CELLS AND TUMOR SCAFFOLD COLLAGEN IN THE TUMOR MICROENVIRONMENT

Yasunori Tome¹; Tasuku Kiyuna¹; Hiroki Maehara¹; Hiromichi Oshiro¹; Robert M. Hoffman²; Fuminori Kanaya¹

¹Department of Orthopedic Surgery, University of the Ryukyus, Nishihara, Okinawa, Japan; ²Department of Surgery,

University of California, San Diego, San Diego, CA, USA

Poster 041 3037788

ACIDIC MICROENVIRONMENTS IN SOFT-TISSUE SARCOMA PROMOTES FOXM1 EXPRESSION AND TUMORIGENESIS

Ryo Miyagi¹; Toshihiko Nishisho¹; Shunichi Toki¹; Koichi Saiyo¹

¹Orthopedic, Institute of Biomedical Sciences Tokushima University Graduate School, Tokushima, Japan

Poster 042 3037829

CYTOTOXIC AND ANTI-METASTATIC EFFECTS OF MYCOPHENOLATE MOFETIL IN OSTEOSARCOMA: DRUG REPURPOSING FROM PROTEOMIC DATA

Jeerawan Klangjorhor¹; Parunya Chaiyawat¹; Pimpisa Teeyakasem¹; Jongkolnee Settakorn²;

Kriengsak Lirdprapamongkol³; Sarawoot Yama⁴; Jisnusun Svasti³; Dumnoensun Pruksakorn¹

¹Orthopedics, Chiang Mai University, Chiang Mai, Thailand; ²Pathology, Chiang Mai University, Chiang Mai, Thailand;

³Chulabhorn Research Institute, Bangkok, Thailand; ⁴Laboratory Animal Center, Chiang Mai, Thailand

Poster 043 3040744

COMPLEX AUTOCRINE AND PARACRINE INTERACTIONS IN A SERIES OF SINGLE-BACKGROUND MURINE FIBROSARCOMA CELL LINES

Jiri Hatina¹; Michaela Kripnerova¹; Hamendra Singh Parmar¹; Zbynek Houdek¹; Pavel Dvorak¹; Katerina Houfkova¹; Martin Pesta¹; Jitka Kuncova²; Jiri Sana³; Lenka Radova³; Ondrej Slaby³

¹Institute of Biology, Charles University Faculty of Medicine in Pilsen, Plzen, Czechia; ²Institut of Physiology, Charles

University Faculty of Medicine in Pilsen, Plzen, Czechia; ³Molecular Oncology II - Solid Cancer, Central European

Institute of Technology, Brno, Czechia

Poster 044 3042297

CXCR4 INHIBITORS AS CHEMOSENSITIZER IN BONE MARROW-DERIVED MESENCHYMAL STEM CELL-MEDIATED OSTEOSARCOMA AND SYNOVIAL SARCOMA CELL APOPTOSIS AND MIGRATION

Serena Pollino¹; Laura Pazzaglia¹; Elisa Bientinesi¹; Barbara Dozza²; Enrico Iucarelli²; Maria Serena Benassi¹; Emanuela Palmerini³

¹Experimental Oncology Lab, Ortopedico Rizzoli, Bologna, Italy; ²Osteoarticular Regeneration Lab, Ortopedico Rizzoli,

Bologna, Italy; ³Chemotherapy Unit, Ortopedico Rizzoli, Bologna, Italy

Poster 045 3042289

THE PHOSPHATASE PTPRG CONTROLS FGFR1 ACTIVITY AND INFLUENCES SENSITIVITY TO FGFR KINASE INHIBITORS

Michal Kostas¹; Ellen M. Haugsten¹; Yan Zhen²; Vigdis Sørensen²; Patrycja Szybowska²; Elisa Fiorito¹; Susanne Lorenz¹; Antoni Wiedlocha²; **Jørgen Wesche**¹

¹Department of Tumor Biology, The Norwegian Radium Hospital, Oslo, Norway; ²Department of Molecular Cell Biology, The Norwegian Radium Hospital, Oslo, Norway

Poster 046 3042323

EUTHYROID HYPOTHYROIDISM [EH] MODULATED BY EXOGENOUS L-TRIIODOTHYRONINE MAY EXTEND SURVIVAL IN ADVANCED SARCOMA-AN UPDATED FOLLOW-UP

Rony Weitzen¹; Aleck Hercbergs²

¹Oncology, Sheba MC-Israel, Ramat Gan, Israel; ²Oncology, Cleveland Clinic, Cleveland, OH, USA

Poster 047 3042408

NOVEL BIOINFORMATICS APPROACH FOR SARCOMA PROTEOGENOMICS; MUTATED NUCLEOTIDES AND AMINO-ACIDS GENERATOR (MUNAGE)

Emi Hattori¹; Kumiko Shiozawa¹; **Tadashi Kondo**¹

¹Division of Rare Cancer Research, National Cancer Center Research Institute, Tokyo, Tokyo, Japan

Poster 048 3042413

EFFECT OF ANLOTINIB, A NOVEL SMALL MOLECULAR TYROSINE KINASE INHIBITOR, ON GROWTH, METASTASIS AND ANGIOGENESIS IN OSTEOSARCOMA

Yingqi Hua¹; Gangyang Wang¹; Mengxiong Sun¹; Tao Zhang¹; Wei Sun¹; Hongsheng Wang¹; Fei Yin¹; Zhuoying Wang¹; Jing Xu¹; Zhenfeng Duan²; Zhengdong Cai¹

¹Shanghai General Hospital, Shanghai, China; ²David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Poster 049 3042579

EFFECT OF CHEMOTHERAPY ON CANCER STEM CELLS AND TUMOR-ASSOCIATED MACROPHAGES IN A PROSPECTIVE STUDY OF PREOPERATIVE CHEMOTHERAPY IN SOFT TISSUE SARCOMA

Keith M. Skubitz¹; Jon Wilson⁴; Edward Cheng³; Bruce Lindgren²; Amy Skubitz⁵

¹Medicine, University of Minnesota, Edina, MN, USA; ²School of Public Health, University of Minnesota, Minneapolis, MN, USA; ³Orthopaedic Surgery, University of Minnesota, Minneapolis, MN, USA; ⁴Arkana Laboratoires, Little Rock, AR, USA; ⁵Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA

Poster 050 3042624

DRUG SENSITIVITY TESTING ON PATIENT-DERIVED SARCOMA CELLS PREDICTS PATIENT RESPONSE TO TREATMENT AND IDENTIFIES C-SARC INHIBITORS AS ACTIVE DRUGS FOR TRANSLOCATION SARCOMAS

Bertha Brodin¹; Antroula Papakonstantinou²; Elisabet Lidbrink²; Otte Brosjö³; Asle Hesla³; Henrik Bauer³; Swapnil Potdar⁴; Olli Kallioniemi⁵; Christina Linder-Stragliotto²

¹Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; ²Breast and Sarcoma, Karolinska University Hospital, Stockholm, Sweden; ³Tumor Orthopedics, Karolinska University Hospital, Stockholm, Sweden; ⁴Institute for Molecular Medicine Finland, Helsinki, Finland; ⁵Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden

Poster 051 3042658

THE EFFECT OF BUPIVACAINE AND LIDOCAINE ON OSTEOSARCOMA CELLS

Troy G. Shields¹; Rosalia de Necochea-Campion²; Xiangpeng Yuan³; Nadine L. Williams¹; Joseph Elsisy¹; Ata Janjuan²; Saied Mirshahidi²; Lee M. Zuckerman¹

¹Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA; ²Biospecimen Laboratory, Loma Linda University Medical Center, Loma Linda, CA, USA; ³Otolaryngology, Loma Linda University Medical Center, Loma Linda, CA, USA

Poster 052 3042684

THE PROTEIN EXPRESSION OF NF1; P16INK4A, PTEN AND THEIR INVOLVED SIGNAL PATHWAY FACTORS IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA

Peng Zhang¹; Guoqing Liu¹; Jinyan Liu¹; Feifei Feng²; Weitao Yao¹

¹Bone and soft tissue sarcoma, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China; ²College of Public Health of Zhengzhou University, Zhengzhou, China

Poster 053 3042693

TWO NOVEL HUMAN MYXOFIBROSARCOMA CELL LINES REPRESENT A CELLULAR MODEL FOR TUMOR HETEROGENEITY

Birgit Lohberger¹; Nicole Stuendl¹; Andreas Leithner¹; Beate Rinner²; Stefan Sauer³; Karl Kashofer³; Bernadette Liegl-Atzwanger³

¹Department of Orthopedics and Trauma, Medical University Graz, Graz, Austria; ²Department of Biomedical Research, Medical University Graz, Graz, Austria; ³Institute of Pathology, Medical University Graz, Graz, Austria

Poster 054 3042695

APOPTOTIC INDUCTION AND G1 CELL CYCLE ARREST OF MULTIDRUG RESISTANT SARCOMA CELL LINES BY THE HISTONE DEACETYLASE INHIBITORS VERINOSTAT AND PANOBINOSTAT

Birgit Lohberger¹; Nicole Stuendl¹; Heike Kaltenecker¹; Andreas Leithner¹; Eva Bernhart²

¹Department of Orthopedics and Trauma, Medical University Graz, Graz, Austria; ²Institute of Molecular Biology and Biochemistry, Medical University Graz, Graz, Austria

Poster 055 3042709

THERAPEUTIC VULNERABILITIES IN UNDIFFERENTIATED SARCOMAS

Susanne Grunewald¹; Thomas Mühlenberg¹; Johanna Falkenhorst¹; Miriam Christoff¹; Julia Ketzer¹; Stefanie Bertram²; Thomas Herold²; Jürgen Treckmann³; Lars-Eric Podleska³; Elizabeth Demicco⁴; Priya Chudasama⁵; Stefan Fröhling⁵; Sebastian Bauer¹

¹Departments of Medical Oncology, University Hospital Essen, West German Cancer Center, Sarcoma Center, Essen, NRW, Germany; ²Department of Pathology, University Hospital Essen, West German Cancer Center, Sarcoma Center, Essen, Germany; ³Department of General-, Visceral- and Transplantation Surgery, University Hospital Essen, Sarcoma Center, Sarcoma Surgery Division, Essen, Germany; ⁴Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; ⁵Division of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Essen, Germany

Poster 056 3042722

SCREENING OF SYNERGISTIC REAGENT WITH PAZOPANIB AGAINST OSTEOSARCOMA USING COMPOUND LIBRARY.

Yuki Yada²; Kunihiro Asanuma¹; Koji Kita¹; Tomohito Hagi¹; Tomoki Nakamura¹; Akihiro Sudo¹

¹Mie University, Yokkaichi, Mie, Japan; ²Mie Prefectural general Medical Center, Yokkaichi, Japan

Poster 057 3042757

TARGETTING EPIDERMAL GROWTH FACTOR RECEPTORS AND UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTORS FOR SARCOMA THERAPY

Ashley J. Graef¹; Jong-Hyuk Kim¹; Daniel A. Vallera¹; Jaime F. Modiano¹

¹University of Minnesota, Minneapolis, MN, USA

Poster 058 3042785

IMPROVING ONCOLYTIC VIROTHERAPY USING VANADIUM-BASED COMPOUNDS IN SARCOMAS

Anabel Bergeron¹; Mohammed Selman¹; Andrew Chen¹; Fanny Tzelepis¹; Rozanne Arulanandam¹; Hesham Abdelbary²; Joel Werier²; Debbie Crans³; Jean-Simon Diallo¹

¹Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada; ²Department of Surgery Orthopaedics, The Ottawa Hospital, Ottawa, ON, Canada; ³Department of Chemistry, Colorado State University, Fort Collins, CO, USA

Poster 059 3042828

SOMATIC TUMOR PASSENGER EVENTS ACT AS A FLIGHT RECORDER “BLACK BOX” TO PINPOINT THE CHROMATIN STATE OF THE TUMOR CELL OF ORIGIN

Aaron L. Sarver¹; David L. Largaespada²

¹Masonic Cancer Center, Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA;

²Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA

Poster 060 3042835

CANONICAL AND RECIPROCAL FUSION GENE EXPRESSION IN TRANSLOCATION ASSOCIATED SOFT TISSUE SARCOMA TUMORS IS ASSOCIATED WITH DISTINCT MOLECULAR SIGNATURES

Joyce Ohm¹; Spencer E. Rosario¹; Jaspreet E. Chatta²; Anne Grand'Maison²

¹Genetics and Genomics, Roswell Park Cancer Institute, Buffalo, NY, USA; ²Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Poster 061 3042904

IDENTIFICATION OF SPLICING FACTOR-3B1 AS A PUTATIVE REGULATOR OF OSTEOSARCOMA METASTASIS

Pooja Hingorani¹; Alexa Trensche²; Anthony Diaz²; Michelina de la Maza¹; Saravana Kumar²; Paul Dickman¹; Janet Foote²; Shalini Sharma²; Aparna R. Sertil²

¹Phoenix Children's Hospital, Phoenix, AZ, USA; ²Basic Medical Sciences, University of Arizona, Phoenix, AZ, USA

Poster 062 3042916

IONIZING RADIATION CAUSES SARCOMAS THROUGH MECHANISMS INDEPENDENT OF INCREASING MUTATIONAL LOAD

David Kirsch¹; Chang-Lung Lee¹; Dadong Zhang¹; Alexander Sibley¹; Andrea Daniel¹; Yvonne Mowery¹; Amy Wisdom¹; Jeremy Gresham¹; Anupama Reddy¹; Cassie Love¹; Sandeep Dave¹; Kouros Owzar¹

¹Duke University, Durham, NC, USA

Poster 063 3042934

PRECLINICAL MODELING OF RESISTANT DISEASE USING AUTOPSY SAMPLES FROM PEDIATRIC PATIENTS WITH SOLID TUMORS

Sara Federico¹; Brittney Gordon²; Kaley Blankenship¹; Armita Bahrami³; Michael Clay³; Michael Dyer²; **Elizabeth Stewart**¹

¹Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA; ²Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA; ³Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA

Poster 064 3043040

TARGETING STRESS GRANULES: A NOVEL APPROACH TO BLOCK SARCOMA METASTASIS

Amal M. EL-Naggar¹; Yemin Wang¹; Melvin Pan¹; Syam Prakash Somasekharan²; Hongwei Cheng²; Didier Surdez³; Poul H. Sorensen¹

¹Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada; ²Vancouver Prostate Centre, Vancouver, BC, Canada; ³Centre de Recherche de l'Institut Curie, Paris, France

Poster 065 2992803

INNATE IMMUNITY TOLL LIKE RECEPTORS TLR1/2; TLR6 AND MUCIN MUC5B ARE BINDING INTERACTION PARTNERS WITH ANTIPROLIFERATIVE PEPTIDE PRP-1 IN HUMAN CHONDROSARCOMA

Karina Galoian¹; Amir Qureshi¹; Alexandra Moran¹; Parthik Patel¹

¹Orthopedics, University of Miami, Miller School of Medicine, Miami, FL, USA

Poster 066 2993194

INHIBITION OF EMBRYONIC STEM CELL MARKERS EXPRESSION BY PRP-1 LEADS TO ELIMINATION OF CANCER STEM CELL POPULATION IN HUMAN CHONDROSARCOMA

Karina Galoian¹; Alexandra Moran¹; Shannon Saigh²; Aaron Hoyt¹

¹Orthopedics, University of Miami, Miller School of Medicine, Miami, FL, USA; ²Flow Cytometry Core, Sylvester Comprehensive Cancer Center, Miami, FL, USA

Poster 067 3042161

TUMOR SUPPRESSOR GENE MUTATION IN THE HEDGEHOG PATHWAY DEFINES A NEW SUBSET OF PLEXIFORM FIBROMYXOMA

Sudeep Banerjee¹; Chih-Min Tang¹; Mayra Yebra¹; Rowan Ustoy¹; Adam Burgoyne⁴; Thomas Savides³; Ann M.P. Tipps²; **Jason Sicklick**¹

¹Surgical Oncology, UCSD, La Jolla, CA, USA; ²Pathology, UCSD, La Jolla, CA, USA; ³Gastroenterology, UCSD, La Jolla, CA, USA; ⁴Medical Oncology, UCSD, La Jolla, CA, USA

Poster 068 3003854

THERAPEUTIC EFFECT OF SCLEROSTIN ON OSTEOSARCOMA

Masanori Okamoto¹; Kazushige Yoshida¹; Jun Sasaki¹; Kaoru Aoki¹; Munehisa Kito¹; Yasuo Yoshimura¹; Shuichiro Suzuki¹; Atsushi Tanaka¹; Akira Takazawa¹; Hisao Haniu²; Takashi Takizawa¹; Atsushi Sobajima¹; Takayuki Kamanaka¹; Naoto Saito²; Hiroyuki Kato¹

¹Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan; ²Institute for Biomedical Sciences, Shinshu University, Matsumoto, Japan

Poster 069 3011949

MACROPHAGES FACILITATE OCCURRENCE AND DEVELOPMENT OF HUMAN OSTEOSARCOMA CELLS MEDIATED BY NF-KB

Peng Zhang¹; Jinyan Liu¹; Feifei Feng²; Weitao Yao¹

¹Bone and soft tissue sarcoma, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China; ²College of Public Health of Zhengzhou University, Zhengzhou, China

Poster 070 3026538

CYCLIN-DEPENDENT PROTEIN KINASE 9 (CDK9) IS A NOVEL PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN OSTEOSARCOMA

Zhenfeng Duan¹; Hangzhan Ma¹; Francis Hornicek¹

¹Orthopaedics, UCLA, Los Angeles, CA, USA

Poster 071 3030414

METHYLATION-SILENCING OF MULTIPLE TUMOR-SUPPRESSOR AND OSTEO/CHONDROGENESIS RELATED GENES IN OSTEOSARCOMA

Naofumi Asano²; Hideyuki Takeshima³; Satoshi Yamashita³; Hironori Takamatsu³; Naoko Hattori³; Eisuke Kobayashi¹; Robert Nakayama²; Morio Matsumoto²; Masaya Nakamura²; Akira Kawai¹; Tadashi Kondo⁴; Toshikazu Ushijima³

¹Musculoskeletal Oncology, National Cancer Center, Tokyo, Japan; ²Orthopaedic surgery, Keio University, Tokyo, Japan; ³Epigenomics, National Cancer Center, Tokyo, Japan; ⁴Rare Cancer Research, National Cancer Center, Tokyo, Japan

Poster 072 3042493

IL-6 MEDIATED SELECTIVE TOXICITY FOR TUMOR-INITIATING CELLS FUNCTIONS TO PREVENT OSTEOSARCOMA METASTASIS

Amanda Saraf¹; Randall Evans¹; Amy Gross¹; Sanjana Rajan¹; Lindsay Ryan¹; Melissa Sammons¹; Sarah Winget¹; Ryan Roberts¹

¹Nationwide Children's Hospital, Columbus, OH, USA

Poster 073 3042628

IDENTIFICATION OF INFLAMMATORY FACTORS AND THE NOTCH PATHWAY AS THERAPEUTIC TARGETS FOR SARCOMA-ASSOCIATED CACHEXIA

Feiqi Lu¹; Jonathan Mandell¹; Alejandro Morales¹; Vu Dinh²; Rebecca Watters¹; **Kurt Weiss**¹

¹Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA; ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

Poster 074 3042650

ANTIPROLIFERATIVE EFFECT OF BUPIVACAINE ON PATIENT-DERIVED SARCOMA CELLS

Lee M. Zuckerman¹; Hamid R. Mirshahidi³; Nadine L. Williams¹; **Joseph Elsisy**¹; Troy G. Shields¹; Salman Otoukesh³; Saied Mirshahidi²

¹Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA; ²Biospecimen Laboratory, Loma Linda University Medical Center, Loma Linda, CA, USA; ³Hematology/Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA

Poster 075 3042651

THE EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON OSTEOSARCOMA CELLS

Joseph Elsisy¹; Lee M. Zuckerman¹; Nadine L. Williams¹; Troy G. Shields¹; Saied Mirshahidi²

¹Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA; ²Biospecimen Laboratory, Loma Linda University Medical Center, Loma Linda, CA, USA

Poster 076 3042751

THE ATR INHIBITOR M4344 INDUCES TUMOR REGRESSION IN A PATIENT-DERIVED XENOGRAFT MODEL OF ALTERNATIVE LENGTHENING OF TELOMERS (ALT)- POSITIVE OSTEOSARCOMA.

Gregory M. Cote¹; Astrid Zimmermann²; Jian Ouyang¹; Anupriya Kulkarni¹; Miguel Rivera¹; Edwin Choy¹; Frank Zenke²; Lee Zou¹

¹Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Merck KGaA, Darmstadt, Germany

Poster 077 3042761

ROLE OF HSF1 IN OSTEOSARCOMA INITIATION AND DEVELOPMENT

Brice W. Moukengue¹; Souad Koll³; Celine Charrier¹; Severine Battaglia¹; Marc Baud'huin¹; Thibaut Quillard²; Valentina Boeva³; Benjamin Ory¹; Francois Lamoureux¹

¹UMR1238-PHY-OS; University of Nantes, Nantes, France; ²CHU of Nantes and University of Nantes, Nantes, France;

³Institut Cochin, Paris, France

Poster 078 3042167

ERIBULIN SHOWS HIGH EFFICACY ON HIGHLY CHEMOTHERAPY-RESISTANT OSTEOSARCOMA IN PATIENT-DERIVED ORTHOTOPIC XENOGRAFT MOUSE MODEL

Tasuku Kiyuna¹; Yasunori Tome¹; Hiroki Maehara¹; Hiromichi Oshiro¹; Robert M. Hoffman²; Fuminori Kanaya¹

¹Orthopedic, University of the Ryukyus, Nishihara, Okinawa, Japan; ²Surgery, University of California, San Diego, CA, USA

Poster 079 3042622

DD LIPO CELL LINES AND PDX TO EXPLORE THE ACTIVITY OF ANTICANCER DRUGS AND COMBINATIONS

Chiara Colombo¹; Valentina Zuco¹; Sandro Pasquali¹; Monica Tortoreto¹; Federica Rotundo¹; Marta Barisella¹; Roberta Sanfilippo¹; Silvia Stacchiotti¹; Alessandro Gronchi¹; Nadia Zaffaroni¹

¹Fondazione IRCCS Istituto Tumori Milano, Milan, Italy

Poster 080 3042654

CIRCULATING TUMOR CELL DETECTION FOR HEMANGIOSARCOMA DIAGNOSIS IN DOGS

Taylor A. DePauw¹; Ashley J. Graef¹; Jaime F. Modiano¹

¹University of Minnesota, Minneapolis, MN, USA

Poster 081 3011719

INCIDENCE OF CARDIOMYOPATHY WITH TRABECTEDIN USE IN SOFT TISSUE SARCOMAS

Steven R. Bialick¹; Lee Hartner¹; Arthur Staddon¹

¹Pennsylvania Hospital of the University of Pennsylvania, Philadelphia, PA, USA

Poster 082 3042939

A PHASE 1B/2 STUDY OF VORINOSTAT IN COMBINATION WITH GEMCITABINE AND DOCETAXEL IN ADVANCED SOFT TISSUE SARCOMAS (STS)

Melissa Burgess¹; Yan Lin¹; Jan Beumer¹; Hussein Tawbi²

¹Medicine, Division of Hematology-Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA;

²MD Anderson Cancer Center, Houston, TX, USA

Poster 083 3044509

EVALUATION OF LENVATINIB, EVEROLIMUS OR THE COMBINATION IN PEDIATRIC SARCOMA MODELS

Raushan Kurmasheva²; Abhik Bandyopadhyay²; Doris Phelps²; Kathryn Bondra²; Terry Shackelford²; Joel Michalek³; Wendong Zhang¹; Michael Roth¹; Jonathan Gill¹; **Richard Gorlick**¹; Peter Houghton²

¹Pediatrics, MD Anderson Cancer Center, Houston, TX, USA; ²Greehey Children's Cancer Research Institute, UT Health

San Antonio, San Antonio, TX, USA; ³Epidemiology and Biostatistics, UT Health Science Center San Antonio,

San Antonio, TX, USA

Poster 084 3040916

RADIOTHERAPY (RT) COMBINED WITH TRABECTEDIN FOR LOCALLY ADVANCED OR METASTATIC, SOFT TISSUE SARCOMA (STS): AN UPDATE OF A SINGLE INSTITUTION EXPERIENCE

Federico Navarra¹; Michela Guardascione²; Elisa Palazzari¹; Stefania Basso³; Marco Gigante¹; Roberto Innocente¹; Gianmaria Miolo²; Giulio Bertola³; Angela Buonadonna²; Antonino De Paoli¹

¹Radiation Oncology, National Cancer Institute CRO IRCCS, Aviano (PN), Italy; ²Medical Oncology, National Cancer

Institute CRO IRCCS, Aviano (PN), Italy; ³Surgical Oncology, National Cancer Institute CRO IRCCS, Aviano (PN), Italy

Poster 085 3042415

LEUCOENCEPHALOPATHY IS A COMMON COMPLICATION IN PATIENTS TREATED WITH HIGH DOSE METHOTREXATE

Sandra Raimbault¹; Pierre Brugieres²; Audrey Longaud¹; Nathalie Gaspar¹; Jean Louis Amegnizin²; Nathalie Bellier³; Brice Fresneau¹; Christelle Dufour¹; Jérôme Hodel²; Dominique Valteau-Couanet¹; Laurence Brugieres¹
¹Pediatrics, Gustave Roussy, Villejuif, France; ²Neuroradiology department, Henri Mondor University Hospital, APHP, Créteil, France; ³Paediatrics, Parly 2 private hospital, Versailles, France

Poster 086 3042845

TARGETING MICROENVIRONMENT AND CELLULAR IMMUNITY IN SARCOMAS WITH WEEKLY TRABECTEDIN COMBINED WITH METRONOMIC CYCLOPHOSPHAMIDE (TARMIC)

Antoine Italiano¹; Julien Adam²; Catherine Sautes-Fridman³; Hervé Fridman³; Alban Bessede⁴; Xavier Buy¹; Nadia Badri⁵; Sophie Cousin¹; Marina Pulido¹; Maud Toulmonde¹
¹Institut Bergonié, Bordeaux, France; ²Institut Gustave Roussy, Villejuif, France; ³Centre Recherche Cordeliers, Paris, France; ⁴Immumol, Bordeaux, France; ⁵Pharmamar, Madrid, Spain

Poster 087 2986862

THE IMPACT OF CHEMOTHERAPY ON PRIMARY BONE TUMORS OF THE VERTEBRAL COLUMN: A NATIONAL CANCER DATABASE REVIEW

Alexander L. Lazarides¹; David Kerr¹; Brian L. Dial¹; Anthony Catanzano¹; Whitney Lane²; Dan Blazer III²; William Eward¹; Brian Brigman¹; Melissa Erickson¹; Sergio Mendoza¹
¹Department of Orthopaedics, Duke University Medical Center, Durham, NC, USA; ²Department of Surgery, Duke University Medical Center, Durham, NC, USA

Poster 088 3030645

NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA: THE GUSTAVE ROUSSY EXPERIENCE

Sarah N. Dumont¹; Elena Cojocar¹; Matthieu Faron¹; Leila Haddag¹; Jean Francois H. Honart¹; Nicolas Kiavue¹; Françoise Rimareix¹; Antonin Levy¹; Cécile Le Péchoux¹; Angela Botticella¹; Philippe Terrier¹; Julien Adam¹; Olivier Mir¹; Andrea Cavalcanti¹; Charles Honoré¹; Axel Le Cesne¹
¹Roussy, Gustave, Villejuif, France

Poster 089 3035286

REAL-WORLD TREATMENT PATTERNS AMONG ADVANCED SOFT TISSUE SARCOMA PATIENTS RECEIVING SYSTEMIC THERAPY IN A COMMUNITY ONCOLOGY SETTING IN THE UNITED STATES

Eric Nadler²; Lisa M. Hess³; Pablo Lee³; Yajun Emily Zhu³; Scott S. Barker³; Thomas Wilson¹; E Susan Amirian¹
¹HEOR, McKesson Specialty Health, The Woodlands, TX, USA; ²Texas Oncology & The US Oncology Network, Dallas, TX, USA; ³Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA

Poster 090 3035291

A RETROSPECTIVE STUDY TO ASSESS THE INCIDENCE OF EARLY AND LATE CARDIOTOXICITY EVALUATED BY MUGA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SARCOMA TREATED WITH DOXORUBICIN

Joanna Vitfell-Rasmussen²; Naja L. Hansen¹; Merete Vaage-Nielsen³; Bo Zerahn¹; Anders Krarup-Hansen²
¹Department of Clinical Physiology and Nuclear Medicine, Herlev and Gentofte University Hospital, Herlev, Denmark; ²Department of Oncology, Herlev and Gentofte University Hospital, Herlev, Denmark; ³Department of Cardiology, Herlev and Gentofte University Hospital, Herlev, Denmark

Poster 091 3041292

NEOADJUVANT CHEMORADIO THERAPY IN ADVANCED SOFT TISSUE SARCOMA (ASTS)

Jeronimo Martinez-Garcia¹; Pablo Puertas²; Antonio Valcarcel²; Juan Angel Fernandez³; Teresa Soria³; Gloria Torres³; Asuncion Soto¹; Pilar Sanchez-Henarejos¹; Ana Puertes¹; Jose Emilio Hernandez⁴; Maria Dolores Abellan⁵; Andres Lopez-Sanchez⁵; Begonia Torregrosa⁵; Isabel de la Fuente⁶; Enrique Cardenas⁶; Jose Luis Navarro⁷; Clemente Jose Fernandez-Pascual⁸; Maria Jose Roca⁹; Jose Luis Alonso-Romero¹

¹Medical Oncology, Clinical University Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain; ²Orthopedics and Traumatology, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; ³Surgery, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; ⁴Pathology, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; ⁵Radiology, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; ⁶Radiotherapy, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; ⁷Nuclear Medicine, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; ⁸Plastic Surgery, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain; ⁹Thoracic Surgery, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain

Poster 092 3041780

OLARATUMAB PLUS DOXORUBICIN FOLLOWED BY OLARATUMAB MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH ADVANCED/METASTATIC SOFT TISSUE SARCOMA: REAL-WORLD UTILIZATION AND OUTCOMES IN THE UNITED STATES

Victor Villalobos²; Lisa M. Hess¹; Yajun Emily Zhu¹; Tomoko Sugihara³; Pablo Lee¹; Volker Wacheck¹; Scott S. Barker¹; Andrew Wagner⁴

¹Eli Lilly and Company, Indianapolis, IN, USA; ²University of Colorado-Denver, Denver, CO, USA; ³Syneos Health, Raleigh, NC, USA; ⁴Harvard University, Boston, MA, USA

Poster 093 3042103

PHASE IB STUDY OF DECITABINE IN COMBINATION WITH GEMCITABINE IN TREATMENT OF REFRACTORY ADVANCED SOFT TISSUE OR BONE SARCOMAS

Varun Monga¹; Umang Swami¹; Rebecca Dodd¹; Munir Tanas²; Sarah Mott³; Mohammed Milhem¹

¹Internal Medicine, University of Iowa, Iowa City, IA, USA; ²Pathology, University of Iowa, Iowa City, IA, USA; ³Holden Comprehensive Cancer Center, Iowa City, IA, USA

Poster 094 3042194

CHARACTERISTICS AND TREATMENT PATTERNS WITH ADVANCED SOFT TISSUE SARCOMA IN KOREA

Hyo Song Kim¹; Chung Mo Nam²; Suk-Yong Jang³; Sun Kyu Choi⁴; Minkyung Han⁵; Seonmin Kim⁴; Maria Victoria Moneta⁶; Sae Young Lee⁷; Jae Min CHO⁷; **Diego Novick**⁸; Sun Young Rha¹

¹Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea (the Republic of); ²Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea (the Republic of); ³Department of Preventive Medicine, Eulji University College of Medicine, Seoul, Korea (the Republic of); ⁴Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea (the Republic of); ⁵Department of Public Health, Yonsei University Graduate School, Seoul, Korea (the Republic of); ⁶Parc Sanitari Sant Joan de Deu, Fundacio Sant Joan de Deu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain; ⁷Eli Lilly and Company, Seoul, Korea (the Republic of); ⁸Global Patients Outcomes and Real World Evidence, Eli Lilly and Company Limited, Windlesham, Surrey, United Kingdom

Poster 095 3042571

TRABECTEDIN-INDUCED MONOCYTES REDUCTION: A POTENTIAL SURROGATE PROGNOSTIC FACTOR?

Marianna Silletta¹; Giuseppe Badalamenti²; roberta sanfilippo³; Anna Maria Frezza³; Mariella Spalato Ceruso¹; Andrea Napolitano¹; Sergio Valeri⁴; Angelo Paolo Dei Tos⁵; Paolo Casali³; Silvia Stacchiotti³; Alessandro Gronchi³; Daniele Santini¹; Giuseppe Tonini¹; Bruno Vincenzi¹

¹Oncology, Campus Bio-Medico, Rome, RM, Italy; ²oncology, policlinico giaccone, Palermo, Italy; ³Oncology, Istituto Nazionale Tumori, Milan, Italy; ⁴Surgical Dep, Campus Bio Medico, Rome, Italy; ⁵Università Padova, Padova, Italy

Poster 096 3042600

CLINICAL OUTCOME OF ERIBULIN IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA: A COHORT STUDY INCLUDING NON-L-SARCOMAS

Makoto Endo¹; Nobuhiko Yokoyama¹; Nokitaka Setsu¹; Toshifumi Fujiwara¹; Kenichiro Yahiro¹; Atsushi Kimura¹; Eijiro Shimada¹; Kenji Tsuchihashi¹; Hitoshi Kusaba¹; Yoshinao Oda¹; Yasuharu Nakashima¹; Yoshihiro Matsumoto¹

¹Kyushu University, Fukuoka, Japan

Poster 097 3042614

PAZOPANIB NEOADJUVANT TRIAL IN SOFT TISSUE SARCOMAS: A REPORT OF MAJOR WOUND COMPLICATIONS DURING DOSE-FINDING PHASE ON ARST 1321

Thomas Scharschmidt¹; Yen-Lin E. Chen²; Dian Wang³; Yueh-Yun Chi⁴; Jing Tian⁴; Mark Kayton⁵; R. Lor Randall⁶; Douglas Hawkins⁷; Aaron Weiss⁸

¹Ohio State University, Columbus, OH, USA; ²Harvard Medical School, Boston, MA, USA; ³Rush Medical Center, Chicago, IL, USA; ⁴University of Florida, Gainesville, FL, USA; ⁵Palm Beach Childrens Hospital, West Palm Beach, FL, USA; ⁶UC Davis, Sacramento, CA, USA; ⁷Seattle Childrens Hospital, Seattle, WA, USA; ⁸Maine Medical Center, Portland, ME, USA

Poster 098 3042618

USE OF CARDIOPROTECTIVE DEXRAZOXANE AND MYELOTXICITY IN ANTHRACYCLINE-TREATED SOFT-TISSUE SARCOMA PATIENTS

Mariella Spalato Ceruso¹; Andrea Napolitano¹; Marianna Silletta¹; Alessandro Mazzocca¹; Sergio Valeri²; Luca Improta²; Daniele Santini¹; Giuseppe Tonini¹; Bruno Vincenzi¹

¹Oncology, Campus Bio-Medico, Rome, RM, Italy; ²General Surgery, Campus Bio-Medico, Rome, Italy

Poster 099 3042688

COMBINATION OF ERIBULIN PLUS GEMCITABINE IN L-SARCOMAS

Maria Lopez-Alvarez¹; David S. Moura¹; Paloma Sanchez-Bustos¹; Ana Salinas-Villegas¹; Nadia Hindi²; Miguel Taron¹; Javier Martín-Broto²

¹Group of Advanced Therapies and Biomarkers in Oncology, Institute of Biomedicine of Seville, Spain; ²Group of Advanced Therapies and Biomarkers in Oncology, Institute of Biomedicine of Seville, University Hospital Virgen del Rocio, Seville, Spain

Poster 100 3042696

PREDICTIVE ROLE OF HMG PROTEINS FOR RESPONSE TO TRABECTEDIN IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS): A SPANISH GROUP FOR RESEARCH ON SARCOMAS (GEIS-38 STUDY)

Nadia Hindi¹; David S. Moura¹; Javier Martinez-Trufero²; Rosa Maria Alvarez Alvarez³; Magda Conceicao⁴; Luis Miguel de Sande Gonzalez⁵; Gloria Marquina⁶; Juana Maria Cano⁷; Josefina Cruz⁸; Claudia Valverde⁹; Maria A. Vaz¹⁰; Javier Lavernia¹¹; Antonio Lopez-Pousa¹²; Robert Diaz Beveridge¹³; Isabel Sevilla¹⁴; Antonio Gutierrez⁴; David Marcilla¹⁵; Miguel Taron¹; Rafael Ramos⁴; Javier Martín-Broto¹

¹Institute of Biomedicine Research (IBIS)- University Hospital Virgen del Rocio/CSIC/University of Seville, Seville, Spain; ²University Hospital Miguel Servet, Zaragoza, Spain; ³Hospital Gregorio Marañon, Madrid, Spain; ⁴Hospital Son Espases, Palma de Mallorca, Spain; ⁵Hospital of León, Leon, Spain; ⁶University Hospital San Carlos, Pozuelo de Alarcon, Spain; ⁷General Hospital of Ciudad Real, Ciudad Real, Spain; ⁸University Hospital of Canary Islands, Santa Cruz De Tenerife, Spain; ⁹University Hospital Vall d'Hebron, Barcelona, Spain; ¹⁰University Hospital Ramon y Cajal, Madrid, Spain; ¹¹Foundation Instituto Valenciano de Oncologia, Valencia, Spain; ¹²Hospital Sant Pau, Barcelona, Spain; ¹³University Hospital La Fe, Valencia, Spain; ¹⁴University Hospital Virgen de la Victoria, Málaga, Spain; ¹⁵University Hospital Virgen del Rocio, Seville, Spain

Poster 101 3042141

REAL-WORLD EXPERIENCES WITH PAZOPANIB TREATMENT FOR PATIENTS WITH ADVANCED SOFT TISSUE AND BONE SARCOMA IN NORTHERN CALIFORNIA

Mee-Na Song¹; Maily Trieu¹; Jeanette Yu¹; Manpreet Sidhu¹; Danny Sam²; **Minggui Pan¹**

¹Oncology, Kaiser Permanente, Santa Clara, CA, USA; ²Internal Medicine Residency Program and Department of Oncology and Hematology, Kaiser Permanente Medical Center, Northern California, USA

Poster 102 3008065

NEUTROPHIL-TO-LYMPHOCYTE RATIO AFTER PAZOPANIB TREATMENT PREDICTS RESPONSE IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA

Hiroshi Kobayashi¹; Tomotake Okuma²; Hiroyuki Oka¹; Toshihide Hirai¹; Takahiro Ohki¹; Masachika Ikegami¹; Ryoko Sawada¹; Yusuke Shinoda¹; Toru Akiyama⁴; Kenji Sato³; Satoshi Abe³; Hirotaka Kawano³; Takahiro Goto²; Sakae Tanaka¹

¹The University of Tokyo Hospital, Tokyo, Japan; ²Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan; ³Faculty of Medicine, University of Teikyo, Tokyo, Japan; ⁴Saitama Medical Center, Jichi Medical University, Saitama, Japan

Poster 103 3026226

THE SIGNIFICANT EFFECTS OF PAZOPANIB ON ADVANCED SOFT TISSUE SARCOMA: A RETROSPECTIVE ANALYSIS IN CHINA

Bushu Xu¹; Wei Xiao¹; Yi Que¹; Xizhi Wen¹; Xing Zhang¹

¹Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Poster 104 3031108

SHOULD NEOADJUVANT CHEMOTHERAPY BECOME STANDARD TREATMENT FOR HIGH-RISK SOFT TISSUE SARCOMAS? A SINGLE CENTRE RETROSPECTIVE ANALYSIS.

Anna C. Virgili Manrique¹; Ana Sebio¹; María J. Quintana²; Oscar Gallego¹; Isidro Gracia³; Ana Peiró³; Laura Trullols³; Manuel Fernandez-Garrido⁴; Katerina Majerkacova⁵; Jose Isern⁵; Jaume Llauger⁶; Diana Hernández⁶; Sandra Valverde⁶; Jaume Palmer⁶; Elisabeth Martínez⁷; Juan Carlos Trujillo⁷; Vicens Artigas⁸; Silvia Bagué⁹; Alberto Gallardo¹⁰; Ruth Orellana¹⁰; Marta Carmona-Campos¹; Antonio Lopez-Pousa¹

¹Medical Oncology, Hospital Sant Pau, Barcelona, Spain; ²Epidemiology, Sant Pau Hospital, Barcelona, Spain;

³Orthopaedic Surgery and Traumatology, Hospital Sant Pau, Barcelona, Spain; ⁴Plastic and Reconstructive Surgery, Hospital Sant Pau, Barcelona, Spain; ⁵Radiation Oncology, Hospital Sant Pau, Barcelona, Spain; ⁶Radiology, Hospital Sant Pau, Barcelona, Spain; ⁷Thoracic Surgery, Hospital Sant Pau, Barcelona, Spain; ⁸General and Digestive Surgery, Hospital Sant Pau, Barcelona, Spain; ⁹Pathology, Royal Marsden NHSFS Hospital, London, United Kingdom;

¹⁰Pathology, Hospital Sant Pau, Barcelona, Spain

Poster 105 3033961

GEMCITABINE AND DOCETAXEL AS TREATMENT OPTION FOR ADVANCED ANGIOSARCOMA

Alexander Fedenko¹; Andrey A. Konev¹; Anastasia A. Tararykova¹

¹Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation

Poster 106 3041672

TROFOSFAMID AND ETOPOSID – AN EFFECTIVE PALLIATIVE CHEMOTHERAPY FOR RECURRENT MENINGEAL SARCOMA

Mikael Eriksson¹; Marie Ahlström¹

¹Oncology, Skane University Hospital, Lund, Sweden

Poster 107 3042807

TEMOZOLOMID MONOTHERAPY AS AN OPTION IN LOCALLY ADVANCED AND METASTATIC SOLITARY FIBROUS TUMOR: A GUSTAVE ROUSSY SERIES

Sarra Akla¹; Yasmina Moukasse²; Siham Ouguellit¹; Sixtine De Percin¹; Miruna Alina Grecea¹; Marc Antoine Benderra¹; Marine Sroussi¹; Maud Velev¹; Naima Lezghed¹; Olivier Mir¹; Matthieu Faron¹; Leila Haddag¹; Philippe Terrier¹; Andrea Cavalcanti¹; Rastilav Bahleda¹; Axel Le Cesne¹; Sarah N. Dumont¹

¹Oncology, Gustave Roussy, Arceuil, France; ²National Oncology of Rabat, Rabat, Morocco

Poster 108 3042842

HEPATOTOXICITY AS A PREDICTIVE FACTOR FOR SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN

Rita Paiva¹; Isabel Fernandes¹; Teresa Pacheco¹; Cecilia de Melo Alvim Moreira¹; Helena Luna Pais¹; Raquel Brás¹; André Mansinho¹; Daniela Macedo¹; Luís Costa¹

¹Medical Oncology, Hospital de Santa Maria, Lisboa, Portugal

Poster 109 2990389

THE RESULTS OF TREATMENT WITH TRABECTEDIN FOR ADVANCED SOFT TISSUE SARCOMAS: A JAPANESE SINGLE-CENTER EXPERIENCE

Tsukasa Yonemoto¹; Hiroto Kamoda¹; Toshinori Tsukanishi¹; Hideyuki Kinoshita¹; Takeshi Ishii¹

¹Chiba Cancer Center, Chiba, Japan

Poster 110 3042740

SAFETY AND EFFICACY OF OLARATUMAB ADDED TO DOXORUBICIN-BASED COMBINATION CHEMOTHERAPY IN THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMA (STS).

Andrea Espejo¹; Vaia Florou²; Ty Subhawong³; Breelyn A. Wilky⁴; Jonathan Trent⁴

¹Internal Medicine, University of Miami Miller School of Medicine, Jackson Memorial Hospital, Miami, FL, USA;

²Hematology/Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA;

³Musculoskeletal Radiology, Sarcoma Research Program, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA;

⁴Hematology/Oncology, Sarcoma Research Program, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA

Poster 111 3003237

PREDICTING SURVIVAL IN LOCALIZED CHONDROSARCOMA

Alexander L. Lazarides¹; David Kerr¹; Sneha Rao¹; Whitney Lane²; Jason Somarelli¹; Dan Blazer III²; Brian Brigman¹; William Eward¹

¹Department of Orthopaedics, Duke University Medical Center, Durham, NC, USA; ²Department of Surgery, Duke University Medical Center, Durham, NC, USA

Poster 112 3042422

PARP INHIBITORS; A NOVEL THERAPEUTIC STRATEGY FOR CHONDROSARCOMA?

Sanne Venneker¹; Alwine B. Kruisselbrink¹; Erik H. Danen²; Judith V. Bovee¹

¹Pathology, Leiden University Medical Center, Leiden, Netherlands; ²Drug Discovery & Safety, Leiden Academic Centre for Drug Research, Leiden, Netherlands

Poster 113 3026463

CLINICAL UTILITY OF 2-HG AS A BIOMARKER IN IDH MUTATED CHONDROSARCOMA

Makoto Nakagawa¹; Fumihiko Nakatani²; Makoto Endo³; Akira Kawai²; Akihiko Yoshida⁴; Shinji Tsutsumi⁵; Kazushi Araki⁵; Yasuharu Nakashima³; Issay Kitabayashi¹

¹Hematological Malignancy, National Cancer Center Research Institute, Tokyo, Japan; ²Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan;

³Orthopaedic Surgery, Kyushu University, Fukuoka, Japan; ⁴Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan;

⁵Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan

Poster 114 3027412

IMMUNE LANDSCAPE OF HIGH GRADE CHONDROSARCOMAS: IDENTIFICATION OF KEY PLAYERS CREATING AN IMMUNOSUPPRESSIVE TUMOR ENVIRONMENT

Iseulys Richert¹; Corinne Bouvier²; Anne Brouchet⁴; Gonzague De Pinieux³; Jean-Yves Blay⁵; **Aurelie Dutour¹**

¹Apoptosis and pediatric cancers, Centre Leon BERARD, Lyon, France; ²Anatomopathology and Cytology, La Timone Hospital APMH, Marseille, France;

³Anatomopathology and Cytology, Hospital and University of Tours, Tours, France;

⁴Anatomopathology Cytology, IUCT Oncopole, Toulouse, France; ⁵Oncology, centre Leon BERARD, Lyon, France

Poster 115 3027640

CLEAR CELL CHONDROSARCOMA: CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES IN 19 PATIENTS

James H. Flint¹; Anthony P. Conley²; Justin Bird¹; Patrick Lin¹; Bryan Moon¹; Robert L. Satcher¹; Valerae Lewis¹

¹Orthopedic Oncology, MD Anderson Cancer Center, Houston, TX, USA; ²Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

Poster 116 3042912

IMPACT OF NODAL INVOLVEMENT ON DISEASE SPECIFIC SURVIVAL IN CHONDROSARCOMA: ANALYSIS OF THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) DATABASE (2004 – 2015)

Gabriel J. Pavey²; Lee D. Cranmer¹; Bonny J. Chau¹; Matthew J. Thompson²; Elizabeth Loggers³; Seth Pollack³;

Michael J. Wagner¹; Edward Y. Kim⁴; Gabrielle Kane⁴; Teresa S. Kim⁵

¹Medical Oncology Division, University of Washington, Seattle, WA, USA; ²Orthopedics, University of Washington, Seattle, WA, USA;

³Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ⁴Radiation Oncology, University of Washington, Seattle, WA, USA;

⁵Department of Surgery, University of Washington, Seattle, WA, USA

Poster 117 3025747

CLEAR CELL CHONDROSARCOMA: REPORT OF 7 CASES AND METAANALYSIS OF LITERATURE

Alexander Klein¹; Hans Roland Dürr¹; Christof Birkenmaier¹; Felix Tauscher¹; Volkmar Jansson¹; Andrea Baur-Melnyk²
¹Musculoskeletal Oncology; Department of Orthopaedic Surgery, Physical Medicine and Rehabilitation, University Hospital, LMU Munich, Munich, Germany; ²Department of Radiology, University Hospital, LMU Munich, Munich, Germany

Poster 118 3042869

PROGNOSTIC FACTORS FOR SURVIVAL IN DEDIFFERENTIATED CHONDROSARCOMA

Ruoyu Miao¹; Edwin Choy²; Kevin Raskin³; Joseph H. Schwab³; Petur Nielsen⁴; Vikram Deshpande⁴; Ivan Chebib⁴; Thomas F. DeLaney¹; Francis Hornicek³; Gregory M. Cote²; Yen-Lin E. Chen¹
¹Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA; ³Department of Orthopedic Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁴Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

Poster 119 3042731

DRUG REPURPOSING AS A SOURCE OF INNOVATIVE THERAPIES IN CHONDROSARCOMA

Pan Pantziarka¹; Gauthier Bouche¹
¹Anticancer Fund, Kingston Upon Thames, Surrey, United Kingdom

Poster 120 3042764

CISPLATIN IN ADVANCED CHORDOMA: A RETROSPECTIVE CASE-SERIES ANALYSIS

Bruna B. David¹; Salvatore Provenzano¹; Bruno Vincenzi²; Tiziana Venesio³; Lorenzo D'Ambrosio³; Giuseppe Badalamenti⁴; Chiara Ancona⁴; Andrea Marrari⁵; Giacomo G. Baldi⁶; Antonina Parafioriti⁷; Noemi Simeone¹; Paolo Casali¹; Silvia Stacchiotti¹
¹Medical Oncology Unit 2 - Adult mesenchymal tumour and rare cancer, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ²Department of Medical Oncology, Università Campus Bio-Medico di Roma, Rome, Italy; ³Sarcoma Unit, Candiolo Cancer Institute – FPO, IRCCS, Candiolo, Italy; ⁴Medical Oncology Unit - Department of Surgical, Oncological, and Oral Sciences, University of Palermo, Palermo, Italy; ⁵Department of Medical Oncology and Hematology, Humanitas Cancer Center and Research Hospital, IRCCS, Rozzano, Italy; ⁶Medical Oncology Unit, Hospital of Prato, Prato, Italy; ⁷Anatomia Patologica, ASST PINI-CTO, Milan, Italy

Poster 121 3007279

WHAT IS THE RISK OF MORTALITY FOLLOWING LOCAL RECURRENCE OF A SURGICALLY TREATED CHORDOMA OF THE SACRUM?

Mario Hevesi¹; **Matthew T. Houdek¹**; Joseph H. Schwab³; Michael Yaszemski¹; Jay Wunder²; Peter Ferguson²; Francis Hornicek⁴; Franklin H. Sim¹; John Healey⁵; Patrick Boland⁵; Peter S. Rose¹
¹Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA; ²Mount Sinai Hospital, Toronto, ON, Canada; ³Orthopedic Surgery, Massachusetts General Hospital, Boston, MA, USA; ⁴University of California Los Angeles, Los Angeles, CA, USA; ⁵Memorial Sloan Kettering Cancer Center, New York, NY, USA

Poster 122 WITHDRAWN

Poster 123 3019538

FACTORS ASSOCIATED WITH 5-YEAR SURVIVAL IN CHORDOMAS: A NATIONAL CANCER DATABASE STUDY

Brian L. Dial¹; David Kerr¹; Alexander L. Lazarides¹; Whitney Lane²; Dan Blazer III²; Brian Brigman¹; William Eward¹; Melissa Erickson¹; Sergio Mendoza¹
¹Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA; ²General Surgery, Duke University Medical Center, Durham, NC, USA

Poster 124 WITHDRAWN

Poster 125 3038724

CIRCULATING TUMOR DNA IS DETECTABLE IN TRANSLOCATION POSITIVE RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)

Samuel Abbou¹; David Hall¹; Donald A. Barkauskas²; Kelly Klega⁴; Anwasha Nag³; Aaron R. Thorner³; Douglas S. Hawkins⁵; Steven DuBois⁴; Brian Crompton⁴

¹QuadW-COG Childhood Sarcoma Biostatistics and Annotation Office, Children's Oncology Group, Monrovia, CA, USA; ²Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; ³Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA, USA; ⁴Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA; ⁵Hematology/Oncology, Seattle Children's Hospital, Seattle, WA, USA

Poster 126 3042621

RELATIVE FUSION GENE LEVEL IN CIRCULATING CELL-FREE DNA SERVES AS A PROGNOSTIC BIOMARKER IN EWING SARCOMA

Shintaro Iwata¹; Hajime Kageyama²; Makiko Itami²; Tsukasa Yonemoto²; Akira Kawai¹

¹National Cancer Center Hospital, Tokyo, Japan; ²Chiba Cancer Center, Chiba, Japan

Poster 127 3042631

PILOT STUDY EVALUATING THE CONCORDANCE OF CIRCULATING TUMOR DNA ALTERATIONS WITH TUMOR-BASED SEQUENCING IN SOFT TISSUE SARCOMA

Bryce Demoret¹; Sherri Z. Millis²; Gabriel Tinoco¹; David Liebner¹; **James L. Chen¹**

¹The Ohio State University, Columbus, OH, USA; ²Foundation Medicine, Cambridge, MA, USA

Poster 128 3042674

CIRCSARC; NON-INVASIVE MONITORING OF SARCOMAS PATIENTS BY CIRCULATING TUMOUR DNA IN PLASMA

Heidi M. Namløs¹; Seyed Hossein Moosavi¹; Bodil Bjerkehagen²; Olga Zaikova³; Susanne Lorenz⁴; Lars Aasheim⁴; Eivind Hovig¹; Nina L. Jebesen⁵; Ola Myklebost⁶; Boye Kjetil⁷; **Leonardo A. Meza-Zepeda¹**

¹Department of Tumor Biology, Oslo University Hospital, Oslo, Norway; ²Department of Pathology, Oslo University Hospital, Oslo, Norway; ³Department of Surgery, Oslo University Hospital, Oslo, Norway; ⁴Department of Core Facilities, Oslo University Hospital, Oslo, Norway; ⁵Department of Oncology, Haukeland University Hospital, Bergen, Norway; ⁶Department of Clinical Science, University of Bergen, Bergen, Norway; ⁷Department of Oncology, Oslo University Hospital, Oslo, Norway

Poster 129 3042933

ULTRA-SENSITIVE DETECTION OF TRANSLOCATIONS IN THE CELL-FREE DNA OF PEDIATRIC SARCOMA PATIENTS

Avanthi T. Shah¹; Tej Azad²; Jake Chabon³; Stan Leung¹; Aviv Spillinger¹; Heng-Yi Liu¹; Marcus Breese¹; Maximilian Diehn³; Ash A. Alizadeh³; Alejandro Sweet-Cordero¹

¹Pediatrics, UCSF, San Francisco, CA, USA; ²Stanford University School of Medicine, Stanford, CA, USA; ³Stanford Cancer Institute, Stanford, CA, USA

Poster 130 3043078

NONINVASIVE MOLECULAR PROFILING AND RESPONSE MONITORING BY CELL-FREE DNA ANALYSIS IN OSTEOSARCOMA

Emily Slotkin¹; Julie Yang²; Dana Tsui²

¹Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Memorial Sloan Kettering Cancer Center, New York, NY, USA

Poster 131 3016587

RNA-SEQUENCING OF TUMOR-EDUCATED PLATELETS, A NOVEL BIOMARKER FOR BLOOD BASED SARCOMA DIAGNOSTICS

Kimberley M. Heinhuis¹; Sjors In 't Veld²; Govert Dwarshuis²; Daan van den Broek³; Nik Sol⁴; Myron Best²; Anne Miek Koenen⁶; Winan J. van Houdt⁶; Frits van Coevorden⁶; Rick Haas⁵; Tom Wurdinger²; Neeltje Steeghs¹

¹Medical Oncology and Clinical Pharmacology, the Netherlands Cancer Institute, Amsterdam, Netherlands; ²Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, Netherlands; ³Laboratory Medicine, the Netherlands Cancer Institute, Amsterdam, Netherlands; ⁴Brain Tumor Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, Netherlands; ⁵Radiotherapy, the Netherlands Cancer Institute, Amsterdam, Netherlands; ⁶Surgical Oncology, the Netherlands Cancer Institute, Amsterdam, Netherlands

Poster 132 3042854

TREATMENT MONITORING IN PATIENTS WITH PEDIATRIC SARCOMAS USING CIRCULATING TUMOR DNA ANALYSIS: A FEASIBILITY STUDY

Jun Zhao¹; Braden McDonald²; Tania Contente-Cuomo²; Ahuva Odenheimer²; Michelina de la Maza¹; Pooja Hingorani¹; Muhammed Murtaza²

¹Pediatric Hematology/Oncology, Phoenix Children's Hospital, Phoenix, AZ, USA; ²Center for Non-invasive Diagnostics, Translational Genomics Research Institute, Phoenix, AZ, USA

Poster 133 3042867

DESMOID TUMORS: A SINGLE INSTITUTION EXPERIENCE.

Ferdinando Carlo Maria Cananzi¹; Federico Sicoli¹; Laura Samà¹; Laura Ruspi¹; Damiano Gentile¹; Jacopo Galvanin¹; Vittorio Quagliuolo²

¹Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy; ²Surgical Oncology Unit, Humanitas Clinical and Research Center, Rozzano (Milan), Italy

Poster 134 3042336

YOUNG PATIENTS WITH DESMOID FIBROMATOSIS HAVE HIGH RATES OF LOCAL RECURRENCE: IS IT TIME TO RETHINK TREATMENT STRATEGIES IN THIS SUBSET?

Andrew J. Bishop¹; Maria A. Zarzour²; Ravin Ratan²; Kiela E. Torres³; Barry Feig³; Wei-Lien Wang⁴; Alexander J. Lazar⁴; Bryan Moon⁵; Christina Roland³; B. Ashleigh Guadagnolo¹

¹Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA; ²Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ³Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ⁴Pathology, MD Anderson Cancer Center, Houston, TX, USA; ⁵Orthopedic Surgery, MD Anderson Cancer Center, Houston, TX, USA

Poster 135 3042570

FAP-RELATED DESMOID TUMORS TREATED WITH LOW-DOSE CHEMOTHERAPY: RESULTS FROM A MULTICENTRE RETROSPECTIVE ANALYSIS

Bruno Vincenzi¹; Salvatore Provenzano²; Antonella Brunello³; Giuseppe Badalamenti⁴; Margherita Nannini⁵; Toni Ibrahim⁶; Peter Hohenberger⁷; Silvia Gasperoni⁸; Andrea Napolitano¹; Mariella Spalato Ceruso¹; Marianna Silletta¹; Vitellaro Marco²; Angelo Paolo Dei Tos⁹; Daniele Santini¹; Giuseppe Tonini¹; Elena Palassini²

¹Oncology, Campus Bio-Medico, Rome, RM, Italy; ²Istituto Nazionale Tumori Milano, Milano, Italy; ³Istituto Oncologico Veneto, Padova, Italy; ⁴Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone", Palermo, Italy; ⁵University of Bologna, Bologna, Italy; ⁶Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; ⁷University Hospital Mannheim, Mannheim, Germany; ⁸Ospedale Universitario Careggi, Firenze, Italy; ⁹University of Padova, Padova, Italy

Poster 136 3042280

SIGNIFICANT RISK FACTORS OF LOCAL RECURRENCE AFTER SURGERY IN EXTRA-PERITONEAL DESMOID-TYPE FIBROMATOSIS: A MULTICENTER STUDY IN JAPAN

Yoshihiro Nishida¹; Shunsuke Hamada²; Akira Kawai³; Toshiyuki Kunisada⁴; Akira Ogose⁵; Yoshihiro Matsumoto⁶; Keisuke Ae⁷; Junya Toguchida⁸; Toshifumi Ozaki⁴; Akihiro Hirakawa⁹; Tomohisa Sakai¹⁰; Koki Shimizu¹⁰; Eisuke Kobayashi³; Tabu Gokita¹¹; Takeshi Okamoto⁸; Tomoya Matsunobu¹²

¹Nagoya University Hospital, Nagoya, Aichi, Japan; ²Aichi Cancer Center Hospital, Nagoya, Japan; ³National Cancer Center Hospital, Tokyo, Japan; ⁴Okayama University Graduate School of Medicine, Okayama, Japan; ⁵Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Uonuma, Japan; ⁶Kyusyu University, Fukuoka, Japan; ⁷Cancer Institute Hospital, Tokyo, Japan; ⁸Kyoto University Graduate School of Medicine, Kyoto, Japan; ⁹The University of Tokyo, Tokyo, Japan; ¹⁰Nagoya University Graduate School of Medicine, Nagoya, Japan; ¹¹Saitama Cancer Center, Ina, Japan; ¹²Kyusyu Rosai Hospital, Kitakyusyu, Kitakyusyu, Japan

Poster 137 3029766

EFFECTS OF MATRIX STIFFNESS ON CULTURED CELLS OF DESMOID-TYPE FIBROMATOSIS

Tomohisa Sakai¹; Yoshihiro Nishida²; Shunsuke Hamada³; Kunihiro Ikuta¹; Takehiro Ota¹; Hiroshi Koike¹; Koki Shimizu¹; Naoki Ishiguro¹

¹Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Japan; ²Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan; ³Department of Orthopaedic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan

Poster 138 3042486

MUTATION STRATIFICATION OF DESMOID-TYPE FIBROMATOSIS USING A RADIOGENOMICS APPROACH – PRELIMINARY RESULTS

Milea Timbergen¹; **Martijn Starmans**⁵; **Melissa Vos**¹; **Guillaume Padmos**²; **Dirk Grünhagen**⁷; **Geert H.J. V. Leenders**⁶; **Kees Verhoef**⁷; **Wiro Niessen**⁵; **Stefan Sleijfer**⁴; **Stefan Klein**³; **Jacob Visser**²

¹Surgical Oncology, Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; ²Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, Netherlands; ³Radiology and Nuclear Medicine, Medical Informatics, Erasmus MC, University Medical Center, Rotterdam, Netherlands; ⁴Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; ⁵Radiology and Nuclear Medicine, Medical Informatics, Erasmus MC, Rotterdam, Netherlands; ⁶Pathology, Erasmus MC, Rotterdam, Netherlands; ⁷Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

Poster 139 3007734

ACTIVITY OF SORAFENIB IN A DIVERSE POPULATION OF PATIENTS WITH DESMOID TUMORS INCLUDING POOR PERFORMANCE STATUS.

Tejas Suresh¹; **Stacey Stein**¹; **Mrinal Gounder**²; **Kenneth Roberts**³; **Gary Friedlaender**⁴; **Dieter Lindskog**⁴; **Kirtesh Patel**³; **Sajid Khan**⁵; **Hari Deshpande**¹

¹Medical Oncology, Yale University, New Haven, CT, USA; ²Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Radiation Oncology, Yale University, New Haven, CT, USA; ⁴Orthopedics, Yale University, New Haven, CT, USA; ⁵Surgery, Yale University, New Haven, CT, USA

Poster 140 3036230

A CLINICAL COMPARISON OF FAMILIAL (APC MUTATED) VS SPORADIC (CTNNB1 MUTATED) DESMOID TUMORS

Gideon Sandler¹; **Yi-Ju Chiang**¹; **Janice Cormier**¹; **Kelly Hunt**¹; **Alexander J. Lazar**¹; **Patrick Lynch**¹; **Christina Roland**¹; **Kiela E. Torres**¹; **Y Nancy You**¹; **Barry Feig**¹

¹Oncology, M D Anderson Cancer Center, Sydney, NSW, Australia

Poster 141 3042762

WNT TARGET GENES ARE NOT DIFFERENTIALLY EXPRESSED IN DESMOID TUMORS BEARING DIFFERENT ACTIVATING BETA-CATENIN MUTATIONS

Milea Timbergen²; **Matthijs L. Janssen**¹; **Kees Verhoef**¹; **Dirk Grünhagen**¹; **Frédéric Chibon**³; **Marcel Smid**⁴; **Stefan Sleijfer**⁶; **Erik A.C. Wiemer**⁴

¹Surgical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, Zuid Holland, Netherlands; ²Surgical Oncology, Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; ³Centre de Recherches en Cancérologie, Toulouse, France; ⁴Medical Oncology, Erasmus MC, Rotterdam, Netherlands; ⁵Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

Poster 142 3042792

DESMOID TUMOURS TREATED WITH ORAL VINORELBINE. A RETROSPECTIVE ANALYSIS OF 14 PATIENTS

Anna Estival²; **James R. Stewart**¹; **Dharmisha Chauhan**¹; **Alison Dunlop**¹; **Christina Messiou**¹; **Khin Thway**¹; **Omar Al-Muderis**¹; **Aisha Miah**¹; **Shane Zaidi**¹; **Robin Jones**¹; **Winette van der Graaf**¹; **Charlotte Benson**¹

¹Sarcoma Unit, Royal Marsden Hospital, London, United Kingdom; ²Medical Oncology, Catalan Institut of Oncology, Barcelona, Spain

Poster 143 3042308

TEMOZOLOMIDE COMBINED WITH PARP INHIBITOR OLAPARIB SHOWS SYNERGISTIC EFFECTS IN DESMOPLASTIC SMALL ROUND CELL TUMOR CELLS

Anke van Erp³; **Laurens Houdt**³; **Emmy Fleuren**¹; **Winette van der Graaf**²; **Yvonne Versleijen-Jonkers**³

¹Division of Clinical Studies, Clinical and Translational Sarcoma Research, The Institute of Cancer Research, Sutton, United Kingdom; ²Division of Clinical Studies, Clinical and Translational Sarcoma Research and The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Sutton, United Kingdom; ³Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands

Poster 144 3042576

PHASE 2 WEEKLY ORAL ONC201 IN DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) AND CLEAR CELL SARCOMA

Pete Anderson²; **Stacey Zahler**²; **G. T. Budd**³; **Dale Shepard**³; **James L. Chen**⁴; **Andrea Hayes-Jordan**¹

¹Pediatric Surgery, University of North Carolina Chapel Hill, Chapel Hill, NC, USA; ²Pediatric Heme/Onc/BMT, Cleveland Clinic, Cleveland, OH, USA; ³Medical Oncology, Taussig Cancer Institute, Cleveland, OH, USA; ⁴Medical Oncology, James Cancer Center, Ohio State University Medical Center, Columbus, OH, USA

Poster 145 3042583

IMPROVED 3 AND 5 YEAR SURVIVAL WITH MULTIMODALITY TREATMENT OF DESMOPLASTIC SMALL ROUND CELL TUMOR

Vivek Subbiah¹; Salah-Eddine Lamhamedi-Cherradi¹; Branko Cuglievan¹; Winston Huh¹; Pete Anderson¹; Raphael Pollock¹; Dina Lev¹; Wei Qiao¹; Mary F. McAleer¹; Robert Benjamin¹; Shreyaskumar Patel¹; Cynthia E. Herzog¹; Najat Daw¹; Barry Feig¹; Alexander J. Lazar¹; Andrea Hayes-Jordan¹; Joseph A. Ludwig¹
¹MD Anderson Cancer Center, Houston, TX, USA

Poster 146 3042655

RECURRENT FGFR4 AND ARID1A SOMATIC ALTERATIONS ARE DETECTED IN DESMOPLASTIC SMALL ROUND CELL TUMORS (DSRCT)

Warren Chow²; Walter Tsark²; Jiing-Kuan Yee²; Xiwei Wu²; Min Guan²; Sally Trabucco¹; Jeffrey Ross¹; Siraj Ali¹; **Sherri Z. Millis**¹
¹Foundation Medicine, Inc., Phoenix, AZ, USA; ²City of Hope, Duarte, CA, USA

Poster 147 3042812

PRECLINICAL EFFICACY OF ANDROGEN RECEPTOR-BASED ANTI-SENSE THERAPY FOR THE TREATMENT OF DESMOPLASTIC SMALL ROUND CELL TUMOR

Brian Menegaz¹; Salah-Eddine Lamhamedi-Cherradi¹; Branko Cuglievan²; Pamela Camacho²; Youngsoo Kim³; Robert MacLeod³; Andrea Hayes-Jordan⁴; Joseph A. Ludwig¹
¹Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ²Pediatric Oncology, MD Anderson Cancer Center, Houston, TX, USA; ³Ionis Pharmaceuticals, Carlsbad, CA, USA; ⁴Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA

Poster 148 3015504

IMPACT OF WHOLE ABDOMINOPELVIC RADIOTHERAPY AND INTRAPERITONEAL RADIOIMMUNOTHERAPY AFTER COMPLETE RESECTION ON SURVIVAL IN PATIENTS WITH DESMOPLASTIC SMALL ROUND CELL TUMOR

Shakeel Modak¹; James Saltsman¹; Neeta Pandit-Taskar³; Todd Heaton¹; Sam Singer²; Nai-Kong Cheung¹; Suzanne Wolden⁴; Michael LaQuaglia¹
¹Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Poster 149 3042568

ADVANCED EPITHELIOID HAEMANGIOENDOTHELIOMA: FEVER, PAIN AND PLEURAL EFFUSION PREDICT A WORSE OUTCOME

Bruno Vincenzi¹; Anna Maria Frezza²; Antonella Brunello³; Lorenzo D'Ambrosio⁴; Giacomo Giulio Baldi⁵; Giuseppe Badalamenti⁶; Tiziana Venesio⁴; Andrea Napolitano¹; Sergio Valeri⁷; Luca Improta⁷; Mariella Spalato Ceruso¹; Marianna Silletta¹; Angelo Paolo Dei Tos⁸; Alessandro Gronchi²; Paolo Casali²; Silvia Stacchiotti²
¹Oncology, Campus Bio-Medico, Rome, RM, Italy; ²Istituto Tumori Milano, Milano, MI, Italy; ³Istituto Oncologico Veneto, Padova, Italy; ⁴Istituto di Candiolo, Candiolo, Italy; ⁵Nuovo Ospedale Santo Stefano, Prato, Italy; ⁶Policlinico Giaccone, Palermo, Italy; ⁷General Surgery, Campus Bio-Medico, Rome, Italy; ⁸University of Padova, Padova, Italy

Poster 150 2998833

THE PROGNOSTIC SIGNIFICANCE OF SURGICAL TREATMENT FOR EXCESSIVE ELDERLY PATIENTS WITH SOFT TISSUE SARCOMA

Hlroyuki Tsuchie¹; Makoto Emori²; Hiroyuki Nagasawa¹; Naohisa Miyakoshi¹; Yasutaka Murahashi²; Emi Mizushima²; Toshihiko Yamashita²; Yoichi Shimada²
¹Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan; ²Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan

Poster 151 3039056

CLINICAL OUTCOMES AND COSTS FOLLOWING UNPLANNED EXCISIONS OF SOFT TISSUE SARCOMAS IN THE ELDERLY: DOES PREOPERATIVE PLANNING CHANGE OUTCOMES?

Sarah B. Bateni¹; Alicia A. Gingrich¹; Sun Y. Jeon¹; Jeffrey S. Hoch¹; Arta M. Monjazeb¹; Steven W. Thorpe¹; Amanda R. Kirane¹; Richard J. Bold¹; Robert J. Canter¹
¹UC Davis Medical Center, Sacramento, CA, USA

Poster 152 3041503

EXTREMITY SOFT TISSUE SARCOMA IN THE ELDERLY: ARE WE OVERTREATING OR UNDERTREATING THIS VULNERABLE PATIENT POPULATION?

Alicia A. Gingrich¹; Sarah B. Bateni¹; Steven W. Thorpe¹; Arta M. Monjazez¹; Amanda R. Kirane¹; Richard J. Bold¹; Robert J. Canter¹

¹UC Davis, Sacramento, CA, USA

Poster 153 WITHDRAWN

Poster 154 3042808

INFLUENCE OF AGE AND SUBTYPE IN OUTCOME OF OPERABLE LIPOSARCOMA

Daniela Greto¹; Giulia Stocchi¹; Cristina Muntoni¹; Giorgio Caramia¹; Monica Lo Russo¹; Anna Peruzzi¹; Donato Pezzulla¹; Mauro Loi¹; Isacco Desideri¹; Pierluigi Bonomo¹; Giulio Francolini¹; Domenico Andrea Campanacci²; Francesco Muratori²; Filippo Frenos²; Lorenzo Livi¹

¹Radiation Oncology, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy; ²Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliera Universitaria Careggi, Florence, Italy

Poster 155 3042893

WORSE SURVIVAL IN OLDER ADULTS WITH RHABDOMYOSARCOMA: RESULTS OF A LARGE SINGLE INSTITUTIONAL COHORT

Ann Raldow¹; Alex Jacobson²; Ruoyu Miao²; Saveli Goldberg²; Haotong Wang²; Edwin Choy²; Gregory M. Cote²; Kevin Raskin²; Francis Hornicek²; Thomas F. DeLaney²; Yen-Lin E. Chen²

¹Radiation Oncology, UCLA, Los Angeles, CA, USA; ²Massachusetts General Hospital, Boston, MA, USA

Poster 156 2998752

PROGNOSIS OF ELDERLY PRIMARY OSTESARCOMA PATIENTS

Hlroyuki Tsuchie¹; Makoto Emori²; Hiroyuki Nagasawa¹; Naohisa Miyakoshi¹; Yasutaka Murahashi²; Emi Mizushima²; Toshihiko Yamashita²; Yoichi Shimada¹

¹Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan; ²Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan

Poster 157 3031071

POSTOPERATIVE COMPLICATIONS, CLINICAL AND FUNCTIONAL OUTCOME OF ELDERLY PATIENTS WITH PRIMARY HIGH GRADE MALIGNANT BONE AND SOFT TISSUE TUMOR

Masato Sugawara¹; Daiichiro Takahara¹; Michiaki Takagi¹

¹Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan

Poster 158 3007555

THE ADDITION OF CYCLES OF IRINOTECAN/TEMOZOLOMIDE TO CYCLES OF VINCRISTINE, DOXORUBICIN, CYCLOPHOSPHAMIDE (VDC) AND CYCLES OF IFOSFAMIDE, ETOPOSIDE (IE) FOR THE TREATMENT OF EWING SARCOMA (ES).

Paul Meyers¹; Emily Slotkin¹; Leonard Wexler¹; Filemon Dela Cruz¹

¹Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Poster 159 3027523

INVESTIGATING THE ROLE OF LSD2 IN EWING SARCOMA

Priyal Patel¹; Kathleen Pishas²; Julia Selich-Anderson²; Stephen Lessnick²

¹Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA; ²Center for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children's Hospital, Nationwide Children's Hospital, Columbus, OH, USA

Poster 160 3034485

PROGNOSTIC VALUE OF TUMOR VOLUME IN PATIENTS WITH LOCALIZED EWING SARCOMA TREATED WITH INTERVAL-COMPRESSED CHEMOTHERAPY: A REPORT FROM CHILDREN'S ONCOLOGY GROUP STUDY AEWS0031

William T. Cash¹; Mark Krailo²; Allen Buxton²; Daniel West³; Bruce Pawel⁴; Paul Dickman⁵; John Healey⁶; John Dormans⁷; Karen Marcus⁸; Scott Sailer⁹; Neyssa Marina¹⁰; Holcombe Grier¹¹; Aaron Weiss¹²; Katherine Janeway¹³; Richard Gorlick¹⁴; Richard Womer¹⁵

¹Pediatric Hematology Oncology, Emory University/Children's Healthcare of Atlanta, Atlanta, GA, USA; ²Statistics, Children's Oncology Group, Monrovia, CA, USA; ³Pediatric Oncology, UCSF Medical Center-Mission Bay, San Francisco, CA, USA; ⁴Pathology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; ⁵Pathology, Phoenix Children's Hospital, Phoenix, AZ, USA; ⁶Orthopedics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA; ⁷Orthopedics, Texas Children's Hospital, Houston, TX, USA; ⁸Radiation Oncology, Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA, USA; ⁹Radiation Oncology, Duke University Medical Center, Raleigh, NC, USA; ¹⁰Five Prime Therapeutics, San Francisco, CA, USA; ¹¹Pediatric Oncology, Dana-Farber/Harvard Cancer Center, Boston, MA, USA; ¹²Pediatric Oncology, Maine Children's Cancer Program, Scarborough, ME, USA; ¹³Pediatric Oncology, Dana-Farber/Harvard Cancer Center, Boston, MA, USA; ¹⁴MD Anderson Cancer Center, Houston, TX, USA; ¹⁵Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Poster 161 3034977

PATTERN OF TRANSLOCATION TESTING IN PATIENTS ENROLLING TO A COOPERATIVE GROUP TRIAL FOR NEWLY DIAGNOSED METASTATIC EWING SARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)

Steven DuBois¹; Mark Krailo²; Allen Buxton²; Stephen Lessnick³; Lisa Teot⁴; Dinesh Rakheja⁵; Brian Crompton¹; Katherine Janeway¹; Richard Gorlick⁶; Julia Glade-Bender⁷

¹Dana-Farber Cancer Institute, Boston, MA, USA; ²Children's Oncology Group, Monrovia, CA, USA; ³Nationwide Children's Hospital, Columbus, OH, USA; ⁴Boston Children's Hospital, Boston, MA, USA; ⁵UT Southwestern, Dallas, TX, USA; ⁶MD Anderson Cancer Center, Houston, TX, USA; ⁷Columbia University, New York, NY, USA

Poster 162 3042747

EXPERIENCE IN DIFFERENTIAL DIAGNOSIS OF EWING SARCOMA AND EWING-LIKE SARCOMA BY TARGETED RNA-SEQ

Juan Diaz-Martin¹; Michele Biscuola¹; Elena Aguado¹; Mercedes Delgado¹; David Marcilla¹; Enrique De Alava¹

¹UGC Anatomía Patológica, HHUU Virgen del Rocío, Seville, Spain

Poster 163 3042879

ROLE OF P21-ACTIVATED KINASES IN DEVELOPMENT AND PROGRESSION OF EWING SARCOMA

Shawki L. Qasim¹

¹Pediatrics, Baylor College of Medicine-Texas Children's Hospital, Houston, TX, USA

Poster 164 3042853

ACTIVATION OF SPECIFIC KINASE PATHWAYS ARE REQUIRED FOR CD99 INHIBITION MEDIATED EWING SARCOMA CYTOTOXICITY

Haydar Çelik¹; Levent Düsünceli¹; Anna Molotkova¹; David Allegakoen¹; Erin Conn¹; Jeffrey Petro¹; Jeffrey Torestky¹;

Aykut Uren¹

¹Oncology, Georgetown University, Washington, DC, USA

Poster 165 3041795

FUNCTIONAL STUDIES REVEAL DYNAMIC ROLE OF FLI IN EWS/FLI-DRIVEN EWING SARCOMA

Megann A. Boone²; Jesse Crow¹; Stephen Lessnick¹

¹Center for Childhood Cancer and Blood Diseases, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA; ²College of Medicine, The Ohio State University, Columbus, OH, USA

Poster 166 3042272

INTEGRIN-MEDIATED SIGNALING AS A NOVEL THERAPEUTIC TARGET IN METASTATIC EWING SARCOMA

Jade Wulff¹; Gargi Ghosal²; Lyazat Kurenbekova¹; Ryan Shuck¹; Jason T. Yustein¹

¹Pediatrics, Baylor College of Medicine, Houston, TX, USA; ²Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, USA

Poster 167 3042275

A RATIONAL COMBINATION THERAPY APPROACH WITH RADIATION THERAPY IN EWING SARCOMA

Jia Xie¹; Marcia M. Mellado-Largarde¹; Jessica Gartrell¹; Brandon Bianski¹; Kaley Blankenship¹; Sara Federico¹; Elizabeth Stewart¹; Anang Shelat¹; **Christopher L. Tinkle**¹

¹St. Jude Children's Research Hospital, Memphis, TN, USA

Poster 168 WITHDRAWN

Poster 169 3042421

THE ROLE OF HIGH DOSE CHEMOTHERAPY IN REFRACTORY AND RECURRENT EWING SARCOMA: REPORT OF A SINGLE CENTRE EXPERIENCE

Rachael Windsor¹; Anthony Hamilton¹; Palma Dileo¹; Maria Michelagnoli¹; Sandra Strauss¹; Jeremy Whelan¹

¹The London Sarcoma Service, University College London Hospitals NHS Foundation Trust, London, United Kingdom

Poster 170 3042564

EWINGS SARCOMA IN ADULTS - IS SOFT TISSUE EWINGS DIFFERENT FROM BONY EWINGS?

Naresh Gundu¹; Arun Garg¹; Manish Pruthi²; Adarsh Barwad³; Ekta Dhamija⁴; Aditi Aggarwal⁶; Rambha Pandey⁵; Ankur Varshney¹; Sameer Rastogi¹

¹Medical Oncology, AiiMS -All India Institute of Medical Sciences, New Delhi, India; ²Musculoskeletal Oncology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India; ³Pathology, All India Institute of Medical Sciences, Delhi, India; ⁴Radiology, All India Institute of Medical Sciences, Delhi, India; ⁵Radiotherapy, All India Institute of Medical Sciences, Delhi, India; ⁶Radiotherapy, Maulana Azad Medical College, Delhi, India

Poster 171 3027502

POTENTIAL EWS-FLI1- FOXM1- BUB1B AXIS CONTRIBUTES TO MITOTIC CELL CYCLE CONTROL IN EWING SARCOMA

Christiane Schaefer¹; Yassmine El Gourari²; Birgit Lechtape¹; Stephanie Klco-Brosius¹; Eberhard Korsching³; Thomas G. Grünwald⁴; Julia S. Gerke⁴; Jenny Potratz²; Uta Dirksen¹

¹Pediatrics III, Hematology/ Oncology, University Hospital Essen, Essen, North Rhine-Westfalia, Germany; ²Department of General Pediatrics, University Hospital Münster, Münster, Germany; ³Institute of Bioinformatics, Westfälische Wilhelms-Universität Münster, Münster, Germany; ⁴Institute of Pathology, Ludwig-Maximilians-Universität München, München, Germany

Poster 172 3028111

CORRELATION BETWEEN PATHOLOGICAL, RADIOLOGICAL AND METABOLIC RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY IN LOCALIZED EWING SARCOMA

Anna Paioli¹; Alessandra Longhi¹; Roberto Luksch³; Giuseppe M. Milano²; Angela Tamburini⁴; Carla Manzitti⁵; Franca Fagioli⁶; Gianni Bisogno⁷; Luca Coccoli⁸; Nadia Puma³; Carlo Morosi⁹; Eugenio Rimondi¹⁰; Marilena Cesari¹; Massimo E. Abate¹; Stefano F. Fanti¹⁴; Antonina Parafioriti¹¹; Alberto Righi¹³; Angelo P. Dei Tos¹²; Stefano Ferrari¹

¹Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy; ²Department of Pediatric Onco-Hematology and Transfusion Medicine, Ospedale Bambino Gesù, Rome, Italy; ³Department of Pediatric Oncology, Istituto Nazionale Tumori, Milan, Italy; ⁴Department of Pediatric Oncology, Ospedale A. Meyer, Firenze, Italy; ⁵Department of Pediatric Hematology/Oncology, Ospedale Gaslini, Genova, Italy; ⁶Department of Pediatric Oncology, Ospedale Regina Margherita, Torino, Italy; ⁷Pediatric Hematology and Oncology Division, Padova University, Padova, Italy; ⁸Pediatric Hematology/Oncology Division, University of Pisa, Pisa, Italy; ⁹Departemet of Radiology, Istituto Nazionale Tumori, Milano, Italy; ¹⁰Departemet of Radiology, Istituto Ortopedico Rizzoli, Bologna, Italy; ¹¹Departement of Pathology, Gaetano Pini-CTO, Milano, Italy; ¹²Department of Pathology, Ospedale Treviso, Treviso, Italy; ¹³Department of Pathology, Istituto Ortopedico Rizzoli, Bologna, Italy; ¹⁴Departement of Nuclear Medicine, Azienda Ospedaliera Univarsitaria Sant Orsola, Bologna, Italy

Poster 173 3040767

INITIAL REPORTS OF LOCAL CONTROL MODALITIES IN EURO EWING 2012: AN INTERNATIONAL RANDOMISED CONTROLLED TRIAL OF CHEMOTHERAPY FOR NEWLY DIAGNOSED EWING SARCOMAS (ES)

Bernadette Brennan¹; Veronica Moroz²; Jennifer Anderton²; Perrine Marec-Bérard³; Line Claude³; Javier Martin-Broto⁴; Hans Gelderblom⁵; Sandra Strauss⁶; Beatrice Seddon⁶; Jeremy Whelan⁶; Keith Wheatley²

¹Paediatric Oncology, Royal Manchester Children's hospital, Manchester, United Kingdom; ²Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom; ³Centre Léon Bérard, Lyon, France; ⁴Grupo Español de Investigación en Sarcomas, Sevilla, Spain; ⁵European Organisation for Research and Treatment of Cancer, Brussels, Belgium; ⁶University College Hospital London, London, United Kingdom

Poster 174 3042720

EXPRESSION OF SLFN11 AND MGMT IN ARCHIVAL TUMOR TISSUE AS POSSIBLE BIOMARKERS OF RESPONSE TO TEMOZOLOMIDE AND IRINOTECAN IN RELAPSED EWING SARCOMA PATIENTS

Brian Turpin²; Therese Bocklage³; Patrick O'Donnell⁴; Jeremy Rubinstein²; Kristina Prus²; **Lars Wagner**¹

¹Pediatrics, University of Kentucky, Lexington, KY, USA; ²Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; ³Pathology, University of Kentucky, Lexington, KY, USA; ⁴Orthopaedic Surgery, University of Kentucky, Lexington, KY, USA

Poster 175 3042799

IGF-1R/MTOR TARGETED THERAPY FOR EWING SARCOMA: A META-ANALYSIS OF FIVE IGF-1R-RELATED TRIALS MATCHED TO PROTEOMIC AND RADIOLOGIC PREDICTIVE BIOMARKERS.

Hesham Amin¹; Ajaykumar Morani²; Najat Daw³; Salah-Eddine Lamhamedi-Cherradi⁴; Vivek Subbiah⁵; Brian Menegaz⁴; Deeksha Vishwamitra¹; Ghazaleh Eskandari¹; Bhawana George¹; Robert Benjamin⁴; Shreyaskumar Patel⁴; Juhee Song⁶; Alexander J. Lazar⁷; Wei-Lien Wang⁷; Razelle Kurzrock⁸; Alberto Pappo⁹; Pete Anderson¹⁰; Gary K. Schwartz¹¹; Dejka M. Araujo⁴; Branko Cuglievan³; Aung Naing⁵; Ravin Ratan⁴; John A. Livingston⁴; **Joseph A. Ludwig**⁴

¹Hematopathology, MD Anderson Cancer Center, Houston, TX, USA; ²Nuclear Medicine, MD Anderson Cancer Center, Houston, TX, USA; ³Pediatric Oncology, MD Anderson Cancer Center, Houston, TX, USA; ⁴Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ⁵Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX, USA; ⁶Biostatistics, MD Anderson Cancer Center, Houston, TX, USA; ⁷Pathology, MD Anderson Cancer Center, Houston, TX, USA; ⁸Center for Personalized Cancer Therapy, University of California San Diego Moores Cancer Center, San Diego, CA, USA; ⁹Pathology, St. Jude's Cancer Research Hospital, Memphis, TN, USA; ¹⁰Pediatric Oncology, Cleveland Clinic, Cleveland, OH, USA; ¹¹Hematology & Oncology, Columbia University Medical Center, New York, NY, USA

Poster 176 3042832

PRECLINICAL EFFICACY OF TARGETING EWSR1 IN EWING SARCOMA AND DESMOPLASTIC SMALL ROUND CELL TUMORS

Brian Menegaz¹; Salah-Eddine Lamhamedi-Cherradi¹; Branko Cuglievan²; Youngsoo Kim³; Robert MacLeod³; Joseph A. Ludwig¹

¹Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ²Pediatric Oncology, MD Anderson Cancer Center, Houston, TX, USA; ³Ionis Pharmaceuticals, Carlsbad, CA, USA

Poster 177 3042870

HOW DO WE ACHIEVE THE GREATER COLLABORATION NEEDED TO IMPROVE OUTCOMES FROM EWING SARCOMA: THE EXPERIENCE OF THE EURO EWING CONSORTIUM

Abigail Evans²; Elena Gatti²; Kimberly Cornfield²; Sandra Strauss²; Jeremy Whelan¹

¹UCLH, London, United Kingdom; ²University College London, London, United Kingdom

Poster 178 3042886

EWS-FLI1 EXPRESSION LEVEL MODULATES T-CELL MEDIATED TUMOR APOPTOSIS IN EWING SARCOMA

Claire Julian¹; Heather Bernard¹; Ariel Klinghoffer¹; Linda McAllister-Lucas¹; **Kelly Bailey**¹

¹University of Pittsburgh, Pittsburgh, PA, USA

Poster 179 3043033

THE ROLE OF DENOSUMAB IN JOINT PRESERVATION FOR PATIENTS WITH GIANT CELL TUMOUR OF BONE: NOT A MAGIC BULLET?

David L. Perrin¹; Julia Visgauss²; David Wilson²; Anthony M. Griffin²; Peter Ferguson²; Jay Wunder²

¹Section of Orthopaedic Surgery, University of British Columbia, Winnipeg, MB, Canada; ²Mount Sinai Hospital, Toronto, ON, Canada

Poster 180 3041709

EPIGENETIC COMPOUND SCREEN REVEALS HISTONE DEACETYLASE INHIBITORS TO EFFECTIVELY TARGET THE NEOPLASTIC CELLS IN GIANT CELL TUMOR OF BONE

Sanne Venneker²; Robin van Eenige¹; Marianne van der Vaart¹; Alice E. Taliento²; Judith V. Bovee²; **Karoly Szuhai**¹
¹Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands; ²Pathology, Leiden University Medical Center, Leiden, Netherlands

Poster 181 3041740

GIANT CELL TUMOUR OF DISTAL RADIUS: RESULTS OF WIDE EXCISION AND AUTOGENOUS NONVASCULARIZED FIBULA GRAFT RECONSTRUCTION

Deepak Kumar¹

¹Orthopaedics, King George's Medical University, Lucknow, Uttar Pradesh, India

Poster 182 3042599

DISCOVERY AND CHARACTERIZATION OF RECURRENT, TARGETABLE ALK FUSIONS IN LEIOMYOSARCOMA

Lara E. Davis¹; Kevin Nusser¹; Joanna Przybyl²; Janet Pittsenbarger¹; Nicolle Hofmann¹; Sushama Varma²;

Sujay Vennam²; Maria Debiec-Rychter³; Matt van de Rijn²; Monika Davare¹

¹Oregon Health & Science University, Portland, OR, USA; ²Stanford University, Stanford, CA, USA; ³KU Leuven, Leuven, Belgium

Poster 183 3014793

GENOME INFORMED THERAPY FOR OSTEOSARCOMA

Leanne Sayles¹; Marcus Breese¹; Amanda Koehne¹; Stan Leung¹; Avanthi T. Shah¹; Sheri Spunt²; Steven DuBois⁴;

Douglas Hawkins³; **Alejandro Sweet-Cordero**¹

¹Pediatrics, University of California San Francisco, San Francisco, CA, USA; ²Pediatrics, Stanford University, San Francisco, CA, USA; ³Pediatrics, University of Washington, Seattle, WA, USA; ⁴Pediatrics, Dana Farber Cancer Institute, Boston, MA, USA

Poster 184 3042488

DISTINCT EVOLUTIONARY TRAJECTORIES UNDERLIE GENOMIC HETEROGENEITY AND COMPLEXITY IN UNDIFFERENTIATED SARCOMAS

Christopher D. Steele¹; Maxime Tarabichi³; Ludmil Alexandrov⁶; Dahmane Oukrif¹; Hongtao Ye²; Matthew Fittall³;
Patrick Lombard¹; Iñigo Martincorena⁴; Patrick Tarpey⁴; Grace Collord⁴; Sandra Strauss⁵; Fitim Berisha²; Marnix Jansen¹;
Sam Behjati⁴; Fernanda M. Amary²; Roberto Tirabosco²; Peter Campbell⁴; Peter Van Loo³; Adrienne Flanagan¹;

Nischalan Pillay¹

¹Research Department of Pathology, University College London - Cancer Institute, London, United Kingdom; ²Department of Cellular and Molecular Pathology, Royal National Orthopaedic Hospital, London, United Kingdom; ³Cancer Genomics Laboratory, The Francis Crick Institute, London, United Kingdom; ⁴Cancer, Aging and Somatic Mutation Group, Wellcome Trust Sanger Institute, Cambridge, United Kingdom; ⁵Oncology, University College London Hospitals, London, United Kingdom; ⁶Department of Cellular and Molecular Medicine, University of California San Diego, San Diego, CA, USA

Poster 185 3042669

COMPREHENSIVE GENOMIC PROFILING OF SYNOVIAL SARCOMAS IDENTIFIES GENOMICALLY DEFINED SUBGROUPS WITH CHARACTERISTIC ALTERATION PATTERNS

Sherri Z. Millis¹; Peter Vorenkamp³; Petra Vorenkamp³; Jeffrey Ross¹; Siraj Ali¹; Sally Trabucco¹; James L. Chen²

¹Foundation Medicine, Inc., Phoenix, AZ, USA; ²The Ohio State University, Columbus, OH, USA; ³Live For Others Foundation, Laguna Beach, CA, USA

Poster 186 3042566

THE FUSION LANDSCAPE AND ACTIONABLE ALTERATIONS OF SARCOMA REVEALED BY "REAL WORLD" GENOMIC SEQUENCING

Jason Roszik¹; Anthony P. Conley¹; Roman Groisberg¹; Roberto Carmagnani Pestana¹; Shiraj Sen¹; Vivek Subbiah¹

¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Poster 187 3042919

BRINGING A PERSONALIZED MEDICINE PIPELINE TO THE CLINIC: A CROSS-SPECIES APPROACH REVEALS NEW THERAPIES AND NEW CHALLENGES

Sneha Rao¹; Jason Somarelli²; Laura Selmic³; Erdem Altunel²; Wayne Glover²; Maya Sheth²; Mark Byrum³; Timothy Fan³; Cindy Eward⁴; Suzanne Bartholf DeWitt⁵; Julia Visgauss⁵; Brian Brigman⁵; David Hsu¹; William Eward⁵

¹School of Medicine, Duke University, Durham, NC, USA; ²Medicine, Duke University, Durham, NC, USA; ³College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Champaign, IL, USA; ⁴Triangle Veterinary Referral Hospital, HOLLY SPRING, NC, USA; ⁵Orthopaedic Surgery, Duke University, Durham, NC, USA

Poster 188 3042711

UTILITY OF FOUNDATION ONE HEME PROFILING IN SARCOMA: INSTITUTIONAL EXPERIENCE AND CLINICAL OUTCOMES

Adrienne Victor¹; Deepak Sahasrabudhe¹; Megan Baumgart¹

¹Medical Oncology, University of Rochester, Rochester, NY, USA

Poster 189 3041968

METASTATIC INITIAL SARCOMA CASE WITH NTRK3 GENE REARRANGEMENT TREATED WITH ENTRECTINIB

Piotr Rutkowski¹; Anna Mariuk-Jarema¹; Tomasz Switaj¹; Pawel Rogala¹; Michal Wagrodzki²; Monika Dudzisz-Sledz¹

¹Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland; ²Pathology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland

Poster 190 3041764

EXTENDED CONTIGAGIST ANALYSIS ADDS TO THE AMENDED PROGNOSTICATION IN GIST BASED ON TUMOR KIT/PDGFRA GENOTYPE STATUS

Agnieszka Wozniak²; Annouschka Laenen¹; Antonio Gutierrez³; Elzbieta Bylina⁴; Patrick Schöffski²; Jean-Yves Blay⁵; Isabelle Hostein⁶; Axel Le Cesne⁷; Eva Wardelman⁸; Sebastian Bauer⁹; Anna Klimczak⁴; Raf Sciot¹⁰; Mehdi Brahmi⁵; Marco Fiore¹¹; Czeslaw Osuch¹²; Maria Debiec-Rychter¹³; Jean-Michel Coindre⁶; Javier Martin-Broto¹⁴; Piotr Rutkowski⁴

¹Leuven Biostatistics and Statistical Bioinformatics Centre, KU Leuven, Leuven, Belgium; ²Laboratory of Experimental Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, KU Leuven, Leuven, Belgium; ³Hospital Universitario Son Espases, Palma, Spain; ⁴Department of Soft Tissue/Bone Sarcoma and Melanoma, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; ⁵Department of Medical Oncology, Centre Leon Berard, Lyon, France; ⁶Department of Biopathology, Institut Bergonie, INSERMU916 and University Victor Segalen, , Bordeaux, France; ⁷Institut Gustave Roussy, Villejuif, France; ⁸Gerhard Domagk Institute of Pathology, , University Hospital Muenster, Muenster, Germany; ⁹Department of Internal Medicine, University of Essen Medical School, Essen, Germany; ¹⁰Department of Pathology, University Hospitals Leuven, Leuven, Belgium; ¹¹Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy; ¹²Department of General, Oncological and Gastroenterological Surgery, University Hospital Cracow, Cracow, Poland; ¹³Department of Human Genetics, KU Leuven, Leuven, Belgium; ¹⁴Instituto de Biomedicina de Sevilla, Virgen del Rocío University Hospital, Sevilla, Spain

Poster 191 3031895

ONCOLOGICAL OUTCOME AFTER DIAGNOSTIC BIOPSIES IN GASTROINTESTINAL STROMAL TUMOURS

Anne M. Schrijver¹; Eva A. Huis In 't Veld¹; Dirk Strauss²; Nicos Fotiadis³; Neeltje Steeghs⁴; Stijn W. Heijmink⁵; Frits van Coevorden¹; Andrew J. Hayes²; Myles J. Smith²; **Winan J. van Houdt**¹

¹Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; ²Surgical Oncology, Royal Marsden Hospital, London, United Kingdom; ³Radiology, Royal Marsden Hospital, London, United Kingdom; ⁴Medical oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; ⁵Radiology, Netherlands Cancer Institute, Amsterdam, Netherlands

Poster 192 3042644

PAEDIATRIC, ADOLESCENT, WILD TYPE, SYNDROMIC GASTROINTESTINAL STROMAL TUMOURS (PAWS-GIST) UNITED KINGDOM (UK) NATIONAL CLINIC: A JOINT PATIENTS/CARERS/SPECIALISTS INITIATIVE

Venkata Bulusu¹; Ruth Casey²; Olivier Giger³; Eamonn Maher⁴; Richard Hardwick⁵; Nicholas Carroll⁶; Michael Leahy⁷; Robin Jones⁸; Charlotte Benson⁹; Palma Dileo⁹; Ian Judson⁸

¹Oncology, Cambridge University Hospitals, Cambridge, United Kingdom; ²Dept of Endocrinology, Cambridge University Hospitals, Cambridge, United Kingdom; ³Dept of Molecular Pathology, Cambridge University Hospitals, Cambridge, United Kingdom; ⁴Dept of Clinical Genetics, Cambridge University Hospitals, Cambridge, United Kingdom; ⁵Dept of Upper GI Surgery, Cambridge University Hospitals, Cambridge, United Kingdom; ⁶Dept of Radiology, Cambridge University Hospitals, Cambridge, United Kingdom; ⁷Oncology, Christie Institute, Manchester, United Kingdom; ⁸Oncology, Royal Marsden Hospital, London, United Kingdom; ⁹Oncology, University College Hospital London, London, United Kingdom

Poster 193 3026367

THE RELATIONSHIP BETWEEN POSITIVE RESECTION MARGINS, TUMOUR RUPTURE AND PROGNOSIS IN GASTROINTESTINAL STROMAL TUMOUR. A POPULATION-BASED ANALYSIS

Toto Hølmekjakk¹; *Bodil Bjerkehagen*²; *Ivar Hompland*³; *Stephan Stoldt*¹; *Boye Kjetil*³

¹Dept. of Abdominal Surgery, Oslo University Hospital, Oslo, Norway; ²Dept. of Pathology, Oslo University Hospital, Oslo, Norway; ³Dept. of Oncology, Oslo University Hospital, Oslo, Norway

Poster 194 3033347

AN INTEGRATED RNA AND MICRORNA PROFILING OF THE MALIGNANT EVOLUTION OF MINIGIST TO GIST

Alessia Mondello¹; *Daniela Gasparotto*¹; *Marta Sbaraglia*²; *Sabrina Rossi*²; *Maurizio Polano*¹; *Chiara Pastrello*³; *Igor Jurisica*³; *Angelo Paolo Dei Tos*⁴; *Roberta Maestro*¹

¹IRCCS CRO Aviano National Cancer Institute, Aviano, Italy; ²Treviso General Hospital, Treviso, Italy; ³University Health Network, Toronto, ON, Canada; ⁴University of Padova, Padova, Italy

Poster 195 3042862

NOVEL DIAGNOSTIC APPROACH FOR GASTROINTESTINAL STROMAL TUMOR USING AN ANTI-KIT DNA APTAMER

Sudeep Banerjee¹; *Partha Ray*¹; *Mayra Yebra*¹; *Chih-Min Tang*¹; *Christian Allan*¹; *Rebekah White*¹; *Jason Sicklick*¹

¹Surgical Oncology, UC San Diego, La Jolla, CA, USA

Poster 196 3009932

PLOCABULIN, A TUBULIN INHIBITOR, HAS ANTITUMOUR ACTIVITY IN PATIENT-DERIVED XENOGRFT (PDX) MODELS OF GASTROINTESTINAL STROMAL TUMOUR (GIST)

Yannick Wang²; *Agnieszka Wozniak*²; *Jasmien Wellens*²; *Yemarshet K. Gebreyohannes*²; *Maria Jose Guillén Navarro*¹; *Carlos Galmarini*¹; *Pablo Manuel Aviles Marin*¹; *Maria Debiec-Rychter*³; *Raf Sciot*⁴; *Patrick Schöffski*²

¹PharmaMar, Madrid, Spain; ²Laboratory of Experimental Oncology, Department of Oncology and Department of General Medical Oncology, KU Leuven, University Hospitals Leuven and Leuven Cancer Institute, Leuven, Belgium; ³Department of Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium; ⁴Department of Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium

Poster 197 3042635

MORE FREQUENT OCCURRENCE OF UNUSUAL CENTRAL NERVOUS SYSTEM METASTASES IN GIST PATIENTS

Amanda Parkes¹; *Filip Janku*¹; *Shubham Pant*¹; *Neeta Somaiah*¹

¹MD Anderson Cancer Center, Houston, TX, USA

Poster 198 3041762

NEW PROTOCOL FOR IMAGE GUIDED SURGERY OF GASTROINTESTINAL STROMAL TUMOUR

Yvonne Schrage¹; *Kim de Valk*¹; *Dirk Grünhagen*²; *Kees Verhoef*²; *John Frangioni*³; *Alexander Vahrmeijer*¹; *Jos van der Hage*¹

¹Surgery, Leiden University Medical Center, Leiden, Netherlands; ²Surgery, Erasmus MC, Rotterdam, Netherlands; ³Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA

Poster 199 3042866

PRIMARY SARCOMA OF THE VULVA AND VAGINA: OUTCOMES AFTER DEFINITIVE THERAPY

Andrea Russo¹; *Alex Haynes*²; *Haotong Wang*¹; *Ruoyu Miao*¹; *John T. Mullen*²; *Thomas F. DeLaney*¹; *Karen Bernstein*¹; **Yen-Lin E. Chen**¹

¹Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA

Poster 200 3038351

INTEGRATED MOLECULAR ANALYSIS OF UNDIFFERENTIATED UTERINE SARCOMAS REVEALS CLINICALLY RELEVANT SUBTYPES

Amrei Binzer²; *Elin Hardell*¹; *Björn Viklund*²; *Mehran Ghaderi*¹; *Tjalling Bosse*³; *Marisa R. Nucci*⁴; *Cheng Han Lee*⁵; *Debra Bell*⁶; *John K. Schoolmeester*⁶; *Anna Måsbäck*⁷; *Gunnar B. Kristensen*⁸; *Ben Davidson*⁸; *Anders Isaksson*²; **Joseph Carlson**¹

¹Dept of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; ²Dept of Medical Sciences, University of Uppsala, Uppsala, Sweden; ³Leiden University Medical Center, Leiden, Netherlands; ⁴Brigham and Women's Hospital, Boston, MA, USA; ⁵VCH Research Institute, Vancouver, BC, Canada; ⁶The Mayo Clinic, Rochester, MN, USA; ⁷Skånes University Hospital, Lund, Sweden; ⁸The Norwegian Radium Hospital, Oslo, Norway

Poster 201 3041759

TREATMENT OF RECURRENT AND METASTATIC UTERINE ADENOSARCOMAS

Michael J. Nathenson¹; Tianqi Chen²; Jyothi P. Jagannathan³; Christy Harris¹; Marisa R. Nucci⁴; Matthew Hemming¹; Priscilla Merriam¹; Katherine Thornton¹; Jeffrey A. Morgan¹; Andrew Wagner¹; Miranda B. Lam⁵; Chandrajit Raut⁶; Paul Catalano²; Monica Bertagnoli⁶; George Demetri¹; Suzanne George¹

¹Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; ²Biostatistics & Computational Biology, Dana Farber Cancer Institute, Boston, MA, USA; ³Radiology, Dana Farber Cancer Institute, Boston, MA, USA; ⁴Pathology, Brigham and Women's Hospital, Boston, MA, USA; ⁵Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA; ⁶Surgical Oncology, Dana Farber Cancer Institute, Boston, MA, USA

Poster 202 3042707

EFFICACY OF TRABECTEDIN IN METASTATIC UTERINE LEIOMYOSARCOMA: A RETROSPECTIVE MULTICENTER STUDY OF THE SPANISH OVARIAN CANCER RESEARCH GROUP (GEICO)

Maria J. Rubio¹; Maria J. Lecumberrí²; Lydia Gaba¹⁰; Silvia Varela⁸; Jesus Alarcon⁶; Maria E. Ortega¹¹; Jaime Espinos⁵; Gloria Marquina¹²; Julia Calzas⁹; Pilar Barretina⁷; Isabel Ruiz³; Ana Santaballa⁴

¹Medical Oncology, Hospital Universitario Reina Sofía, Córdoba, Córdoba, Spain; ²Medical Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain; ³Medical Oncology, Hospital Universitari Sant Joan de Reus, Reus, Spain; ⁴Medical Oncology, Hospital Universitari i Politecnic La Fe, Valencia, Spain; ⁵Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain; ⁶Medical Oncology, Hospital Universitari Son Espases, Palma de Mallorca, Spain; ⁷Medical Oncology, Institut Catala d'Oncologia - ICO Girona, Girona, Spain; ⁸Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain; ⁹Medical Oncology, Hospital Universitario de Fuenlabrada, Madrid, Spain; ¹⁰Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain; ¹¹Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain; ¹²Medical Oncology, Hospital Universitario Clinico San Carlos, Madrid, Spain

Poster 203 WITHDRAWN

Poster 204 3042769

PROGNOSTIC FACTORS IN ENDOMETRIAL STROMAL SARCOMA (ESS): A SUBGROUP ANALYSIS OF THE GEIS 26 STUDY (SPANISH GROUP FOR RESEARCH ON SARCOMAS)

Ana Sebio¹; Nadia Hindi²; Josefina Cruz³; Juana Maria Cano⁴; Jeronimo Martinez-Garcia⁵; Luis Miguel de Sande Gonzalez⁶; Maria A. Vaz⁷; Jordi Rubio⁸; Jose A. Perez-Fidalgo⁹; Javier Martín-Broto²; Luis Vicioso¹⁰; Isabel Sevilla¹⁰

¹Medical Oncology, Hospital Santa Creu i Sant Pau, Barcelona, Spain; ²Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain; ³Medical Oncology, Hospital Universitario de Canarias, Tenerife, Spain; ⁴Medical Oncology, Hospital General de Ciudad Real, Ciudad Real, Spain; ⁵Medical Oncology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; ⁶Medical Oncology, Complejo Hospitalario de Leon, Leon, Spain; ⁷Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain; ⁸Medical Oncology, Institut Catala d'Oncologia - Girona, Girona, Spain; ⁹Medical Oncology, Hospital Clinico Universitario de Valencia, Valencia, Spain; ¹⁰Medical Oncology, Hospital Universitario Virgen de la Victoria, Malaga, Spain

Poster 205 3028803

UPFRONT ISOLATED LIMB PERFUSION (ILP) IN UNTREATED PATIENTS WITH UNRESECTABLE NON-METASTATIC PRIMARY SOFT-TISSUE SARCOMAS (STS) OF THE LIMB: A RETROSPECTIVE SERIES ON 41 PATIENTS

Tarek Assi²; Andrea Cavalcanti³; Axel Le Cesne²; Matthieu Faron³; Jean Francois H. honart³; Achraf Hadiji³; Olivier Camuzard²; Tony Ibrahim²; Cécile Le Péchoux⁴; Julien Adam¹; Olivier Mir²; Sarah N. Dumont²; Philippe Terrier¹; Charles Honoré³

¹Pathology, Gustave Roussy, Paris, France; ²Medical Oncology, Gustave Roussy, Villejuif, France; ³Surgical Oncology, Gustave Roussy, Villejuif, France; ⁴Radiation Oncology, Gustave Roussy, Villejuif, France

Poster 206 3042668

SURVEILLANCE CHEST COMPUTED TOMOGRAPH (CT) IMAGING DURING CHEMOTHERAPY IN PEDIATRIC SARCOMA PATIENTS: IS THE RADIATION RISK JUSTIFIED?

Rhea M. Nambiar¹; Anna L. Tamulonis¹; Antonio Logan¹; Janay McKnight¹; Paul Kent¹

¹Rush University Medical Center, Hawthorn Woods, IL, USA

Poster 207 3041924

ADVANCED IMAGING IS A COST-EFFECTIVE SURVEILLANCE STRATEGY FOLLOWING SOFT TISSUE SARCOMA RESECTION

Gireesh B. Reddy¹; Daniel Cunningham²; Chinmay Paranjape³; Brian Brigman²; William Eward²

¹School of Medicine, Duke University, Durham, NC, USA; ²Department of Orthopaedic Surgery, Duke University, Durham, NC, USA; ³Department of Orthopaedic Surgery, University of North Carolina, Chapel Hill, NC, USA

Poster 208 3042664

RADIATION EXPOSURE IN PEDIATRIC SARCOMA PATIENTS RECEIVING INITIAL CHEMOTHERAPY

Kelsey Danley¹; Paul Kent¹; Antonio Logan¹

¹Pediatric Hematology/Oncology, Rush University Medical Center, Chicago, IL, USA

Poster 209 3042864

ACCURACY OF FDG-POSITRON EMISSION TOMOGRAPHY (PET) SCAN IN DESMOPLASTIC SMALL ROUND CELL TUMOR

Manjusha Namuduri¹; James Saltsman¹; Emily Slotkin¹; Todd Heaton¹; Michael La Quaglia¹; Shakeel Modak¹

¹Pediatrics, Memorial Sloan Kettering Cancer Center, Stamford, CT, USA

Poster 210 3042859

COMPLIANCE OF RADIOLOGICAL FOLLOW-UP FOLLOWING RESECTION OF PRIMARY INTRAABDOMINAL SOFT TISSUE SARCOMA WITH ESMO/ESNWG GUIDELINES: A 10-YEAR AUDIT OF PRACTICE FROM A UK QUATERNARY REFERRAL CENTRE

James Glasbey¹; James Bundred¹; Jennifer Hunt¹; Robert Tyler¹; Anant Desai¹; David Gourevitch¹; Max Almond¹; Samuel Ford¹

¹Department of Soft Tissue Sarcoma Surgery, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom

Poster 211 3041967

DIFFERENTIATING WELL-DIFFERENTIATED LIPOSARCOMAS FROM LIPOMAS USING A RADIOMICS APPROACH – PRELIMINARY RESULTS

Melissa Vos¹; **Martijn P.A. Starmans**²; Milea Timbergen¹; Sebastian van der Voort²; Guillaume Padmos⁴; Wouter Kessels²; Wiro Niessen²; Dirk Grünhagen³; Stefan Sleijfer⁵; Kees Verhoeve³; Stefan Klein²; Jacob Visser⁴

¹Medical Oncology and Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; ²Radiology and Nuclear Medicine & Medical Informatics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands; ³Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; ⁴Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands; ⁵Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

Poster 212 3037023

SIGNAL INTENSITY OF MRI COULD PREDICT THE EFFICACY OF MELOXICAM TREATMENT IN PATIENTS WITH DESMOID-TYPE FIBROMATOSIS

Koki Shimizu¹; Shunsuke Hamada²; Tomohisa Sakai¹; Hiroshi Urakawa³; Eisuke Arai¹; Kunihiro Ikuta¹; Takehiro Ota¹; Hiroshi Koike¹; Naoki Ishiguro¹; Yoshihiro Nishida⁴

¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; ²Department of Orthopedic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan; ³Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan; ⁴Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan

Poster 213 3037261

THE UTILITY OF FLUORINE-18-FDG PET/MRI FOR DIAGNOSING BONE AND SOFT TISSUE MALIGNANCIES SECONDARY TO PREEXISTING BENIGN CONDITIONS

Yoichi Kaneuchi¹; Michiyuki Hakozaiki¹; Hitoshi Yamada¹; Takahiro Tajino²; Osamu Hasegawa³; Shin-ichi Konno¹

¹Orthopaedic Surgery, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan; ²Orthopaedic Surgery, Southern Tohoku Fukushima Hospital, Fukushima City, Fukushima, Japan; ³Radiology, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan

Poster 214 3042206

THE UTILITY OF PET/CT VERSUS BONE SCAN FOR DIAGNOSIS AND MONITORING OF PEDIATRIC SARCOMA PATIENTS

Adit L. Tal¹; Hiten Doshi²; Fauziya Parkar²; Tony Abraham²; Charito Love²; Rui Yang³; Bang Hoang³; David Loeb¹; Alexander Chou¹; David Geller³; Renee Moadel²

¹Pediatrics, Montefiore Medical Center, Bronx, NY, USA; ²Nuclear Medicine, Montefiore Medical Center, Bronx, NY, USA;

³Orthopedic Surgery, Montefiore Medical Center, Bronx, NY, USA

Poster 215 3041981

COMBINING ONCOLYTIC VIROTHErapy AND PD-1 INHIBITION IN AN ANIMAL MODEL OF ISOLATED LIMB PERFUSION TO IMPROVE LOCAL AND DISTANT DISEASE CONTROL IN ADVANCED EXTREMITY SOFT TISSUE SARCOMA

Andrew J. Hayes¹; Henry Smith²; Michelle Wilkinson¹; Joan Kyula-Currie²; Victoria Roulstone²; David Mansfield²; Martin McLaughlin²; Kevin Harrington²

¹Sarcoma Unit, Royal Marsden Hospital, London, United Kingdom; ²Targeted Therapy Team, Institute of Cancer Research, London, United Kingdom

Poster 216 3014823

NEOADJUVANT THERAPY INDUCES A POTENT INFLAMMATORY AND CORRESPONDING REGULATORY RESPONSE WITHIN THE SARCOMA IMMUNE MICROENVIRONMENT

Teresa Kim¹; Matthew Spraker³; Y. David Seo¹; Kimberly Smythe²; Robert Pierce²; Taylor Hain²; Edward Y. Kim³; Gabrielle Kane³; Isaac Jenkins⁵; Qianchuan (Chad) He⁴; Seth Pollack²

¹Surgery, University of Washington, Seattle, WA, USA; ²Clinical Research Division, Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ³Radiation Oncology, University of Washington, Seattle, WA, USA;

⁴Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;

⁵Clinical Biostatistics, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Poster 217 3015167

PD-1 BLOCKADE COMBINED WITH ONCOLYTIC HERPES HSV1716 VIROIMMUNOTHERAPY ENHANCES SURVIVAL IN AN IMMUNOGENIC MURINE OSTEOSARCOMA MODEL

Mary F. Wedekind¹; Chun-Yu Chen²; Pin-Yi Wang²; Brian Hutzen²; Mark Currier²; Ryan Roberts¹; Ben Kelly³; David Gordon³; Peter White³; Joe Conner⁴; Timothy Cripe¹

¹Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH, USA; ²Center for Cancer and Blood Diseases, Research Institute, Nationwide Children's Hospital, Columbus, OH, USA; ³Institute of Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA; ⁴Virtu Biologics, Ltd, Glasgow, United Kingdom

Poster 218 3025852

DECREASED T CELL INFILTRATION IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)—MEDIATED BY WNT, TGF- β AND MEX3B—PREDICTS POOR SURVIVAL

Benjamin J. DiPardo¹; Catherine S. Grasso⁴; Arun S. Singh³; Bartosz Chmielowski³; Joseph G. Crompton¹; James S. Tomlinson²; William H. McBride⁵; Fritz C. Eilber²; Antoni Ribas³; Anusha Kalbasi⁵

¹Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA; ²Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA; ³Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; ⁴Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; ⁵Division of Molecular and Cellular Oncology, Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA

Poster 219 3041781

THE IMMUNE MICROENVIRONMENT IN LEIOMYOSARCOMA, DEDIFFERENTIATED LIPOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA

Alexander T. Lee¹; Connie Szecsei²; Martina Millighetti²; Khin Thway¹; Ian Judson¹; Robin Jones¹; Paul Huang²

¹Sarcoma Unit, Royal Marsden Hospital, London, United Kingdom; ²Institute of Cancer Research, London, United Kingdom

Poster 220 3030228

KRAS/P53 MEDIATED MURINE MODEL OF RHABDOMYOSARCOMA HAS AN IMMUNE INERT MICROENVIRONMENT AND IS AN IDEAL MODEL TO TEST NOVEL IMMUNOTHERAPIES.

Michael J. Monument¹; Arvind K. Singla¹; Asmaa Affan¹; Joseph K. Kendal¹; Karys Hildebrand¹; Franz J. Zemp³; Pinaki Bose²; Douglas J. Mahoney³; Frank R. Jirik²

¹Department of Surgery, University of Calgary, Calgary, AB, Canada; ²Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada; ³Department of Microbiology, Immunology & Infectious Diseases, University of Calgary, Calgary, AB, Canada

Poster 221 3042164

HOST IMMUNE RESPONSE IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA - A 10-YEAR RETROSPECTIVE ANALYSIS

Joseph Sheridan¹; Andrew Horvai¹; Ross Okimoto¹; Rosanna Wustrack¹

¹University of California San Francisco, San Francisco, CA, USA

Poster 222 3042484

TUMOR INFILTRATING LYMPHOCYTES MAY PREDICT FOR DISTANT METASTASIS IN SOFT TISSUE SARCOMAS TREATED WITH PREOPERATIVE RADIATION THERAPY

Meena Bedi¹; **John Charlson¹**; Mohamed Mostafa¹; Callisia Clarke¹; Candice Johnstone¹; Saul Suster¹

¹Medical College of Wisconsin, Milwaukee, WI, USA

Poster 223 3042550

IMMUNE PROFILING OF INTRATUMORAL TERTIARY LYMPHOID STRUCTURES IN DEDIFFERENTIATED LIPOSARCOMA

Jennifer Wang¹; Tom Wei-Wu Chen²; Shefali Chopra¹; Jen C. Lee²; **William W. Tseng¹**

¹University of Southern California Keck School of Medicine, Los Angeles, CA, USA; ²National Taiwan University College of Medicine, Taipei, Taiwan

Poster 224 3042552

COMPREHENSIVE GENOMIC PROFILING IDENTIFIES A POTENTIAL IMMUNOTHERAPEUTIC OPPORTUNITY IN GASTROINTESTINAL STROMAL TUMORS

Dexter X. Jin¹; Ethan Sokol¹; Sherri Millis¹; Garrett Frampton¹; Siraj Ali¹; Sally Trabucco¹

¹Foundation Medicine, Inc., Cambridge, MA, USA

Poster 225 3042554

INTERLEUKIN-13 IN THE SARCOMA MICROENVIRONMENT PROMOTES EXPRESSION OF THE INTERLEUKIN-13 RECEPTOR ALPHA-2

Ian W. Folkert¹; Samir Devalaraja²; Zahidul Alam²; Minghong Li²; Patricia Young²; Malay Halder²

¹Surgery, University of Pennsylvania, Philadelphia, PA, USA; ²Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

Poster 226 3042690

IMMUNOMODULATORY ROLE OF PAZOPANIB IN ADVANCED SOFT-TISSUE SARCOMAS

David S. Moura¹; Nadia Hindi²; Paloma Sanchez-Bustos¹; Maria Lopez-Alvarez¹; Josefina Cruz⁴; Magda Conceicao⁵; Javier Martinez-Trufero⁶; Roberto Diaz-Beveridge⁷; Claudia Valverde³; Miguel Taron¹; Javier Martín-Broto²

¹Group of Advanced Therapies and Biomarkers in Oncology, Institute of Biomedicine of Seville, Seville, Seville, Spain; ²Group of Advanced Therapies and Biomarkers in Oncology, Institute of Biomedicine of Seville, University Hospital Virgen del Rocío, Seville, Spain; ³Medical Oncology Department, Vall d'Hebron Hospital, Barcelona, Spain; ⁴Medical Oncology Department, University Hospital of Canarias, Tenerife, Spain; ⁵Medical Oncology Department, University Hospital Son Espases, Palma, Spain; ⁶Medical Oncology Department, University Hospital Miguel Servet, Zaragoza, Spain; ⁷Medical Oncology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain

Poster 227 3042754

SOX2/OCT4-HIGH SUBGROUP OF RELAPSED AND METASTATIC OSTEOSARCOMA HAS HIGH PD-L1

Hannah Beird¹; Chia-Chin Wu¹; John A. Livingston²; Shailesh Advani³; Zhenlin Ju⁴; Alexandre Reuben⁵; Davis Ingram⁷; Wei-Lien Wang⁷; Alexander J. Lazar⁷; Cheuk Hong Leung⁶; Akash Mitra¹; Richard Gorlick⁸; Najat Daw⁸; Valerae Lewis⁹; Phillip Futreal¹

¹Genomic Medicine, UT MD Anderson Cancer Center, Houston, TX, USA; ²Department of Sarcoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA; ³Georgetown University, Washington, DC, USA; ⁴Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston, TX, USA; ⁵Department of Thoracic Head & Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA; ⁶Department of Biostatistics, UT MD Anderson Cancer Center, Houston, TX, USA; ⁷Department of Pathology, UT MD Anderson Cancer Center, Houston, TX, USA; ⁸Department of Pediatrics, UT MD Anderson Cancer Center, Houston, TX, USA; ⁹Department of Orthopedic Oncology, UT MD Anderson Cancer Center, Houston, TX, USA

Poster 228 3042756

INDUCTION OF ANTI-TUMOR IMMUNITY AND EFFECTS ON SURVIVAL OF NEOADJUVANT ONCOLYTIC VIROTHERAPY IN DOGS WITH OSTEOSARCOMA: AN UPDATE OF THE VIGOR CLINICAL TRIAL

Kelly M. Makielski²; Shruthi Naik¹; Michael S. Henson²; Kathleen M. Stuebner²; Alexandru-Flaviu Tabaran²; Ingrid Cornax²; M. G. O'Sullivan²; Nagendra Palani²; Daryl Gohl²; Rochelle Hartson²; Andrea Eckert²; Donna Groschen²; Kelly Bergsrud²; Julia Zyla²; Kristina Kiefer²; Lauren Mills²; Milcah C. Scott²; Aaron L. Sarver²; Michael Farrar²; Stephen J. Russell¹; Jaime F. Modiano²

¹Mayo Clinic, Rochester, MN, USA; ²University of Minnesota, Minneapolis, MN, USA

Poster 229 3042851

RESPONSE TO SUBSEQUENT THERAPY IN NY-ESO-1 POSITIVE SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY

Sant P. Chawla¹; Seth Pollack²; Matthew Block⁷; Mihaela Druta³; Khanh Do⁴; John C. Morris⁵; Joseph W. Kim⁶; Chet Bohac⁸; Hailing Lu⁹; Sacha Gnjatic¹⁰; Robin L. Jones¹¹; P. Hwu¹²; Neeta Somaiah¹³

¹Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; ²Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; ³Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; ⁴Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; ⁵Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; ⁶Medical Oncology, Yale University, New Haven, CT, USA; ⁷Medical Oncology, Mayo clinic, Rochester, MN, USA; ⁸Clinical Development, Immune Design, South San Francisco, CA, USA; ⁹Science, Immune Design, Seattle, WA, USA; ¹⁰Immunology, Mt. Sinai, New York City, NY, USA; ¹¹Medical Oncology, Royal Marsden, London, United Kingdom; ¹²Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ¹³Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

Poster 230 3042145

IMMUNE RESPONSE, SAFETY, AND OVERALL SURVIVAL OF NY-ESO-1+ SOFT TISSUE SARCOMA PATIENTS TREATED WITH CMB305 THERAPY

Sant P. Chawla¹; **Seth Pollack²**; Matthew Block¹¹; Mihaela Druta³; Khanh Do⁴; John C. Morris⁵; Joseph W. Kim⁶; Chet Bohac⁷; Hailing Lu⁷; Sacha Gnjatic⁸; R. L. Jones⁹; P. Hwu¹⁰; Neeta Somaiah¹⁰

¹Medical Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA; ²Medical Oncology, Fred Hutchinson Cancer Center, Seattle, WA, USA; ³Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA; ⁴Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; ⁵Medical Oncology, University of Cincinnati, Cincinnati, OH, USA; ⁶Medical Oncology, Yale University, New Haven, CT, USA; ⁷Science, Immune Design, Seattle, WA, USA; ⁸Immunology, Mt. Sinai, New York City, NY, USA; ⁹Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; ¹⁰Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ¹¹Medical Oncology, Mayo clinic, Rochester, MN, USA

Poster 231 3034622

MACROPHAGES DOMINATE THE IMMUNE LANDSCAPE ACROSS MOST SARCOMA SUBTYPES

Amanda R. Dancsok¹; David M. Thomas²; Maya Kansara²; Jean-Yves Blay³; Robert Maki⁴; Torsten O. Nielsen¹; Elizabeth G. Demicco⁵

¹Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; ²Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; ³Centre Léon Bérard, Lyon, France; ⁴Northwell Health Monroeville Cancer, Lake Success, NY, USA; ⁵Mount Sinai Hospital, Toronto, ON, Canada

Poster 232 3034818

SOLUBLE PD-L1 IN PATIENTS WITH SOFT TISSUE TUMORS

Kunihiro Asanuma¹; Tomoki Nakamura¹; Tomohito Hagi¹; Koji Kita¹; Akihiro Sudo¹

¹Orthopedic Surgery, Mie University, Tsu, Mie, Japan

Poster 233 3036245

PROGNOSTIC ROLE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN PATIENTS WITH SARCOMA TREATED WITH IMMUNOTHERAPY

Vaia Florou¹; *Wungki Park*¹; *Breelyn A. Wilky*¹

¹Medicine, University of Miami, Miami, FL, USA

Poster 234 3041760

DISULFIRAM INDUCES IMMUNOGENIC CELL DEATH AND ENHANCES ANTI-PD-1-MEDIATED TUMOR SUPPRESSION IN OSTEOSARCOMA

*Gangyang Wang*¹; *Fei Yin*¹; *Tao Zhang*¹; *Jing Xu*¹; *zhuoying wang*¹; *Xinghui Wang*²; **Yingqi Hua**¹; *Zhengdong Cai*¹

¹Shanghai General Hospital, Shanghai, China; ² Department of Surgery, Massachusetts General Hospital, Boston, MA, USA

Poster 235 3042362

CHARACTERIZING THE IMMUNE LANDSCAPE IN ALVEOLAR SOFT PART SARCOMA

*Akash Mitra*¹; **Hyun Jun Kim**²; *Hannah Beird*¹; *Phillip Futreal*¹

¹Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²University of Cincinnati College of Medicine, Cincinnati, OH, USA

Poster 236 3042557

EXPRESSION OF PROGRAMMED DEATH LIGAND 1 (PD-L1) AND EFFECT OF IMMUNOTHERAPY IN MALIGNANT SOFT TISSUED SARCOMA

*Song Ee Park*¹; *Joo Young Ha*²; *Edward Hyunseung Oh*¹; *Min suk Kwon*³; *Hee Jun Kim*¹

¹Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea (the Republic of); ²Department of Internal Medicine, Asan medical center, Seoul, Korea (the Republic of); ³Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea (the Republic of)

Poster 237 3042637

THE SAINT: INITIAL RESULTS OF A PHASE 1/2 STUDY OF SAFETY/EFFICACY USING SAFE AMOUNTS OF IPILIMUMAB, NIVOLUMAB AND TRABECTEDIN AS FIRST LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA

Erlinda M. Gordon¹; *Victoria M. Chua-Alcala*¹; *Katherine M. Kim*¹; *S. Sreenath M. Andrali*¹; *Doris M. Quon*¹; *Steven M. Wong*¹; *William W. Tseng*²; *Seth Pollack*³; *Amornchit M. Srikureja*¹; *Noah Federman*⁴; *Sant P. Chawla*¹

¹Sarcoma Oncology Center, Santa Monica, CA, USA; ²Surgery, USC Keck School of Medicine, Los Angeles, CA, USA; ³Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ⁴Pediatrics, UCLA School of Medicine, Los Angeles, CA, USA

Poster 238 3042673

ACTIVITY OF TREMELIMUMAB AND DURVALUMAB IN ADVANCED SARCOMAS: PRELIMINARY RESULTS OF A SIGNAL-SEEKING PHASE 2 TRIAL

Maya Kansara¹; *Subotheni Thavaneswaran*¹; *John Grady*¹; *Mark Cowley*¹; *Audrey Silvestri*¹; *Mandy L. Ballinger*¹; *Elektra Hajdu*¹; *Emily Collignon*¹; *Lucille Sebastian*²; *Katrin Sjoquist*²; *Wendy Hague*²; *Amy Prawira*¹; *Anthony Joshua*¹; *Charles Bailey*³; *Ulf Schmitz*³; *Trevor Pugh*⁴; *Torsten O. Nielsen*⁵; *Amanda R. Dancsok*⁵; *Chee Lee*²; *John Simes*³; *David M. Thomas*¹

¹Cancer Genomic Medicine, Garvan Institute, Sydney, NSW, Australia; ²NHMRC Clinical Trials Centre, Sydney, NSW, Australia; ³Gene and Stem Cell Therapy Program, Centenary Institute, Sydney, NSW, Australia; ⁴Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; ⁵Vancouver Coastal Health Research Institute and Faculty of Medicine, Department of Pathology and Laboratory Medicine, Vancouver, BC, Canada

Poster 239 3042804

ACTIVITY OF SINGLE-AGENT PD-1 INHIBITOR (PD-1I) THERAPY IN ADVANCED SARCOMA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS

Dionisia M. Quiroga¹; *David Liebner*¹; *Jennifer Philippon*¹; *Sarah Hoffman*¹; *Yubo Tan*¹; *James L. Chen*¹; *Scott Lenobel*¹; *Paul Wakely*¹; *Gabriel Tinoco*¹

¹The Ohio State University, Columbus, OH, USA

Poster 240 3042810

INTERFERON GAMMA MAKES “COLD” SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA “HOT”: RESULTS OF A PHASE 0 TRIAL

Shihong Zhang¹; Venu Pillarisetty²; Lee D. Cranmer¹; Stanley Riddell¹; R. L. Jones³; Seth Pollack¹

¹Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ²Surgery, University of Washington, Seattle, WA, USA; ³Royal Marsden Hospital, London, United Kingdom

Poster 241 3041695

SARCOMA MOUSE MODEL FOR COMBINED ONCOLYTIC VIRUS AND IMMUNE CHECKPOINT INHIBITOR THERAPY

Shailaja Raj²; Eric Routh¹; Mitra Kooshki¹; Shelby Puckett¹; Pierre Triozzi¹; Paul Savage²; Douglas Lyles¹

¹Oncology, Wake Forest Baptist University Hospital, Winston Salem, NC, USA; ²Section of Hematology and Oncology, Wake Forest Baptist University Hospital, Winston Salem, NC, USA

Poster 242 3042803

EFFICACY OF CHECKPOINT INHIBITORS IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMAS

Varun Monga¹; Keith M. Skubitz²; Umang Swami¹; Sarah Mott⁶; Angela C. Hirbe³; Brian Van Tine³; Peter Oppelt³;

Hillary Dietz³; Scott Okuno⁵; Steven Robinson⁵; Madeline OConnor⁵; Mahesh Seetharam⁵; Steven Attia⁵; John Charlson⁴; Mark Agulnik⁷; Mohammed Milhem¹

¹Internal Medicine, University of Iowa, Iowa City, IA, USA; ²University of Minnesota, Iowa City, IA, USA; ³Washington University, St Louis, MO, USA; ⁴Medical College of Wisconsin, Milwaukee, WI, USA; ⁵Mayo Clinic, Rochester, MN, USA; ⁶Holden Comprehensive Cancer, Iowa City, IA, USA; ⁷Northwestern University, Chicago, IL, USA

Poster 243 3042935

TUMOR SLICE CULTURE REPRESENTS A UNIQUE MODEL IN WHICH TO INTERROGATE THE IMMUNE RESPONSE TO HUMAN SOFT TISSUE SARCOMA

Teresa Kim¹; Xiuyun Jiang¹; Y. David Seo¹; Kevin Sullivan¹; Heidi Kenerson¹; Raymond Yeung¹; Venu Pillarisetty¹

¹Surgery, University of Washington, Seattle, WA, USA

Poster 244 3042775

EXPANSION AND CHARACTERIZATION OF TUMOR-INFILTRATING LYMPHOCYTES IN SOFT TISSUE SARCOMA

Alice Ko¹; Minji Lee²; Nalan Gokgoz²; Jay Wunder²; Irene Andrulis²

¹Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada; ²Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada

Poster 245 3004039

KAPOSI'S SARCOMA IN THE ERA OF HAART: A SINGLE INSTITUTIONAL RETROSPECTIVE REVIEW

Kamya Sankar²; Kelly Foster¹; Chad Achenbach²; Mark Agulnik¹

¹Hematology/Oncology, Northwestern University, Chicago, IL, USA; ²Medicine, Northwestern University, Chicago, IL, USA

Poster 246 3042748

KAPOSI SARCOMA, A SINGLE CENTER EXPERIENCE

Cecilia de Melo Alvim Moreira¹; Isabel Fernandes¹; Teresa Pacheco¹; Rita Paiva¹; Raquel Brás¹; Soares de Almeida²; Daniela Macedo¹; Luis Costa¹; João Borges-Costa²

¹Medical Oncology, Centro Hospitalar Lisboa Norte, Bobadela, Loures, Portugal; ²Dermatology, Centro Hospitalar Lisboa Norte, Lisboa, Portugal

Poster 247 3017154

THE MEF2-CLASS IIA HDAC AXIS IN LEIOMYOSARCOMAS; PROLIFERATIVE OPTIONS AND POSSIBLE THERAPEUTIC TARGETS

Eros Di Giorgio¹; Elisa Franforte¹; Harikrishnareddy Paluvai¹; Claudio Brancolini¹

¹Medical sciences, Università degli studi di Udine, Udine, Italy

Poster 248 3026534

PEDIATRIC LIPOSARCOMA: A REPORT FROM THE TEXAS CHILDREN'S RARE TUMOR REGISTRY

Sarah Whittle¹; Murali Chintagumpala¹; Rajkumar Venkatramani¹

¹Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Pearland, TX, USA

Poster 249 3042560

INTEGRATED WHOLE EXOME AND RNA SEQUENCING FOR DEDIFFERENTIATED LIPOSARCOMA

Makoto Hirata¹; Naofumi Asano²; Kotoe Katayama¹; Yusuke Tsuda¹; Akihiko Yoshida⁴; Toru Motoi⁵; Yoshinao Oda⁶; Masaya Sekimizu²; Eisuke Kobayashi⁴; Takahiro Goto⁵; Yukihide Iwamoto⁶; Shintaro Iwata⁷; Yoshihiro Nishida⁸; Toru Hiruma⁹; Hiroaki Hiraga¹⁰; Hirotaka Kawano¹¹; Robert Nakayama¹²; Tadashi Kondo²; Hidewaki Nakagawa¹³; Akira Kawai⁴; Rui Yamaguchi¹; Hitoshi Ichikawa²; Koichi Matsuda³

¹Institute of Medical Science, University of Tokyo, Tokyo, Japan; ²National Cancer Center Research Institute, Tokyo, Japan; ³Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan; ⁴National Cancer Center Hospital, Tokyo, Japan; ⁵Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan; ⁶Graduate School of Medical Sciences, Kyushu University, Tokyo, Japan; ⁷Chiba Cancer Center, Chiba, Japan; ⁸Nagoya University Graduate School of Medicine, Nagoya, Japan; ⁹Kanagawa Cancer Center, Yokohama, Japan; ¹⁰Hokkaido Cancer Center, Sapporo, Japan; ¹¹Faculty of Medicine, University of Tokyo, Tokyo, Japan; ¹²Keio University School of Medicine, Tokyo, Japan; ¹³RIKEN Center for Integrative Medical Sciences, Tokyo, Japan

Poster 251 3008000

SURGICAL AND CLINICAL OUTCOMES OF ATYPICAL LIPOMATOUS TUMOR OF THE TRUNK AND EXTREMITY

Richard Gurich²; Christopher N. Johnson¹; Jonathon Sharpton²; Moni Neradilek³; Thompson Matthew²; Eleanor Chen²; Darin Davidson²

¹Parkview Cancer Institute, Fort Wayne, IN, USA; ²University of Washington, Seattle, WA, USA; ³The Mountain-Whisper-Light Statistics, Seattle, WA, USA

Poster 252 3029964

CLINICOPATHOLOGIC CHARACTERISTICS AND CLINICAL OUTCOMES OF LIPOSARCOMA: A RETROSPECTIVE ANALYSIS OF SINGLE CENTER EXPERIENCE FOR 25 YEARS

Heejung Chae²; Jeong Eun Kim²; Wanlim Kim²; Jong-Seok Lee¹; Si Yeol Song³; Min Hee Lee⁴; Hye Won Chung⁴; Kyung-Ja Cho⁵; Joon Seon Song⁵; Jin-Hee Ahn²

¹Orthopedic Surgery, Asan Medical Center, Seoul, Korea (the Republic of); ²Oncology, Asan Medical Center, Seoul, Korea (the Republic of); ³Radiation Oncology, Asan Medical Center, Seoul, Korea (the Republic of); ⁴Radiology, Asan Medical Center, Seoul, Korea (the Republic of); ⁵Pathology, Asan Medical Center, Seoul, Korea (the Republic of)

Poster 253 3041958

WATCHFUL WAITING IN PATIENTS WITH WELL-DIFFERENTIATED LIPOSARCOMA IN THE EXTREMITY

Melissa Vos¹; Dirk Grünhagen²; Hanna Kosela-Paterczyk³; Piotr Rutkowski³; Stefan Sleijfer⁴; Kees Verhoef²

¹Medical Oncology and Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; ²Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; ³Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Institute-Oncology Center, Warsaw, Poland; ⁴Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

Poster 254 3025636

TRANSIENT INTERFERON SUPPRESSION RENDERS NERVE SHEATH SARCOMAS SUSCEPTIBLE TO VIRO-IMMUNOTHERAPY

Mohammed Ghonime¹; Kevin Cassady¹

¹Center for Childhood Cancer and Blood Diseases, Nationwide Children's Hospital, Columbus, OH, USA

Poster 255 3036063

STING ACTIVITY PREDICTS RESISTANCE TO ONCOLYTIC VIROTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS

Joel Lee¹; Kevin Cassady¹; Mohammed Ghonime¹

¹College of Medicine, Ohio State University, Columbus, OH, USA

Poster 256 3042150

S-100 EXPRESSION AS A POSSIBLE PROGNOSTIC FACTOR FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMOR

Alexandre P. Sousa¹; Mariana Afonso²; Pedro Martins¹; Sofia Conde³; Ana Ferreira⁴; Marta Soares⁴; Flavio Videira¹; Augusto Moreira¹; Jorge Guimaraes dos Santos¹; Matilde Ribeiro¹; Joaquim Abreu de Sousa¹

¹Oncologia Cirurgica, Instituto Português de Oncologia Porto, Porto, Portugal; ²Pathology, IPO Porto, Porto, Portugal; ³Radiotherapy, IPO Porto, Porto, Portugal; ⁴Oncology, IPO Porto, Porto, Portugal

Poster 257 3005918

STAGING AND SURVEILLANCE OF MYXOIDLIPOSARCOMA: IS CT SCAN ENOUGH?

Julia Visgauss¹; David Wilson¹; David Perrin¹; Anthony M. Griffin¹; Peter Ferguson¹; Jay Wunder¹

¹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

Poster 258 3032305

DEVELOPMENT OF A MODEL TO PREDICT OVERALL SURVIVAL OF MYXOID LIPOSARCOMA PATIENTS

Dayton D. McMillan¹; Pramod N. Kamalopathy¹; Adam Z. Kline¹; Aditya Karhade¹; Santiago Lozano Calderon¹; Joseph H. Schwab¹

¹Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA

Poster 259 3042699

TIME TRENDS AND PROGNOSTIC FACTORS FOR OVERALL SURVIVAL IN MYXOID LIPOSARCOMA: 901 CASES WITH A MEDIAN FOLLOW-UP OF 8 YEARS

Jules Lansu¹; Winan J. van Houdt²; Michael Schaapveld³; Iris van Walraven¹; Michiel van de Sande⁴; Vincent Ho⁵; Marcel Verheij¹; Rick Haas¹

¹Radiotherapy, Netherlands Cancer Institute, Amsterdam, Netherlands; ²Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; ³Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands; ⁴Orthopedic Surgery, LUMC, Leiden, Netherlands; ⁵Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, Netherlands

Poster 260 3042648

SHORT TAU INVERSION RECOVERY MAGNETIC RESONANCE IMAGING FOR STAGING AND SCREENING IN MYXOID LIPOSARCOMA

Alexander Chien²; Craig Zuppan³; Li Lei³; **Troy G. Shields¹**; Joseph Elsisy¹; Peter Pham²; Lee M. Zuckerman¹

¹Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA; ²Radiology, Loma Linda University Medical Center, Loma Linda, CA, USA; ³Pathology, Loma Linda University Medical Center, Loma Linda, CA, USA

Poster 261 3042848

MANAGEMENT OF MYXOID LIPOSARCOMA: A SURVEY OF THE MEMBERS OF THE CONNECTIVE TISSUE ONCOLOGY SOCIETY

Troy G. Shields¹; Joseph Elsisy¹; Nadine L. Williams¹; Lee M. Zuckerman¹

¹Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA

Poster 262 3036403

ONCOLOGICAL OUTCOMES OF MYXOID LIPOSARCOMA IN EXTREMITIES AND TRUNK AFTER WIDE EXCISION AND ADJUVANT TREATMENT

YoungHyun Choi¹; Wanlim Kim¹; JongSeok Lee¹; Hye Won Chung²

¹Department of Orthopedic Surgery, Asan Medical Center, Seoul, Korea (the Republic of); ²Department of Radiology, Asan Medical Center, Seoul, Korea (the Republic of)

Poster 263 3042698

OVERCOMING TRABECTEDIN RESISTANCE OF MYXOID LIPOSARCOMA BY COMBINING IT WITH PPAR γ AGONISTS

Roberta Frapollini¹; Ezia Bello¹; Silvia Brich²; Ilaria Craparotta¹; Sara Ballabio¹; Laura Mannarino¹; Sergio Marchini¹; Laura Carrassa¹; Roberta Sanfilippo³; Alessandro Gronchi⁴; Paolo Casali³; Silvana Pilotti²; **Maurizio D'Incalci¹**

¹Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; ²Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ³Medical Oncology Unit 2; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁴Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Poster 264 3042591

A COMPARISON OF ONCOLOGICAL AND SURGICAL OUTCOMES IN ENDOPROSTHETIC RECONSTRUCTION VERSUS ROTATIONPLASTY FOR PEDIATRIC LOWER EXTREMITY BONE SARCOMAS

Kim Tsoi¹; Tony Tan²; Sevan Hopyan²

¹Division of Orthopaedic Surgery, University of Toronto, Toronto, ON, Canada; ²Division of Orthopaedic Surgery, Hospital for Sick Children, Toronto, ON, Canada

Poster 265 3042779

PRESS FIT VS. CEMENTED FEMORAL STEMS IN ARTHROPLASTY FOR ONCOLOGIC INDICATIONS

Courtney Kaiser¹; Jason Kim¹; Joseph H. Schwab¹; Kevin Raskin¹; **Santiago Lozano Calderon**¹

¹Massachusetts General Hospital Orthopaedic Oncology, Boston, MA, USA

Poster 266 2986857

THE IMPACT OF FACILITY VOLUME ON SURVIVAL IN PATIENTS WITH PRIMARY BONE TUMORS OF THE VERTEBRAL COLUMN

Alexander L. Lazarides¹; Brian L. Dial¹; David Kerr¹; John Steele¹; Whitney Lane¹; Dan Blazer III²; William Eward¹; Brian Brigman¹; Melissa Erickson¹; Sergio Mendoza¹

¹Department of Orthopaedics, Duke University Medical Center, Durham, NC, USA; ²Department of Surgery, Duke University Medical Center, Durham, NC, USA

Poster 267 3005698

POSTIVE MARGIN STATUS IS PROGNOSTIC OF POORER SURVIVAL IN PRIMARY BONE TUMORS OF THE SPINE: A NATIONAL CANCER DATABASE STUDY

Brian L. Dial¹; David Kerr¹; Alexander L. Lazarides¹; Anthony Catanzano¹; Whitney Lane²; Dan Blazer III²; Melissa Erickson¹; Sergio Mendoza¹

¹Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA; ²General Surgery, Duke University Medical Center, Durham, NC, USA

Poster 268 3005744

EPIDEMIOLOGIC AND SURVIVAL TRENDS IN PRIMARY MALIGNANT OSSEOUS TUMORS OF THE SPINE: A NATIONAL CANCER DATABASE STUDY

David Kerr¹; Brian L. Dial¹; Alexander L. Lazarides¹; Anthony Catanzano¹; Whitney Lane²; Dan Blazer III²; Melissa Erickson¹; Sergio Mendoza¹

¹Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA; ²General Surgery, Duke University Medical Center, Durham, NC, USA

Poster 269 3026668

PIN OR REPLACE: AN ALGORITHM FOR THE MANAGEMENT OF NON-PATHOLOGIC FEMORAL NECK FRACTURES IN CANCER PATIENTS

Jonathan Morris¹; **Eugenia Schwarzkopf**¹; Patrick Boland¹; John Healey¹; Daniel Prince¹

¹Orthopedic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Poster 270 3041708

SOFT TISSUE SARCOMAS OF THE ANKLE AND FOOT: CLINICAL OUTCOME AND PROGNOSTIC FACTORS

Hideto Obata¹; Takafumi Ueda²; Norifumi Naka³; Hidetatsu Outani⁴; Hideki Yoshikawa⁴

¹orthopaedic surgery, Yukoukai General Hospital, Ibaraki, Osaka, Japan; ²orthopaedic surgery, National Hospital Organization Osaka National Hospital, Osaka, Osaka, Japan; ³orthopaedic surgery, Osaka International Cancer Institute, Osaka, Osaka, Japan; ⁴orthopaedic surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

Poster 271 3042687

EFFECT OF BODY MASS INDEX (BMI) ON OUTCOMES OF PATIENTS WITH BONE TUMORS WHO UNDERGO ENDOPROSTHETIC JOINT RECONSTRUCTION

Joseph Elsissy¹; Ikenna Nwachuku²; Troy G. Shields¹; Jonathan Creech¹; Lee M. Zuckerman¹

¹Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA; ²Loma Linda University School of Medicine, Loma Linda, CA, USA

Poster 272 3042938

COMPUTER-ASSISTED NAVIGATION FOR SURGERY OF ILIOSACRAL BONE SARCOMAS: WHAT IS THE EVIDENCE?

Mohamed Yakoub¹; Patrick Boland¹; John Healey¹; **Nicola Fabbri**¹

¹Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Poster 273 3012715

FUNCTION AFTER DISTRACTION OSTEOGENESIS FOUR BONE RECONSTRUCTION OF OSSEOUS TUMORS IN THE UPPER AND LOWER EXTREMITY

Eugenia Schwarzkopf¹; Molly Friel Klima¹; Yoely Tavarez¹; Daniel Prince¹

¹Orthopaedic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Poster 274 3017401

USE OF MAGNETIC GROWING INTRAMEDULLARY NAILS IN COMPRESSION DURING INTERCALARY ALLOGRAFT RECONSTRUCTION

Robert C. Vercio¹; Troy G. Shields¹; Lee M. Zuckerman¹

¹Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA

Poster 275 3033167

LONG TERM (>15 YEARS) OUTCOME OF CUSTOM CROSS-PIN FIXATION OF TUMOR ENDOPROSTHESES STEMS

Nicholas N. Bernthal¹; Alexander Upfill-Brown¹; Zachary D. Burke¹; Francis Hornicek¹; Jeffery J. Eckardt¹

¹Department of Orthopaedic Surgery, University of California, Los Angeles, Santa Monica, CA, USA

Poster 276 3042772

OPTIMIZING THE USE OF INDOCYANINE GREEN FOR OSTEOSARCOMA TUMOR DETECTION USING A XENOGRAFT MURINE MODEL

Yoav Zvi¹; Brian Batko¹; Kenji Sato¹; Rui Yang¹; Bang Hoang¹; David Geller¹

¹Orthopaedic Surgery, Montefiore Medical Center, Bronx, NY, USA

Poster 277 3042640

TARGETED MUSCLE REINNERVATION: A STRATEGY TO PREVENT NEUROMAS AND PHANTOM LIMB PAIN IN ONCOLOGIC AMPUTEES

John Alexander¹; Julie West²; Jason Hehr²; Byers Bowen²; Steven Schulz²; Joel Mayerson¹; Ian Valerio²;

Thomas Scharschmidt¹

¹Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, OH, USA; ²Plastic Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA

Poster 278 3042850

USE OF FLAP RECONSTRUCTION AFTER RADICAL SURGERY FOR TRUNCAL AND EXTREMITY SARCOMAS

Sergio D. Quildrian¹; Gonzalo Cervelo¹; Julieta Gerino¹; Anabella Dafinoti¹; Leandro Nikisch¹; Jorge Chapela¹

¹Surgery of Soft Tissue Tumors - Sarcoma and Melanoma Unit, Angel H Roffo Institute of Oncology - University of Buenos Aires, Ciudad de Buenos Aires, Ciudad de Buenos Aires, Argentina

Poster 279 3005268

MIDTERM FOLLOW-UP OF A CUSTOM NON-FLUTED DIAPHYSEAL PRESS-FIT TUMOR PROSTHESIS SYSTEM

Julia Visgauss¹; David Wilson¹; David Perrin¹; Anthony M. Griffin¹; Jay Wunder¹; Peter Ferguson¹

¹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

Poster 280 3007952

DUAL MOBILITY COMPONENTS CEMENTED INTO AN ACETABULAR RECONSTRUCTIVE CAGE FOR LARGE OSSEOUS DEFECTS IN THE SETTING OF PERIACETABULAR METASTATIC DISEASE

Darren Plummer¹; John Alexander¹; Sravya Vajapey¹; Travis Frantz¹; Steven Niedermeier¹; Robert Pettit¹;

Thomas Scharschmidt¹

¹Orthopaedic Surgery, The Ohio State University James Cancer Hospital, Columbus, OH, USA

Poster 281 3033191

LONG TERM OUTCOMES OF TOTAL HUMERAL REPLACEMENT FOR PRIMARY BONE TUMORS IN 18 PATIENTS

Nicholas N. Bernthal¹; Zachary D. Burke¹; Alexander Upfill-Brown¹; Richard Hwang¹; Francis Hornicek¹;

Jeffery J. Eckardt¹

¹Department of Orthopaedic Surgery, University of California, Los Angeles, Santa Monica, CA, USA

Poster 282 3036524

CHARACTERIZATION OF A BONE BIOREPOSITORY: COMPARISON OF SARCOMAS AND BONE METASTASES FROM BREAST, PROSTATE, RENAL, LUNG CANCERS, AND MYELOMA

Kerith R. Wang⁶; William K. Kelly¹; Scot A. Brown²; Peter McCue³; Matthew J. Schiewer⁶; Karen M. Bussard⁶; Alessandro Fatatis⁴; Lucia Languino⁶; Benjamin Leiby⁵; Raymond O'Neill³; Jianhong Li³; Emily R. Bochner⁶; Eric V. Mastrodonardo⁶; John A. Abraham²

¹Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA; ²Orthopaedic Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA; ³Pathology, Anatomy, and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, PA, USA; ⁴Pharmacology & Physiology, Drexel University, Philadelphia, PA, USA; ⁵Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA; ⁶Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA

Poster 283 3042485

AN INVESTIGATION OF BONE REGENERATION BY USING BONE SUBSTITUTE MATERIALS AFTER BONE TUMOR CURETTAGE

Shinichirou Yoshida¹; Munenori Watanuki¹; **Masami Hosaka**¹; Takuya Sekiguchi¹; Toshihisa Yano¹; Eiji Itoi¹; Shin Hitachi²; Mika Watanabe³

¹Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan; ²Diagnostic Radiology, Tohoku University Hospital, Sendai, Japan; ³Pathology, Tohoku University Hospital, Sendai, Japan

Poster 284 3033250

FUNCTIONAL OUTCOME AND COMPLICATIONS OF EXTERNAL HEMIPELVECTOMY IN THE SEVEN PATIENTS UNDERWENT FOR MALIGNANT BONE AND SOFT TISSUE TUMORS

Daichiro Takahara¹; Masato Sugawara¹; Yuya Takakubo¹; Michiaki Takagi¹

¹Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan

Poster 285 3042529

RELATIVE PERCENTAGE OF CIRCULATING ACTIVATED EFFECTOR NKT CELLS FOLLOWING FIRST CYCLE OF CHEMOTHERAPY CORRELATES WITH HISTOLOGIC NECROSIS IN OSTEOSARCOMA PATIENTS

Thomas Badgett¹; Jacob Bleesing³; Jennifer Pope²; Rajaram Nagarajan³; Nicholas Yeager⁴; Kerry McGowan⁵; Joseph Walden¹; Zi Ye⁶; Philip Westgate⁶; **Lars Wagner**¹

¹Pediatrics, University of Kentucky, Lexington, KY, USA; ²Pediatrics, Carolinas Medical Center, Charlotte, OH, USA; ³Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; ⁴Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA; ⁵Pediatrics, Norton Children's Hospital, Louisville, KY, USA; ⁶Statistics, University of Kentucky, Lexington, KY, USA

Poster 286 3042815

IDENTIFYING JUDICIOUS APPLICATIONS FOR SPONTANEOUS BONE CANCER OF DOGS AS A MODEL FOR PEDIATRIC OSTEOSARCOMA

Jaime F. Modiano¹; Lauren Mills²; Nuri A. Temiz³; Aaron L. Sarver⁴

¹Veterinary Clinical Sciences and Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; ²Pediatrics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; ³Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; ⁴Institute for Health Informatics and Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA

Poster 287 3042819

MODULATION OF MRNA TRANSLATION REGULATION IN HIGHLY METASTATIC OSTEOSARCOMA CELLS INHIBITS LUNG METASTASIS PROGRESSION

Michael M. Lizardo¹; Haifeng Zhang¹; Gian Luca Negri¹; Poul H. Sorensen¹

¹Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada

Poster 288 3004242

FACTORS ASSOCIATED WITH LIFE IN ADULTS WITH LOCALIZED OSTEOSARCOMA

Alexander L. Lazarides¹; David Kerr¹; Gireesh B. Reddy¹; Whitney Lane²; Jason Somarelli¹; Dan Blazer III²; Brian Brigman¹; William Eward¹

¹Department of Orthopaedics, Duke University Medical Center, Durham, NC, USA; ²Department of Surgery, Duke University Medical Center, Durham, NC, USA

Poster 289 3027652

HIGH GRADE INTRAMEDULLARY OSTEOSARCOMA: DOES HISTOLOGIC SUBTYPE AFFECT OUTCOME?

James H. Flint¹; Wei-Lien Wang²; Alexis Pascoe³; John A. Livingston⁴; Justin Bird¹; Patrick Lin¹; Bryan Moon¹; Robert L. Satcher¹; Valerae Lewis¹

¹Orthopedic Oncology, MD Anderson Cancer Center, Houston, TX, USA; ²Pathology, MD Anderson Cancer Center, Houston, TX, USA; ³University of Texas Health Science Center, Houston, TX, USA; ⁴Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

Poster 290 3042179

THE CLINICAL OUTCOME OF THE OSTEOARTICULAR EXTRACORPOREAL IRRADIATED AUTOGRAFT FOR BONE SARCOMA

Satoshi Takenaka¹; Nobuhito Araki²; Takafumi Ueda³; Shigeki Kakunaga³; Yoshinori Imura⁴; Norifumi Naka⁴; Hidetatsu Outani¹; Kenichiro Hamada¹; Naohiro Yasuda¹; Hideki Yoshikawa¹

¹Orthopaedic surgery, Osaka University, Suita Osaka, Osaka, Japan; ²Orthopaedic surgery, Ashiya Municipal Hospital, Ashiya, Japan; ³Orthopaedic surgery, Osaka National Hospital, Osaka, Japan; ⁴Orthopaedic surgery, Osaka International Cancer Institute, Osaka, Japan

Poster 291 3042183

OSTEOBLASTOMA-LIKE OSTEOSARCOMA: IS GRADING USEFUL?

Marco Gambarotti¹; Angelo Paolo Dei Tos²; Daniel Vanel¹; Piero Picci¹; Dino Gibertoni³; Michael Klein⁴; Alberto Righi¹

¹Anatomy and Pathological Histology, Rizzoli Orthopaedic Institute, Bologna, BO, Italy; ²Department of Pathology & Molecular Genetics, Treviso General Hospital, Treviso, Italy; ³Unit of Hygiene, Public Health and Biostatistics, Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; ⁴Department of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, NY, USA

Poster 292 3042200

CXCR4 AS POTENTIAL MARKER IN OSTEOSARCOMA

Elisa Bientinesi¹; Laura Pazzaglia¹; Barbara Dozza²; Amalia Conti³; Serena Pollino¹; Emanuela Palmerini⁴; Enrico Iucarelli²; Piero Picci¹; Maria Serena Benassi¹

¹Experimental Oncology Lab, Ortopedico Rizzoli, Bologna, Italy; ²Osteoarticular Regeneration Lab, Ortopedico Rizzoli, Bologna, Italy; ³Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; ⁴Chemotherapy Unit, Ortopedico Rizzoli, Bologna, Italy

Poster 293 3042729

ONCOLOGIC OUTCOME IN PATIENTS WITH OSTEOSARCOMA OF THE EXTREMITIES AND PATHOLOGIC FRACTURES: DIFFERENCES IN MICRO RNA PROFILE

Santiago Lozano Calderon¹; Cassandra Garbutt¹; Jason Kim¹; Ivan Chebib¹; Vikram Deshpande¹; Petur Nielsen¹; Dimitrios Spentzos¹

¹Massachusetts General Hospital Orthopaedic Oncology, Boston, MA, USA

Poster 294 3042782

CSF-1R IS A POTENTIAL PREDICTIVE BIOMARKER OF THE THERAPEUTIC RESPONSE OF OSTEOSARCOMA IN THE GSF-GETO OS2006 STUDY

Régis Brion¹; Julia Gilhodes²; Bastien Ouvrard¹; Nathalie Gaspar³; Charlotte Syrykh⁴; Aurore Siegfried⁴; Corinne Bouvier⁵; Laurence Brugieres³; Sophie Piperno-Neumann⁶; **Françoise Rédini¹**; Anne Gomez-Brouchet⁴

¹Univ Nantes, INSERM UMR1238; Nantes, France; ²Claudius Regaud institute, IUCT-Oncopole, Biostatistics Unit, Toulouse, France; ³Gustave Roussy Cancer campus, Dept of children and adolescent oncology, Villejuif, France; ⁴IUCT-Oncopole, Department of pathology, Toulouse, France; ⁵CHU La Timone, Department of pathology, Marseille, France; ⁶Curie institute, Department of medical oncology, Paris, France

Poster 295 3042798

DO POSTOPERATIVE INFECTIONS INFLUENCE THE SURVIVAL OF OSTEOSARCOMA PATIENTS? RESULTS OF A MULTICENTER TRIAL

Dimosthenis Andreou¹; Christine Schwering¹; Georg Gosheger¹; Maya Niethard²; Maria A. Smolle⁴; Frank Traub³; Simon Adam⁵; Hans Roland Dürr⁶; Jendrik Harges¹; Per-Ulf Tunn²; Andreas Leithner⁴

¹Department of General Orthopedics and Tumororthopedics, Münster University Hospital, Münster, Germany; ²Department of Orthopedic Oncology, HELIOS Klinikum Berlin-Buch, Berlin, Germany; ³Department of Orthopedics, Tübingen University Hospital, Tübingen, Germany; ⁴Department of Orthopedic Surgery and Traumatology, Medical University of Graz, Graz, Austria; ⁵Department of Orthopedics, Ludwig-Maximilians University Munich, Campus Grosshadern, Munich, Germany

Poster 296 3042922

MYC AMPLIFICATION IN OSTEOSARCOMA PATIENTS IS A BIOMARKER FOR POOR OUTCOME AND VERY RAPID DISEASE PROGRESSION

Theresa Beech²; *Christiane M. Robbins*¹; *Colleen Pearson*³; *Sherri Millis*⁴; *Pete Anderson*⁵

¹Osteosarcoma Collaborative, Rockville, MD, USA; ²Because of Daniel, Rockville, MD, USA; ³Boston University Medical Center, Boston, MA, USA; ⁴Foundation Medicine, Cambridge, MA, USA; ⁵Ped Heme Onc/BMT Onc, Cleveland Clinic, Cleveland, OH, USA

Poster 297 3027666

A PHASE II STUDY OF PAZOPANIB WITH ORAL TOPOTECAN IN PATIENTS WITH METASTATIC OSTEOSARCOMA

Mark Agulnik¹; *Nisha Mohindra*¹; *Mohammed Milhem*²; *Steven Attia*³; *Steven Robinson*⁴; *Alfred Rademaker*¹; *Scott Okuno*⁴; *Brian Van Tine*⁵

¹Hematology/Oncology, Northwestern University, Chicago, IL, USA; ²University of Iowa, Iowa City, IA, USA; ³Mayo, Jacksonville, FL, USA; ⁴Mayo, Rochester, MN, USA; ⁵Washington University, St. Louis, MO, USA

Poster 298 3033727

MULTI-ARM TRIAL IN LOCALIZED OSTEOSARCOMA: MOVING FROM A DREAM TO REALITY

Gauthier Bouche¹; *Pan Pantziarka*¹

¹The Anticancer Fund, Strombeek-Bever, Belgium

Poster 299 3039394

ANGIOPOIETIN LIKE 2: A POTENTIAL NOVEL BIOMARKER FOR PATIENTS WITH OSTEOSARCOMA

Bhavana Setty¹; *Maren Cam*²; *Hakan Cam*²

¹Pediatrics-Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH, USA; ²The Research Institute at Nationwide Children's Hospital, Nationwide Children's Hospital, Columbus, OH, USA

Poster 300 3042556

EVALUATION OF THE EFFICACY AND TOXICITY OF HIGH DOSE OF THIOTEPA (HDT) AS ADJUVANT TREATMENT TO STANDARD CHEMOTHERAPY (SCT) IN RELAPSED OSTEOSARCOMA: FINAL RESULTS OF THE MULTI-CENTRIC RANDOMIZED PHASE II TRIAL OSIITP

Perrine Marec-Berard¹; *Cécile DALBAN*²; *Laurence Brugieres*³; *Nathalie Gaspar*³; *Jean-Claude Gentet*⁵; *Cyril Lervat*⁴; *Nadege Corradini*¹; *Marie-Pierre Castex*⁶; *Claudine Schmitt*⁶; *Helene Pacquement*⁷; *Marie-Dominique Tabone*⁸; *Caroline Hernandez*²; *David Perol*⁹; *Jean-Yves Blay*¹⁰

¹Pediatric Oncology, Centre Leon Berard/IHOPE, Lyon, France; ²Biostatistics Unit - Department of Clinical Research and Innovation, Centre Leon Berard, Lyon, France; ³Institut Gustave Roussy, Villejuif, France; ⁴Centre Oscar Lambret, Lilles, France; ⁵La Timone Hospital, Marseille, France; ⁶Centre Hospitalier, Toulouse, France; ⁷Pediatric Oncology, Institut Curie, Paris, France; ⁸A. Trousseau Hospital, Paris, France; ⁹Biostatistics Unit - Department of Clinical Research and Innovation, Centre Léon Berard, Lyon, France; ¹⁰Medicine, Centre Léon Berard, Lyon, France

Poster 301 3042677

EFFICACY AND SAFETY OF CHEMOTHERAPY IN RELAPSED OSTEOSARCOMA

Takeshi Okamoto¹; *Akio Sakamoto*¹; *Junya Toguchida*²

¹Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto prefecture, Japan; ²Institute for Frontier Medical Sciences, Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto Prefecture, Japan

Poster 302 3042898

UTILIZING A NOVEL FORMULATION OF NICLOSAMIDE TO TREAT CANINE METASTATIC OSTEOSARCOMA

Gireesh B. Reddy¹; *David Kerr*²; *Artak Tovmasyan*³; *Prasad Walke*⁴; *Brian Brigman*²; *David Hsu*³; *Jason Somarelli*³; *David Needham*⁴; *William Eward*²

¹School of Medicine, Duke University, Durham, NC, USA; ²Department of Orthopaedic Surgery, Duke University, Durham, NC, USA; ³Duke Cancer Institute, Duke University, Durham, NC, USA; ⁴University of Southern Denmark, Odense, Denmark

Poster 303 3030032

COMBINED RADIATION THERAPY AND SURGERY PROVIDE EXCELLENT LOCAL CONTROL FOR PATIENTS WITH EXTRASKELETAL OSTEOSARCOMA

Andrew J. Bishop¹; John A. Livingston²; Dejka M. Araujo²; Bryan Moon³; Shreyaskumar Patel²; Wei-Lien Wang⁴; Alexander J. Lazar⁴; B. Ashleigh Guadagnolo¹

¹Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA; ²Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ³Orthopedic Surgery, MD Anderson Cancer Center, Houston, TX, USA;

⁴Pathology, MD Anderson Cancer Center, Houston, TX, USA

Poster 304 3030493

CLINICAL OUTCOME OF PERIOSTEAL OSTEOSARCOMA: A SINGLE INSTITUTIONAL STUDY

Shigeki Kakunaga¹; Satoshi Takenaka²; Yoshinori Imura³; Hidetatsu Outani²; Kenichiro Hamada²; Norifumi Naka³; Takafumi Ueda¹; Yasuaki Aoki⁴

¹Osaka National Hospital, Osaka, Japan; ²Osaka University, Suita, Japan; ³Osaka International Cancer Center, Osaka, Japan; ⁴Himeji Red Cross Hospital, Himeji, Japan

Poster 305 3042661

THE EFFECT OF RADIOTHERAPY COMBINED WITH IRON OXIDE-BASED NANOVEHICLE AND PHOTOSENSITIZER IN OSTEOSARCOMA

Yu-Chi Wang¹; Tse-Ying Liu¹

¹Biomedical Engineering, National Yang-Ming University, Taipei, Taiwan

Poster 306 3042663

OSTEOFIBROUS DYSPLASIA LIKE ADAMANTINOMA IS NOT ADAMANTINOMA

Georges Basile¹; Mark Gebhardt¹; Antonio Perez-Atayde¹; Emily Rademacher¹; Megan Anderson¹

¹Orthopaedic Surgery, Boston Children's Hospital, Boston, MA, USA

Poster 307 3037697

REFERRAL PATTERNS OF SOFT TISSUE SARCOMAS TO A TERTIARY SARCOMA CENTER OVER A 20 YEAR PERIOD

Nicholas Wallace¹; Joseph Nelson¹; Caitlin McCarthy¹; Erin Ackert¹; Taylor Wood¹; Sybil Biermann¹; Geoffrey Siegel¹

¹Orthopaedic Surgery, University of Michigan, Ann Arbor, MI, USA

Poster 308 3041866

THE INFLUENCE OF HEALTH INSURANCE STATUS ON OUTCOMES IN SOFT TISSUE SARCOMA

Jacob E. Shabason¹; Sriram Venigalla¹; Ronnie Sebro³; Giorgos C. Karakousis²; Robert J. Wilson⁴; Kristy L. Weber⁴

¹Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; ²Department of Surgery, Division of Endocrine and Oncologic Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; ³Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; ⁴Department of Orthopaedic Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

Poster 309 3042750

CLINICOPATHOLOGIC FEATURES, TREATMENT UTILIZATION TRENDS AND OUTCOMES OF PRIMARY BREAST SARCOMA : A POPULATION BASED ANALYSIS

Vipul Pareek¹; Malla Mithun¹; **Sagilla George**¹; Sixia Chen³; Alexander Stubblefield³; Abhishek Tripathi¹; Sanjay Patel²; Hassan Hatoum¹

¹Hematology and Oncology, Stephenson Cancer Center // University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; ²Urologic Oncology, Stephenson Cancer Center // University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; ³Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

Poster 310 3042849

INDETERMINATE PULMONARY NODULES AT DIAGNOSIS IN PEDIATRIC RHABDOMYOSARCOMA: ARE WE UNDERTREATING PATIENTS? A REPORT FROM THE EUROPEAN PAEDIATRIC SOFT-TISSUE SARCOMA STUDY GROUP-RMS-2005 STUDY

Bas Vaarwerk²; Kieran McHugh³; Gianni Bisogno⁴; Nadege Corradini⁵; Meriel Jenney⁶; Daniel Orbach⁷; Julia C. Chisholm⁸; Andrea Ferrari⁹; Ilaria Zanetti⁴; Gian Luca De Salvo¹⁰; Carlo Morosi⁹; Hervé J. Brisse¹¹; Rick R. van Rijn¹²; Johannes H. Merks¹

¹Princess Máxima Center for Pediatric Oncology, Amsterdam, Noord-Holland, Netherlands; ²Pediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands; ³Department of Radiology, Great Ormond Street Hospital for Children, London, United Kingdom; ⁴Pediatric Hematology and Oncology Division, Department of Woman and Children's Health, Padova University Hospital, Padova, Italy; ⁵Institut d'Hématologie et d'Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France; ⁶Department of Pediatric Oncology, Children's Hospital for Wales, Cardiff, United Kingdom; ⁷SIREDO Oncology Center, PSL University, Paris, France; ⁸Children and Young People's Department, Royal Marsden Hospital, Sutton, United Kingdom; ⁹Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy; ¹⁰Clinical Trials and Biostatistics Unit, IRCCS Istituto Oncologico Veneto, Padova, Italy; ¹¹Imaging department, Institut Curie, Paris, France; ¹²Department of Pediatric Radiology, Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands

Poster 311 3042865

THE USE OF HEALTHCARE SERVICES TWO YEARS BEFORE DIAGNOSIS IN DANISH SARCOMA PATIENTS, 2000-2013

Mathias Raedkjaer¹; Katja Maretty-Kongstad²; Thomas Baad-Hansen²; Akmal Safwat²; Michael M. Petersen³; Johnny Keller²; Peter Vedsted⁴

¹Department of Experimental Clinical Oncology, Aarhus University Hospital, Silkeborg, Denmark; ²Aarhus University Hospital, Aarhus, Denmark; ³Copenhagen University Hospital, Copenhagen, Denmark; ⁴Aarhus University, Aarhus, Denmark

Poster 312 3042880

THE ASSOCIATION BETWEEN SOCIOECONOMIC POSITION AND TUMOUR SIZE, GRADE, STAGE, AND MORTALITY IN DANISH SARCOMA PATIENTS – A NATIONAL, OBSERVATIONAL STUDY FROM 2000 TO 2013

Mathias Raedkjaer¹; Katja Maretty-Kongstad²; Thomas Baad-Hansen²; Akmal Safwat²; Michael M. Petersen³; Johnny Keller²; Peter Vedsted⁴

¹Department of Experimental Clinical Oncology, Aarhus University Hospital, Silkeborg, Denmark; ²Aarhus University Hospital, Aarhus, Denmark; ³Copenhagen University Hospital, Copenhagen, Denmark; ⁴Aarhus University, Aarhus, Denmark

Poster 313 3042903

NODAL INVOLVEMENT AND SURVIVAL IN SYNOVIAL, CLEAR CELL, ANGIO, RHABDO AND EPITHELIOID SARCOMA

Haotong Wang¹; Ruoyu Miao¹; Graham Boyd¹; Saveli Goldberg¹; Gregory M. Cote¹; Edwin Choy¹; Thomas F. DeLaney¹; **Yen-Lin E. Chen¹**

¹Radiation Oncology, MGH, Burlington, MA, USA

Poster 314 3042961

SARCOMA TREATMENT IN ONTARIO: A POPULATION-BASED STUDY

Anthony Bozzo¹; Greg Pong¹; Hsien Seow¹; Michelle Ghert¹

¹McMaster University, Hamilton, ON, Canada

Poster 315 3030594

THE ROUTE TO DIAGNOSIS (RTD) OF SARCOMA PATIENTS: A QUALITATIVE STUDY IN THE NETHERLANDS (NL) AND THE UNITED KINGDOM (UK)

Victorien Soomers¹; Ingrid Desar¹; Shane Zaidi³; Suzanne E. Kaal¹; Andrew J. Hayes³; H.W.B. Schreuder⁴; R. L. Jones³; Winette van der Graaf²; Olga Husson²

¹Medical Oncology, Radboudumc, Nijmegen, Netherlands; ²Institute of Cancer Research, London, United Kingdom; ³Sarcoma Unit, Royal Marsden Hospital, London, United Kingdom; ⁴Orthopaedic Surgery, Radboudumc, Nijmegen, Netherlands

Poster 316 3021215

OUTCOME DATA OF ADVANCED SOFT TISSUE SARCOMA PATIENTS FROM A TERTIARY REFERRAL CENTER: NOT SO BAD AS OFTEN REPORTED?

*Jakob Lochner¹; Franka Menge¹; Jens Jakob¹; Peter Hohenberger¹; **Bernd Kasper¹***

¹Mannheim University Medical Center, Mannheim, Germany

Poster 317 3027342

A CLINICOPATHOLOGIC EXAMINATION OF MYXOFIBROSARCOMA. RATES OF LOCAL RECURRENCE, METASTASES AND PATIENT SURVIVAL FROM A SINGLE INSTITUTION

***Fan Yang¹**; Farnaz Dadrass¹; Julie Bloom¹; Yale Fillingham¹; Matthew Colman¹; Steven Gitelis¹; Alan Blank¹*

¹Orthopedics, Rush University, Chicago, IL, USA

Poster 318 3029786

METASTASECTOMY IN SOFT TISSUE SARCOMA IS ASSOCIATED WITH A POST-METASTASIS SURVIVAL BENEFIT. RESULTS FROM A BI-CENTRE STUDY INCLUDING 135 PATIENTS.

***Maria A. Smolle¹**; Veroniek M. Van Praag²; Florian Posch³; Marko Bergovec¹; Ronald Heregger³; Joanna Szkander³;*

Bernadette Liegl-Atzwanger⁴; Freyja-Maria Smolle-Jüttner⁵; Michiel A. van de Sande²; Andreas Leithner¹

¹Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria; ²Department of Orthopaedic Surgery, Leiden University Medical Centre, Leiden, Netherlands; ³Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Graz, Austria; ⁴Institute of Pathology, Medical University of Graz, Graz, Austria; ⁵Division of Thoracic and Hyperbaric Surgery, Medical University of Graz, Graz, Austria

Poster 319 3037787

SOFT TISSUE SARCOMA OF THE EXTREMITY: ASSOCIATION BETWEEN TREATMENT DELAY, TUMOR FEATURES AND SURVIVAL

***Ambria S. Moten¹**; Sujana Movva²; Margaret von Mehren²; Sanjay Reddy³; Krisha Howell⁴; Elizabeth Handorf⁵;*

Jeffrey Farma³

¹Surgery, Temple University Hospital, Philadelphia, PA, USA; ²Dept of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; ³Surgery, Fox Chase Cancer Center, Philadelphia, PA, USA; ⁴Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; ⁵Biostatistics, Fox Chase Cancer Center, Philadelphia, PA, USA

Poster 320 3041954

DESCRIPTIVE ANALYSIS OF LONG-TERM SURVIVORS AMONG PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA

***Armelle Dufresne¹**; Melodie Carbonnaux¹; Mehdi Brahmi¹; Camille Schiffler¹; Pierre Méeus¹; Marie-Pierre Sunyach¹;*

Amine Bouhamama¹; Marie Karanian¹; Daniel Pissaloux¹; Gualter Vaz¹; Jean-Yves Blay¹

¹Centre Leon Berard, Lyon, France

Poster 321 WITHDRAWN

Poster 322 3042697

THE CLINICAL CHARACTERISTICS AND OUTCOMES OF PRIMARY BREAST SARCOMA: RETROSPECTIVE STUDY OVER 20 YEARS FROM A SINGLE, TERTIARY CENTER

***Hye Yeong Kim¹**; Jae Ho Jeong²; Jeong Eun Kim²; Jin-Hee Ahn²*

¹Internal Medicine, Asan Medical Center, Seoul, Korea (the Republic of); ²Medical Oncology, Asan Medical Center, Seoul, Korea (the Republic of)

Poster 323 3042704

TWENTY-EIGHT-YEAR EXPERIENCE OF SOFT-TISSUE AND BONE SARCOMAS AT A TERTIARY CARE HOSPITAL IN KOREA

Hyeon-Su Im²; Jae Ho Jeong¹; Jeong Eun Kim¹; Wanlim Kim³; Jong Seok Lee¹; Kyung-Ja Cho⁴; Joon Seon Song⁴; Si Yeol Song⁵; Hye Won Chung⁶; Min Hee Lee⁶; Jin-Hee Ahn¹

¹Department of Oncology, Asan medical center, Seoul, Korea (the Republic of); ²Department of Internal Medicine, Asan medical center, Seoul, Korea (the Republic of); ³Department of Orthopedic Surgery, Asan medical center, Seoul, Korea (the Republic of); ⁴Department of Pathology, Asan medical center, Seoul, Korea (the Republic of); ⁵Department of Radiation Oncology, Asan medical center, Seoul, Korea (the Republic of); ⁶Department of Radiology, Asan medical center, Seoul, Korea (the Republic of)

Poster 324 3042875

MULTIMODAL TREATMENT IN PATIENTS (PTS) WITH ADVANCED/METASTATIC SOFT TISSUE SARCOMA (A/M STS): IMPROVMENT IN OVERALL SURVIVAL (OS) IS MAINLY ASSOCIATED WITH COMBINATION OF CHEMOTHERAPY (RX) AND SURGERY (SX).

Philipp Ivanyi¹; Katharina Stange¹; Hendrik Eggers¹; Chritoph Reuter¹; Martin Panzica²; Patrick Zardo⁵; Florian Laenger³; Hans Christiansen⁴; Arnold Ganser¹; Viktor Gruenwald¹

¹Dep. for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany, Germany; ²Department for trauma and tumor surgery, Hannover Medical School, Hannover, Hannover, Germany; ³Department for Pathology, Hannover Medical School, Hannover, Germany; ⁴Department for Radiotherapy, Hannover Medical School, Hannover, Germany; ⁵Department for Thoracic surgery, Hannover Medical School, Hannover, Germany

Poster 325 3017541

PROGNOSTIC SIGNIFICANCE OF SARCOPENIA IN PATIENTS WITH SOFT TISSUE SARCOMA

YoungHyun Choi¹; Wanlim Kim¹; JongSeok Lee¹; Hye Won Chung²

¹Department of Orthopedic Surgery, Asan Medical Center, Seoul, Korea (the Republic of); ²Department of Radiology, Asan Medical Center, Seoul, Korea (the Republic of)

Poster 326 3025847

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES FOR PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA RECEIVING SYSTEMIC THERAPY IN BRAZIL

Andreia C. de Melo³; Patricia X. Santi⁴; Sabina B. Aleixo⁵; Cicero L. Martins⁶; Patricia M. Beato⁷; Fabio L. Fernandez⁸; Claudia M. Guimaraes⁹; Renato W. de Oliveira¹; Henrique F. de Souza¹; Guilherme S. Julian¹; Fabiana G. de Menezes⁹; **Diego Novick**²

¹Evidências – Kantar Health, Sao Paulo, Sao Paulo, Brazil; ²Eli Lilly and Company, Windlesham, United Kingdom; ³Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro, RJ, Brazil; ⁴Centro de Estudos e Pesquisas de Hematologia e Oncologia / FM ABC, Santo Andre, Brazil; ⁵Hospital Evangélico de Cachoeiro de Itapemirim, Hospital Evangélico de Cachoeiro de Itapemirim, Brazil; ⁶Instituto COI de Educação e Pesquisa, Rio de Janeiro, Brazil; ⁷Fundação Amaral Carvalho, Jau, Brazil; ⁸Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil; ⁹Eli Lilly do Brasil, Sao Paulo, Brazil

Poster 327 3027452

NETWORK META-ANALYSIS OF RANDOMIZED TRIALS FOR SECOND OR LATER-LINE TREATMENTS OF METASTATIC LIPOSARCOMA

Moon Hee Lee¹; Jinchul Kim¹; Joo Han Lim¹; Jinhyun Cho¹; Hyunkyung Park¹

¹hematology-oncology, Inha university college of medicine and hospital, Incheon, Korea (the Republic of)

Poster 328 3027524

DESCRIPTIVE EPIDEMIOLOGY AND CLINICAL OUTCOMES OF SOFT TISSUE SARCOMAS IN ADOLESCENT AND YOUNG ADULT PATIENTS IN JAPAN

Toru Akiyama¹; Koichi Ogura²; Takashi Fukushima¹; Katsushi Takeshita³; Akira Kawai²

¹Orthopaedic surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan; ²Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan; ³Orthopaedic surgery, Jichi Medical University, Tochigi, Japan

Poster 329 3038308

PATTERNS OF CARE OF ADVANCED SOFT TISSUE SARCOMAS (STS) NON-GIST IN FOUR EUROPEAN COUNTRIES (EU4)

Ettore Mari¹; Alejandra Martinez de Pinillos²; Paola Nasuti²; Filippo Guglielmetti¹; Caroline Anger²

¹IQVIA, Milan, Italy; ²IQVIA, London, United Kingdom

Poster 330 3042802

A MATCHED COHORT STUDY OF ADJUVANT RADIO-CHEMOTHERAPY VERSUS RADIOTHERAPY ALONE IN SOFT TISSUE SARCOMA PATIENTS

Daniela Greto¹; Anna Peruzzi¹; Giulia Stocchi¹; Monica Lo Russo¹; Cristina Muntoni¹; Giorgio Caramia¹; Sara Lucidi¹; Pierluigi Bonomo¹; Mauro Loi¹; Giulio Francolini¹; Isacco Desideri¹; Domenico Andrea Campanacci²; Davide Matera²; Nicola Mondanelli²; Lorenzo Livi¹

¹Radiation Oncology, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy;

²Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliera Universitaria Careggi, Florence, Italy

Poster 331 3042925

RISK STRATIFICATION OF SOFT TISSUE SARCOMA FOR PREDICTION OF LOCAL RECURRENCE

Cameron Killen²; Cathleen Cahill²; Julie Stoner³; Pravina Kota³; Kimberley Hollabaugh³; **Lukas M. Nystrom¹**;

Jeremy White³

¹Orthopaedic Surgery, Cleveland Clinic, Cleveland, OH, USA; ²Loyola University Chicago, Maywood, IL, USA;

³Oklahoma University, Oklahoma City, OK, USA

Poster 333 3042160

CLINICAL IMPLEMENTATION OF A NANOSTRING-BASED PANSARCOMA FUSION ASSAY

Angela Goytain¹; Julie Ho¹; Samuel Leung¹; Chick H. Kuick²; Huiyi Chen²; Cheng Han Lee¹; Kenneth T. Chang²; Tony Ng¹; Torsten O. Nielsen¹

¹Department of Pathology, University of British Columbia and Vancouver Coastal Health Research Institute, Vancouver, BC, Canada;

²Department of Pathology and Laboratory Medicine, KK Women's and Children's Hospital and the Duke-NUS Medical School, Singapore, Singapore

Poster 334 3041833

VIRTUAL BIOBANKING FOR RETROPERITONEAL SARCOMA – A TARPSWG INITIATIVE

Winan J. van Houdt¹; Sally M. Burtenshaw²; Chandrajit Raut³; Marco Fiore⁴; Alessandro Gronchi⁴; Rebecca Gladdy²

¹Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; ²Surgical Oncology, Princess Margaret Cancer Centre, Mount Sinai Hospital, Toronto, ON, Canada; ³Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ⁴Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

Poster 335 3041966

IDENTIFICATION OF RECURRENT FUSIONS WITHIN SUCCINATE DEHYDROGENASE A (SDHA) IN WELL DIFFERENTIATED RETROPERITONEAL LIPOSARCOMA

Robert Tyler¹; Anant Desai²; Valerie Pestinger¹; Andrew Beggs¹

¹Surgical Research Laboratory, Institute of Cancer and Genomic Sciences, Birmingham University, Birmingham, United Kingdom;

²Sarcoma and General Surgery, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom

Poster 336 3025780

SENSITIVITY OF DIFFERENT BIOPSY METHODS IN SOFT TISSUE AND BONE SARCOMAS: CORE NEEDLE VS. INCISIONAL BIOPSY

Alexander Klein¹; Theresa Fell¹; Volkmar Jansson¹; Hans Roland Dürr¹; Thomas Knösel²

¹Musculoskeletal Oncology; Department of Orthopaedic Surgery, Physical Medicine and Rehabilitation, University Hospital, LMU Munich, Munich, Germany;

²Institute of Pathology, Hospital of University Munich, LMU Munich, Munich, Germany

Poster 337 3028837

UTILITY OF CORE NEEDLE BIOPSY IN RETROPERITONEAL LIPOSARCOMA: A FIFTEEN YEAR REVIEW

Ashley N. Flaman²; Carolyn Nessim¹; Denis H. Gravel²; Iris Y. Teo²; Bibiana Purgina²

¹Surgery, The Ottawa Hospital, Ottawa, ON, Canada; ²Pathology, The Ottawa Hospital, Ottawa, ON, Canada

Poster 338 3035429

WHAT IS THE DIAGNOSTIC ACCURACY OF BIOPSIES OF SOFT TISSUE SARCOMAS?

Anthony M. Griffin¹; *Nicolle Clements¹; Jay Wunder¹; Peter Ferguson¹*

¹*Orthopaedic Surgery, Mount Sinai Hospital, Toronto, ON, Canada*

Poster 339 3035892

DIAGNOSTIC ACCURACY OF PERCUTANEOUS BIOPSY IN RETROPERITONEAL SARCOMA

Max Almond¹; *Fabio Tirota²; Alessandro Gronchi²; Carlo Morosi²; Hannah Tattersall¹; James Hodson¹; Tommaso Cascella²; Marta Barisella²; Alfonso Marchiano²; Giorgio Greco²; Anant Desai¹; Samuel Ford¹; Marco Fiore²*

¹*Sarcoma Surgery, University Hospital Birmingham, Birmingham, United Kingdom; ²Istituto dei Tumori, Milan, Italy*

Poster 340 3042770

MDM2 AMPLIFICATION AND FUSION GENE SS18-SSX IN A POORLY DIFFERENTIATED SARCOMA: A RARE BUT PUZZLING CONJUNCTION

Florence Pedeutour¹; *Ilaria Di Mauro¹; Lénaïg Mescam-Mancini²; Bruno Chetaille²; Marick Lae⁵; Gaele Pierron⁶; Dominique Ranchere-Vince³; Berengere Dadone-Montaudie¹; Thibault Fabas¹; Jean-François Michiels⁴*

¹*Laboratory of Solid Tumors Genetics, Nice University Hospital, Nice, France; ²Biology of Cancer, Institut Paoli Calmettes, Marseille, France; ³Pathology, Centre Léon-Bérard, Lyon, France; ⁴Pathology, Nice University Hospital, Nice, France; ⁵Pathology, Institut Curie, Paris, France; ⁶Somatic Genetics, Institut Curie, Paris, France*

Poster 341 3041738

DESMOID FIBROMATOSIS THROUGH THE PATIENTS' EYES: TIMES TO CHANGE THE FOCUS AND ORGANISATION OF CARE?

Olga Husson¹; *Eugenie Younger²; Alison Dunlop²; Lucy Dean²; Dirk Strauss²; Charlotte Benson²; Andy Hayes²; Aisha Miah²; Winan J. van Houdt³; Shane Zaidi²; Myles J. Smith²; John Williams²; Robin Jones²; Winette van der Graaf¹*

¹*Institute of Cancer Research, Sutton, London, United Kingdom; ²Royal Marsden Hospital, London, United Kingdom; ³Netherlands Cancer Institute, Amsterdam, Netherlands*

Poster 342 3041928

IS ANYBODY LISTENING? CLINICIAN UNDER-RECOGNITION OF SYMPTOM SEVERITY IN RETROPERITONEAL SARCOMA PATIENTS: A COMPARISON OF PHYSICIAN ASSESSMENTS AND PATIENT SELF-REPORTED OUTCOMES

Andrea M. Covelli¹; *Deanna Ng²; Sally Burtenshaw²; Rebecca Gladly²; Savtaj Brar³; Carol Swallow²*

¹*Surgical Oncology, University of Toronto, Toronto, ON, Canada; ²Surgical Oncology, Princess Margaret Cancer Centre, Mount Sinai Hospital, Toronto, ON, Canada; ³Surgical Oncology, Mount Sinai Hospital, Toronto, ON, Canada*

Poster 343 3042701

EXPERIENCES OF PATIENTS WITH BONE CANCER: THE ROLE OF ILLNESS AND DEVELOPMENT TRAJECTORIES, HEALTHCARE PROFESSIONALS, SOCIAL SUPPORT AND COPING STRATEGIES

Ana Martins⁷; *Lesley Storey²; Mary Wells³; Lorna A. Fern⁴; Lindsey Bennister⁵; Craig Gerrand¹; Maria Onasanya⁶; Julie Woodford¹; Rachael Windsor⁷; Jeremy Whelan⁷; Rachel Taylor⁷*

¹*The Royal National Orthopaedic Hospital, London, United Kingdom; ²Queens University Belfast, Belfast, United Kingdom; ³Imperial College Healthcare NHS Trust, London, United Kingdom; ⁴National Cancer Research Institute, London, United Kingdom; ⁵-, London, United Kingdom; ⁶patient representative, London, United Kingdom; ⁷University College London Hospitals NHS Trust, London, United Kingdom*

Poster 344 3022139

PERCEPTIONS OF CLINICAL TRIAL ENROLLMENT AND MOLECULAR PROFILING IN PATIENTS WITH BONE AND SOFT TISSUE SARCOMA

Ari Rosenberg¹; *Sheetal Kircher¹; Elizabeth Hahn²; Karl Bilimoria³; Jeffrey Wayne³; Alfred Rademaker⁴; Mark Agulnik¹*

¹*Hematology and Oncology, Northwestern University, Chicago, IL, USA; ²Medical Social Sciences and Preventative Medicine, Northwestern University, Chicago, IL, USA; ³Surgical Oncology, Northwestern University, Chicago, IL, USA; ⁴Preventive Medicine, Northwestern University, Chicago, IL, USA*

Poster 345 3031162

PATIENT-REPORTED FUNCTIONAL OUTCOMES IN A COHORT OF HAND AND FOOT SARCOMA SURVIVORS TREATED WITH LIMB SPARING SURGERY AND RADIATION THERAPY

Safia K. Ahmed¹; Suneetha Kaggal³; Jessica Sawyer²; William S. Harmsen³; Ivy Petersen¹

¹Radiation Oncology, Mayo Clinic, Rochester, MN, USA; ²Radiation Oncology, Essentia Health- Duluth Clinic, Duluth, MN, USA; ³Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA

Poster 346 3043080

A SCANDINAVIAN POINT OF VIEW -CARING FOR PATIENTS WITH SARCOMA ACROSS BOUNDARIES

Stine Naess¹

¹Department of Early Cancer Trials and Research Support, Oslo University Hospital, Oslo, Norway

Poster 347 3042521

DEPRESSION AND ANXIETY AMONG NEWLY DIAGNOSED SARCOMA PATIENTS

Amirrtha Srikanthan¹; Bonnie Leung²; Aria Shokoochi²; Alannah Smrke²; Heather Rennie²; Alan Bates²; Cheryl Ho²

¹Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; ²Medical Oncology, The BC Cancer, Vancouver, BC, Canada

Poster 348 3042929

RELAX: AN IMMERSION VIRTUAL REALITY RELAXATION INTERVENTION FOR QUALITY OF LIFE IMPROVEMENT IN CANCER PATIENTS

Erlinda M. Gordon¹; Bryan M. Li²; Seiya M. Liu²; Sant P. Chawla¹; Seiji M. Liu²; Stephen M. Liu²

¹Sarcoma Oncology Center, Santa Monica, CA, USA; ²IFGCURE, Santa Monica, CA, USA

Poster 349 3012461

CAREER AND FINANCIAL SITUATION OF PATIENTS DIAGNOSED WITH SOFT TISSUE SARCOMAS

Nele Laros¹; Ulf Seifart²; Susanne Gutermuth³; Markus Wartenberg³; Peter Hohenberger¹; **Bernd Kasper**¹

¹Mannheim University Medical Center, Mannheim, Germany; ²Klinik Sonnenberg, Marburg, Germany; ³Das Lebenshaus e.V., Wölfersheim, Germany

Poster 350 3029744

PREFERENCES FOR END-OF-LIFE DISCUSSIONS AND CARE AMONG PATIENTS WITH ADVANCED OR RECURRENT SARCOMA

Aiko Maejima¹; Kan Yonemori²; Motokiyo Komiyama¹; Akira Kawai³; Hiroyuki Fujimoto¹

¹Department of Urology, National Cancer Center Hospital, Tokyo, Japan; ²Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; ³Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan

Poster 351 3042822

A NOVEL APPROACH FOR ASSESSING FUNCTIONAL BURDEN OF SOFT TISSUE SARCOMA SURGERY: DIGITAL PHENOTYPING AND RECOVERY AFTER RESECTION OF RETROPERITONEAL AND ABDOMINAL SOFT TISSUE TUMORS

Ian Solsky¹; Josh Barback²; Emily Huang²; Karen De Amorim Bernstein³; Yen-Lin E. Chen³; Thomas F. DeLaney³; John T. Mullen⁴; JP Onnela²; **Alex Haynes**¹

¹Ariadne Labs, Boston, MA, USA; ²Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA;

³Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁴Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA

Poster 352 3042895

DEFINITIVE HIGH DOSE PROTON THERAPY FOR UNRESECTED OSTEOSARCOMAS OF THE SPINE AND PELVIS: A VIABLE ALTERNATIVE?

Haotong Wang¹; Ruoyu Miao¹; Joseph H. Schwab¹; Edwin Choy²; Gregory M. Cote²; David Ebb²; Francis Hornicek³; Thomas F. DeLaney¹; **Yen-Lin E. Chen**¹

¹Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA; ³Orthopedic Oncology, UCLA, Los Angeles, CA, USA

Poster 353 3027641

RADIOTHERAPY FOR EXTREMITY SOFT TISSUE SARCOMA: THE ROLE OF A NORMAL SOFT TISSUE STRIP IN VMAT PLANNING

Chan-Kyung J. Cho¹; Nevin McVicar¹; Robynn Ferris¹; Kerry James¹; Karen Goddard¹; Steven Thomas¹

¹Radiation Oncology, BC Cancer, Vancouver, BC, Canada

Poster 354 3041869

FEMUR FRACTURE IN PRIMARY SOFT-TISSUE SARCOMA OF THE THIGH AND GROIN TREATED WITH INTENSITY-MODULATED RADIATION THERAPY: OBSERVED VS EXPECTED RISK

Michael Folkert¹; Dana Casey³; Sean Berry²; Aimee M. Crago⁴; Nicola Fabbri⁵; Sam Singer⁴; Kaled Alektiar³

¹Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA; ²Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ³Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA;

⁴Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁵Orthopedic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

⁴Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁵Orthopedic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Poster 355 3042909

HISTOPATHOLOGIC RESPONSE TO NEOADJUVANT RADIATION THERAPY DOES NOT PREDICT ONCOLOGIC OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA OF THE TRUNK AND EXTREMITY

Sneha Rao¹; Alexander L. Lazarides²; Bruce Leckey³; Whitney Lane⁴; Julia Visgauss²; Jason Somarelli²;

Daniel Nussbaum⁴; David Kirsch⁵; Brian Brigman²; Dan Blazer III⁴; Diana Cardona³; William Eward²

¹School of Medicine, Duke University, Durham, NC, USA; ²Orthopaedics, Duke University, Durham, NC, USA;

³Pathology, Duke University, Durham, NC, USA; ⁴Surgery, Duke University, Durham, NC, USA; ⁵Radiation Oncology, Duke University, Durham, NC, USA

Duke University, Durham, NC, USA

Poster 356 3042911

ACUTE POST-OPERATIVE WOUND COMPLICATIONS FOLLOWING PRE-OPERATIVE PROTON BEAM IRRADIATION FOR SOFT TISSUE SARCOMAS

Colleen Kiernan¹; Nikita Rajkot¹; Andrew J. Bishop¹; Stephen Hahn¹; B. Ashleigh Guadagnolo¹; Christina Roland¹;

Quynh-Nhu Nguyen¹; Barry Feig¹

¹MD Anderson Cancer Center, Houston, TX, USA

Poster 357 3042914

PROTON-BASED HIGH-DOSE PRE-OPERATIVE RADIATION IS ASSOCIATED WITH HIGHER LOCAL CONTROL THAN LOW-DOSE PRE-OPERATIVE RADIATION WITH EQUIVALENT RATE OF WOUND COMPLICATION IN SACROCCYGEAL CHORDOMAS

Genevieve Maquilan¹; Aashish Bhatt²; Ruoyu Miao³; Francis Hornicek⁴; Joseph H. Schwab⁵; Thomas F. DeLaney³;

Yen-Lin E. Chen³

¹Radiation Oncology, Massachusetts General Hospital Cancer Center at Cooley Dickinson Hospital, Northampton, MA, USA; ²Radiation Oncology, The Ohio State University, Columbus, OH, USA; ³Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁴Orthopaedic Surgery, University of California, Los Angeles, Santa Monica, CA, USA;

⁵Orthopaedics, Massachusetts General Hospital, Boston, MA, USA

⁵Orthopaedics, Massachusetts General Hospital, Boston, MA, USA

Poster 358 3042987

URETERAL STRICTURE AND RADIATION DOSE CONSTRAINT IN THE TREATMENT OF RETROPERITONEAL SARCOMA

Graham Boyd¹; Kyung-Wook Jee¹; Ruoyu Miao¹; John T. Mullen²; Francis McGovern³; Alex Haynes²;

Thomas F. DeLaney¹; **Yen-Lin E. Chen¹**

¹Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA; ³Urology, Massachusetts General Hospital, Boston, MA, USA

Urology, Massachusetts General Hospital, Boston, MA, USA

Poster 359 3042212

LONG TERM OUTCOMES AND TOXICITIES FROM A PHASE II TRIAL OF FOCAL CONFORMAL RADIATION THERAPY (RT) FOR CHILDREN WITH RHABDOMYOSARCOMA (RMS)

Matthew J. Krasin²; Christopher L. Tinkle²; Sue Kaste¹; Mary Elizabeth McCarville¹; Chia-ho Hua²; Andrew M. Davidoff³;

Barry Shulkin¹; Alberto Pappo⁴

¹Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, USA; ²Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA; ³Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA; ⁴Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA

⁴Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA

Poster 360 3042856

ACHIEVING HIGH RATES OF LOCAL CONTROL AND FAVORABLE TOXICITY USING STEREOTACTIC BODY RADIOTHERAPY FOR SARCOMA PULMONARY METASTASES: A MULTI-INSTITUTIONAL EXPERIENCE

Karen De Amorim Bernstein¹; Brian Baumann²; Edwin Choy¹; Kristy L. Weber³; Ashok Muniappan¹; Abigail Berman³; Arthur Staddon³; Lee Hartner³; Brian Van Tine²; Stephen Hahn⁴; Eli Glatstein³; Charles Simone II⁵; Suneel Nagda³; William Levine³; James Kolker³; Thomas F. DeLaney¹; Yen-Lin E. Chen¹

¹Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA; ²Radiation Oncology, Washington University, Saint Louis, MO, USA; ³Radiation Oncology, UPenn, Philadelphia, PA, USA; ⁴Radiation Oncology, MD Anderson, Houston, TX, USA; ⁵Radiation Oncology, University of Maryland School Of Medicine, Baltimore, MD, USA

Poster 361 3011135

TIME DEPENDENT DYNAMICS OF WOUND COMPLICATIONS AFTER PREOPERATIVE RADIOTHERAPY IN EXTREMITY SOFT TISSUE SARCOMAS

Jules Lansu¹; Jan Groenewegen¹; Frits van Coevorden²; Winan J. van Houdt²; Alexander van Akkooi²; Hester van Boven³; Marcel Verheij¹; Rick Haas¹

¹Radiotherapy, Netherlands Cancer Institute, Amsterdam, Netherlands; ²Surgery, Netherlands Cancer Institute, Amsterdam, Netherlands; ³Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands

Poster 362 3014815

EFFICACY OF ADJUVANT RADIOTHERAPY IN NON-EXTREMITY SOFT TISSUE SARCOMA WITH MODERATE CHEMOSENSITIVITY

Hyojeong Kim¹; Young Mi Seol¹; Young Jin Choi¹; Eun Mi Lee²

¹Hematooncology, Pusan National University Hospital, Busan, Korea (the Republic of); ²Hematooncology, Kosin University Gaspel Hospital, Busan, Korea (the Republic of)

Poster 363 3019507

IMPACT OF RADIATION DOSE AND METHOD OF DELIVERY ON SURVIVAL IN CHORDOMAS

Brian L. Dial¹; David Kerr¹; Alexander L. Lazarides¹; Anthony Catanzano¹; Whitney Lane²; Dan Blazer III²; Brian Brigman¹; William Eward¹; Melissa Erickson¹; Sergio Mendoza¹

¹Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA; ²General Surgery, Duke University Medical Center, Durham, NC, USA

Poster 364 3026070

EARLY ANALYSIS OF PROSPECTIVE PHASE II CLINICAL TRIAL ON PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY (RT) COMBINED WITH CHEMOTHERAPY IN PRIMARY MARGINALLY RESECTABLE HIGH GRADE SOFT TISSUE SARCOMAS (STS) OF EXTREMITIES OR TRUNK WALL

Piotr Rutkowski¹; Mateusz Spalek²; Aneta Borkowska²; Michal Wagrodzki³; Andrzej Cieszanowski⁴; Patricia Castaneda-Wysocka⁴; Tomasz Switaj¹; Slawomir Falkowski¹; Monika Dudzisz-Sledz¹; Anna M. Czarnecka¹; Edyta Dabrowska-Szewczyk²; Hanna Kosela-Paterczyk¹

¹Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland; ²Radiotherapy, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland; ³Pathology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland; ⁴Radiology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland

Poster 365 3038606

PATTERNS OF PRACTICE SURVEY: RADIOTHERAPY FOR EXTREMITY SOFT TISSUE SARCOMA

Chan-Kyung J. Cho¹; Charles Catton²; Caroline Holloway¹; Karen Goddard¹

¹Radiation Oncology, BC Cancer, Vancouver, BC, Canada; ²Princess Margaret Hospital, Toronto, ON, Canada

Poster 366 3041914

EFFECT OF RADIOTHERAPY ON MRI MEASURES OF TUMOR INVASIVENESS AND OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIOTHERAPY AND SURGICAL EXCISION

Dustin C. Buller¹; Courtney Toombs²; Francis Lee²; Gary Friedlaender²; Dieter Lindskog²

¹Department of Orthopaedic Surgery, University of Texas Southwestern Medical School, Dallas, TX, USA; ²Department of Orthopaedics & Rehabilitation, Yale University School of Medicine, New Haven, CT, USA

Poster 367 3042496

PHASE 1 TRIAL OF PREOPERATIVE IMAGE GUIDED INTENSITY MODULATED PHOTON RADIATION THERAPY (IMRT) WITH SIMULTANEOUSLY INTEGRATED BOOST TO THE HIGH-RISK MARGIN FOR RETROPERITONEAL SARCOMAS

Thomas F. DeLaney¹; Yen-Lin E. Chen¹; Beow Yeap⁴; Ying J. Hitchcock²; Kilian Salerno³; John Kane⁵; Alex B. Haynes¹⁰; Rachel M. Deering⁴; Claire Clendenen⁴; Dan Blazer III¹¹; David Kirsch⁶; Jeff M. Michalski⁷; Elizabeth H. Baldini⁸; Dian Wang⁹

¹Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Radiation Oncology, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA; ³Radiation Oncology, Roswell Park Memorial Cancer institute, Buffalo, NY, USA; ⁴Cancer Center, Massachusetts General Hospital, Boston, MA, USA; ⁵Surgical Oncology, Roswell Park Memorial Cancer institute, Buffalo, NY, USA; ⁶Radiation Oncology, Duke University Medical Center, Durham, NC, USA; ⁷Radiation Oncology, Washington University Medical Center, St. Louis, MO, USA; ⁸Radiation Oncology, Brigham and Women's Hospital/Dana Farber Cancer Institute, Boston, MA, USA; ⁹ Radiation Oncology, Rush University Medical Center, Chicago, IL, USA; ¹⁰Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA; ¹¹Surgical Oncology, Duke University Medical Center, Durham, NC, USA

Poster 368 3042574

NOVEL THERAPY WITH 103PD-DIRECTIONAL BRACHYTHERAPY DEVICE FOR RECURRENT SOFT TISSUE SARCOMAS: SAFETY AND EARLY POSTOPERATIVE OUTCOMES

Francisco Igor Macedo¹; Matthew Studenski²; Raphael Yechieli²; Breelyn A. Wilky³; Jonathan Trent³; Dido Franceschi¹; Alan S. Livingstone¹

¹Division of Surgical Oncology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA; ²Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA; ³Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA

Poster 369 3042878

TOMOTHERAPY IMRT IN MANAGEMENT OF EXTREMITY SOFT TISSUE SARCOMAS - 8 YEARS' EXPERIENCE, NORTHERN CENTRE FOR CANCER CARE, FREEMAN HOSPITAL

Jayshree Veeratterapillay¹; Anthony Waton¹; **Judith Mott¹**; Tracy Wintle¹; Daniela Lee¹

¹Clinical Oncology, Northern Centre for Cancer Care, Newcastle Upon Tyne, United Kingdom

Poster 370 3041714

COMPLETION RATE AND TOXICITY OF HYPO-FRACTIONATED RADIOTHERAPY FOR RETROPERITONEAL AND PELVIC SOFT TISSUE SARCOMAS

Hilario Yankey¹; Casey Hollawell¹; **Krishna Howell¹**; Joshua E. Meyer¹; Margaret von Mehren²; John Abraham²; Sujana Movva²; Jeffrey Farma²; Sanjay Reddy²; Eric Ross²

¹Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; ²Fox Chase Cancer Center, Philadelphia, PA, USA

Poster 371 3042784

EFFICACY AND SAFETY OF STEREOTACTIC BODY RADIATION THERAPY SBRT WITH CONCURRENT TRABECTEDIN IN METASTATIC SOFT-TISSUE SARCOMA PATIENTS. A SINGLE INSTITUTION EXPERIENCE

Daniela Greto¹; Monica Lo Russo¹; Cristina Muntoni¹; Giorgio Caramia¹; Anna Peruzzi¹; Giulia Stocchi¹; Virginia Maragna¹; Maria Ausilia Teriaca¹; Isacco Desideri¹; Giulio Francolini¹; Mauro Loi¹; Pierluigi Bonomo¹; Domenico Andrea Campanacci²; Giovanni Beltrami²; Guido Scoccianti²; Pierluigi Cuomo²; Lorenzo Livi¹

¹Radiation Oncology, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy; ²Orthopaedic Oncology and Reconstructive Surgery, Azienda Ospedaliera Universitaria Careggi, Florence, Italy

Poster 372 3042873

OPTIMIZING TREATMENT DECISIONS FOR PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA (STS): INDIVIDUAL IDENTIFICATION OF RESPONDERS TO ADJUVANT RADIOTHERAPY (AXRT).

David J. Biau¹; Peter Ferguson²; Anthony M. Griffin²; Peter Chung³; Charles Catton³; Justine Jacot⁴; Raphael Porcher⁴; Jay Wunder²

¹Hôpital Cochin, Paris, IDF, France; ²Surgical Oncology - orthopedics, Mount Sinai, Toronto, ON, Canada; ³Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada; ⁴Hopital Hotel Dieu, Paris, IDF, France

Poster 373 3042826

ANGIOSARCOMA OF THE SCALP AND FACE TREATED WITH HIGH-DOSE-RATE SURFACE APPLICATOR (HDR SA) BRACHYTHERAPY

Miranda B. Lam¹; Michelle Nezoslosky¹; Chandrajit P. Raut³; Katherine Thornton²; Ivan Buzurovic¹; Phillip M. Devlin¹; Elizabeth H. Baldini¹

¹Radiation Oncology, Brigham and Women's Hospital / Dana Farber Cancer Institute, Boston, MA, USA;

²Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; ³Surgery, Brigham and Women's Hospital / Dana Farber Cancer Institute, Boston, MA, USA

Poster 374 3042910

PREDICTORS OF LYMPH NODE INVOLVEMENT AND BENEFIT OF REGIONAL RADIOTHERAPY IN SOFT TISSUE SARCOMA

George Q. Yang¹; Arash Naghavi¹

¹Radiation Oncology, H. L. Moffitt, Tampa, FL, USA

Poster 375 3018125

PENCIL BEAM SCANNING PROTON RADIOTHERAPY REDUCES DOSE TO THE PLANNED SURGICAL SKIN FLAP AND UNINVOLVED BONE IN PREOPERATIVE RADIOTHERAPY FOR SOFT TISSUE SARCOMAS OF THE LOWER EXTREMITY

Sommer Nurkic¹; Benjamin Wilke³; Zuofeng Li¹; Xing Shen¹; MengWei Ho¹; Danny Indelicato¹; Parker Gibbs²; Andre Spiguel²; Mark Scarborough²; **Michael Rutenberg**¹

¹Radiation Oncology, University of Florida, Jacksonville, FL, USA; ²Orthopedic Surgery, University of Florida, Gainesville, FL, USA; ³Orthopedic Surgery, Mayo Clinic, Jacksonville, FL, USA

Poster 376 3026104

PRELIMINARY DATA OF PROSPECTIVE PHASE II CLINICAL TRIAL WITH PREOPERATIVE HYPOFRACTIONATED RADIOTHERAPY (RT) IN PATIENTS WITH LOCALIZED MYXOID LIPOSARCOMAS

Piotr Rutkowski¹; Hanna Kosela-Paterczyk¹; Michal Wagrodzki²; Aneta Borkowska³; Anna Szumera-Cieckiewicz²; Andrzej Cieszanowski⁴; Tadeusz Morysinski¹; Jakub Palucki⁴; Mateusz Spalek³

¹Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland; ²Pathology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland; ³Radiotherapy, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland; ⁴Radiology, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland, Warszawa, Poland

Poster 377 3042686

ADVANCED RADIATION TECHNIQUES TO PRESERVE FERTILITY IN FEMALE PATIENTS RECEIVING PELVIC RADIOTHERAPY FOR SOFT TISSUE TUMORS

Edward Y. Kim¹; Elizabeth Loggers²; Seth Pollack²; Lee D. Cranmer²; Teresa Kim⁴; Gary Mann³; Gabrielle Kane¹

¹Radiation Oncology, University of Washington, Seattle, WA, USA; ²Medical Oncology, Seattle Cancer Care Alliance, Seattle, WA, USA; ³Surgical Oncology, Roswell Park, Buffalo, NY, USA; ⁴Surgery, University of Washington, Seattle, WA, USA

Poster 378 3042794

IS SURVEILLANCE IMAGING IN PAEDIATRIC PATIENTS TREATED FOR LOCALIZED RHABDOMYOSARCOMA USEFUL? THE EUROPEAN EXPERIENCE

Bas Vaarwerk¹²; Coralie Mallebranche³; Maria C. Affinita⁴; Madeleine R. Adams⁵; Johanna H. van der Lee²; Meriel Jenney⁶; Andrea Ferrari⁶; Julia C. Chisholm⁷; Anne S. Defachelle⁸; Nadege Corradini⁹; Veronique Minard-Colin¹⁰; Kieran McHugh¹¹; Gianni Bisogno⁴; Rick R. van Rijn¹³; Daniel Orbach³; Johannes H. Merks¹

¹Princess Máxima Center for pediatric oncology, Utrecht, Netherlands; ²Paediatric Clinical Research Office, Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands; ³Siredo Oncology Center, PSL Research University, Paris, France; ⁴Paediatric Haematology and Oncology Division, Department of Woman and Children's Health, Padova University Hospital, Padova, Italy; ⁵Department of Paediatric Oncology, Children's Hospital for Wales, Heath Park, Wales, United Kingdom; ⁶Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy; ⁷Children and Young People's Department, Royal Marsden Hospital, Sutton, United Kingdom; ⁸Department of Paediatric Oncology, Centre Oscar Lambret, Lille, France; ⁹Department of Paediatric Oncology, Centre Léon Bérard, Lyon, France; ¹⁰Department of Paediatric and Adolescent Oncology, Gustave-Roussy, Villejuif, France; ¹¹Department of Radiology, Great Ormond Street Hospital for Children, London, United Kingdom; ¹²Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands; ¹³Paediatric Radiology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands

Poster 379 3026152

MANAGEMENT OF PEDIATRIC PERITONEAL RHABDOMYOSARCOMATOSIS WITH CYTOREDUCTIVE SURGERY (CRS), HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) AND WHOLE ABDOMINAL RADIOTHERAPY (WART)

Gideon Sandler¹; *Lianchun Xiao*¹; *Winston Huh*¹; *Andrea Hayes-Jordan*¹

¹Oncology, M D Anderson Cancer Center, Sydney, NSW, Australia

Poster 380 3042806

EMBRYONAL AND ALVEOLAR RHABDOMYOSARCOMAS IN ADULTS: A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS

Cas Drabbe¹; *Charlotte Benson*¹; *Eugenie Younger*¹; *Robin Jones*¹; *Ian Judson*²; *Julia C. Chisholm*¹; *Shane Zaidi*¹; *Cyril Fisher*²; *Khin Thway*¹; *Omar Al-Muderis*¹; *Christina Messiou*¹; *Dirk Strauss*¹; *Olga Husson*¹; *Aisha Miah*¹; *Winette van der Graaf*¹

¹Royal Marsden Hospital, London, UK, Nijmegen, Netherlands; ²The Institute of Cancer Research, London, United Kingdom

Poster 381 3015934

DISEASE OUTCOME IN PATIENTS WITH INTERMEDIATE- AND HIGH- RISK RHABDOMYOSARCOMA BASED ON CHEMOTHERAPY REGIMEN: A SINGLE CENTER RETROSPECTIVE ANALYSIS

Kathryn S. Sutton¹; *Leah N. Bryan*²; *Karen Wasilewski*¹; *Thomas A. Olson*¹; *Bradley A. George*¹; *William G. Woods*¹

¹Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA; ²Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA

Poster 382 3026150

RHABDOMYOSARCOMA IN ADULTS: A SEER POPULATION-BASED STUDY OF 1942 PATIENTS

Sheng Yang¹; *Jiping Wang*²

¹Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China;

²Division of Surgical Oncology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Poster 383 3029847

VAC REGIMEN TO RHABDOMYOSARCOMA: THE DIFFERENCES OF RESPONSE AND PROGNOSIS IN PATIENTS OF AYA AND OLDER AGES

Kenji Nakano¹; *Junichi Tomomatsu*¹; *Mayu Yunokawa*¹; *Masatoshi Nishizawa*¹; *Makiko Ono*¹; *Shinichiro Taira*¹; *Shunji Takahashi*¹; *Keisuke Ae*²; *Seiichi Matsumoto*²

¹Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan;

²Orthopedic Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Poster 384 3042657

OPTIONAL PET SCAN UPSTAGING FOR CASES OF PEDIATRIC RHABDOMYOSARCOMA

Anna L. Tamulonis¹; *Berkelee Asare*¹; *Antonio Logan*¹; *Paul Kent*¹

¹Rush University Medical Center, Chicago, IL, USA

Poster 385 3027030

LIPOSARCOMA-SPECIFIC RADIATION THERAPY FOR RETROPERITONEAL SARCOMA - A REPORT FROM TARPSWG

Rick Haas²; *Sylvie Bonvalot*¹; *Rosalba Miceli*³; *Dirk Strauss*⁴; *Carol Swallow*⁵; *Peter Hohenberger*⁶; *Frits van Coevorden*⁷; *Piotr Rutkowski*⁸; *Dario Callegaro*⁹; *Andrew J. Hayes*⁴; *Charles Honoré*¹⁰; *Mark Fairweather*¹¹; *Rebecca Gladdy*⁵; *Jens Jakob*⁶; *Milena Szacht*⁶; *Marco Fiore*⁹; *Peter Chung*¹²; *Winan J. van Houdt*⁷; *Chandrajit Raut*¹¹; *Alessandro Gronchi*⁹
¹Department of Surgery, Institute Curie, Paris, France; ²Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, Netherlands; ³Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁴Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; ⁵Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada; ⁶Division of Surgical Oncology & Thoracic Surgery, Mannheim University Hospital, Mannheim, Germany; ⁷Department of Surgical Oncology, the Netherlands Cancer Institute, Amsterdam, Netherlands; ⁸Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; ⁹Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ¹⁰Department of Surgery, Institute Gustave Roussy, Paris, France; ¹¹Department of Surgery, Brigham and Women's Hospital and Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; ¹²Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada

Poster 386 3005908

MALNUTRITION AND PERIOPERATIVE NUTRITIONAL SUPPORT IN RETROPERITONEAL SARCOMA (RPS) PATIENTS. RESULTS FROM A PROSPECTIVE FEASIBILITY STUDY

Paola Previtali¹; *Daniela Codazzi*¹; *Luigi Mariani*²; *Chiara Colombo*³; *Giuseppe Cottone*¹; *Jacopo Colombo*¹; *Jessica Pitti*³; *Nicolò N. Rampello*³; *Roberta Casirani*¹; *Lavinia Bergesio*¹; *Virna Berto*¹; *Franco Valenza*¹; *Alessandro Gronchi*³; *Marco Fiore*³
¹Anesthesiology and Intensive Care, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ²Biometrics and Statistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ³Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Poster 387 3039242

POST-OPERATIVE RADIOTHERAPY IMPROVES OVERALL SURVIVAL IN MARGIN-POSITIVE RETROPERITONEAL SARCOMAS

Alexandra C. Istfi¹; *Stephanie A. Terezakis*⁵; *Christian Meyer*²; *Nita Ahuja*⁴; *Fabian M. Johnston*³
¹General Surgery, Western University, London, ON, Canada; ²Medical Oncology, Johns Hopkins Hospital, Baltimore, MD, USA; ³Surgical Oncology, Johns Hopkins Hospital, Baltimore, MD, USA; ⁴Surgical Oncology, Yale University, New Haven, CT, USA; ⁵Radiation Oncology, Johns Hopkins Hospital, Baltimore, MD, USA

Poster 388 3042844

MEASURING THE IMPACT OF COMPLICATIONS AFTER SURGERY FOR RETROPERITONEAL SARCOMA (RPS): IS COMPREHENSIVE COMPLICATION INDEX (CCI) BETTER THAN CLAVIEN-DINDO CLASSIFICATION (CDC)?

Ferdinando Carlo Maria Cananzi¹; *Laura Ruspi*¹; *Damiano Gentile*¹; *Federico Sicoli*¹; *Laura Samà*¹; *Vittorio Quagliuolo*²
¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy; ²Surgical Oncology Unit, Humanitas Clinical and Research Center, Rozzano (Milan), Italy

Poster 389 3042913

MANAGEMENT AND OUTCOME OF INTERMEDIATE-HIGH GRADE RETROPERITONEAL SARCOMAS: A SINGLE INSTITUTION STUDY

Ruoyu Miao¹; *Graham Boyd*¹; *Matthew DiMaria*¹; *Haotong Wang*¹; *Genevieve Maquilan*¹; *Alex Haynes*²; *Thomas F. DeLaney*¹; *Edwin Choy*³; *Gregory M. Cote*³; *John T. Mullen*²; *Yen-Lin E. Chen*¹
¹Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; ²Department of Orthopedic Oncology, Massachusetts General Hospital, Boston, MA, USA; ³Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA

Poster 390 3028735

MANAGEMENT OF LOCOREGIONAL RECURRENCE AFTER RADICAL RESECTION OF A PRIMARY NON-METASTATIC RETROPERITONEAL SOFT TISSUE SARCOMA: RESULTS OF A RETROSPECTIVE SERIES IN A TERTIARY CARE CENTER

Charles Honoré³; Matthieu Faron³; Olivier Mir¹; Leila Haddag²; Sarah N. Dumont¹; Julien Adam⁴; Philippe Terrier⁴; Cécile Le Péchoux⁵; Axel Le Cesne¹

¹Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; ²Radiology, Gustave Roussy Cancer Campus, Villejuif, France; ³Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; ⁴Pathology, Gustave Roussy Cancer Campus, Villejuif, France; ⁵Radiation Therapy, Gustave Roussy Cancer Campus, Villejuif, France

Poster 391 3003334

OUTCOME AND QUALITY OF LIFE AFTER RESECTION FOR RETROPERITONEAL SARCOMA

Martin Almquist¹; Daniel Andulv¹; Pall Hallgrimsson¹

¹Dept. of Surgery, Skåne University Hospital, Klagshamn, Sweden

Poster 392 3029453

NO BENEFIT OF PREOPERATIVE CHEMOTHERAPY FOR PRIMARY RETROPERITONEAL SARCOMAS: RESULTS FROM A SINGLE CENTER PROPENSITY MATCHED ANALYSIS

Matthieu Faron³; Sarah N. Dumont¹; Olivier Mir¹; Julien Adam²; Leila Haddag⁴; Cécile Le Péchoux⁵; Philippe Terrier²; Axel Le Cesne¹; **Charles Honoré³**

¹Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; ²Pathology, Gustave Roussy Cancer Campus, Villejuif, France; ³Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; ⁴Radiology, Gustave Roussy Cancer Campus, Villejuif, France; ⁵Radiation Therapy, Gustave Roussy Cancer Campus, Villejuif, France

Poster 393 3039706

EVALUATION OF TREATMENT RESPONSE TO PREOPERATIVE THERAPY IN RETROPERITONEAL LEIOMYOSARCOMA

Naruhiko Ikoma¹; Wei-Lien Wang²; Christina Roland¹; Kiela E. Torres¹; Ravi Vinod³; Kelly Hunt¹; Janice Cormier¹; Barry Feig¹

¹Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ²Pathology, MD Anderson Cancer Center, Houston, TX, USA; ³Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA

Poster 394 3042182

ROLE OF NUTRITIONAL STATUS IN THE EARLY POSTOPERATIVE PROGNOSIS OF PATIENTS OPERATED FOR RETROPERITONEAL LIPOSARCOMA (RLS): A SINGLE CENTER EXPERIENCE

Krassen M. Kirov¹; HaoPing Xu¹; Pascal Crenn²; Philippe Goater¹; Dimitri Tzanis¹; Mohammed Toufik Bouhadiba¹; Khoubeyb Abdelhafidh¹; Youlia M. Kirova¹; Sylvie Bonvalot¹

¹Institut Curie, Paris, France; ²Unit of Nutrition, Hôpital Raymond Poincaré (APHP), Garches, France

Poster 395 3042575

WHY WERE NON-METASTATIC PRIMARY RETROPERITONEAL SARCOMAS NOT RESECTED?

Deanna Ng¹; Sally M. Burtenshaw¹; Ana Olteanu¹; Rebecca Gladdy¹; Savtaj Brar¹; Peter Chung²; Charles Catton²; Korosh Khalili³; Carol Swallow¹

¹Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; ²Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; ³Joint Department of Medical Imaging, University of Toronto, Toronto, ON, Canada

Poster 396 3042602

WHY PRIMARY RETROPERITONEAL SARCOMA (PRPS) PATIENTS (PTS) UNDERGOING TREATMENT AT STRASS INSTITUTIONS DID NOT ENROLL IN STRASS: THE STREXIT STUDY FROM EORTC STBSG AND TARPSWG

Chandrajit Raut¹; Dirk Strauss²; Rick Haas³; Hans Gelderblom⁴; Sylvie Bonvalot⁵; Charles Honoré⁶; Monica Bertagnoli¹; Sally Burtenshaw⁷; Mark Fairweather⁸; Deanna Ng⁷; Saskia Litiere⁹; Bianca Colleoni⁹; Angelique Deleersnijder⁹; Sandrine Marreaud⁹; Winan J. van Houdt¹⁰; Nikolaos Vassos²; Lorenzo Conti¹¹; Dario Callegaro¹¹; Alessandro Gronchi¹¹; Carol Swallow⁷

¹Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA; ²Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; ³Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; ⁴Department of Clinical Oncology, Leiden University Medical Centre, Leiden, Netherlands; ⁵Department of Surgery, Curie Institute, Paris, France; ⁶Department of Surgery, Gustave Roussy Institute, Villejuif, France; ⁷Department of Surgical Oncology, Mount Sinai Hospital and Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; ⁸Division of Surgical Oncology, Department of Surgery, Brigham and Women's Hospital and Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; ⁹European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; ¹⁰Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; ¹¹Department of Surgery, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy

Poster 397 3042735

SHOULD LOCALIZED RETROPERITONEAL SARCOMAS BE TREATED IN REFERENCE CENTERS?: RESULTS OF A SINGLE INSTITUTION

Marta Carmona-Campos¹; Anna C. Virgili Manrique¹; Ana Sebio¹; Oscar Gallego¹; Vicens Artigas⁶; Silvia Daniela Camacho¹; Sara Moron¹; Manuel Rodriguez-Blanco⁶; Katerina Majerkacova²; Jose Isern²; Silvia Bagué⁹; Ruth Orellana⁷; Isidro Gracia³; Ana Peiró³; Laura Trullols³; Jaume Llauger⁸; Diana Hernández⁸; Sandra Valverde⁸; Jaume Palmer⁸; Manuel Fernandez-Garrido⁵; María J. Quintana⁴; Antonio Lopez-Pousa¹

¹Medical Oncology, Sant Pau Hospital, Baracelona, Barcelona, Spain; ²Radiation Oncology, Sant Pau Hospital, Barcelona, Spain; ³Orthopedic surgery and traumatology, Sant Pau Hospital, Barcelona, Spain; ⁴Epidemiology, Sant Pau Hospital, Barcelona, Spain; ⁵Plastic and reconstructive surgery, Sant Pau Hospital, Barcelona, Spain; ⁶General and Digestive Surgery, Sant Pau Hospital, Barcelona, Spain; ⁷Pathology, Sant Pau Hospital, Barcelona, Spain; ⁸Radiology, Sant Pau Hospital, Barcelona, Spain; ⁹Pathology, Royal Marsden Hospital, Londres, United Kingdom

Poster 398 3026103

PREDICTIVE FACTORS FOR COMPLICATIONS AFTER SURGICAL TREATMENT FOR SCHWANNOMAS OF THE EXTREMITIES

Toshihide Hirai¹; Hiroshi Kobayashi¹; Toru Akiyama²; Tomotake Okuma³; Hiroyuki Oka⁴; Yusuke Shinoda¹; Masachika Ikegami¹; Takahiro Ohki³; Ryoko Sawada¹; Takahiro Goto³; Sakae Tanaka¹

¹Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo Hospital, Tokyo, Japan; ²Department of Orthopaedic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan; ³Department of Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan; ⁴Department of Medical Research and Management for Musculoskeletal Pain, 22nd Century Medical & Research Center, Faculty of Medicine, The University of Tokyo Hospital, Tokyo, Japan

Poster 399 3027924

CLINICOPATHOLOGICAL AND RADIOLOGIC FEATURES OF GASTRIC SCHWANNOMA

Yohei Oguri¹; Haruhiko Cho¹; Haruna Onoyama¹; Ryouki Oohinata¹

¹surgery, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan

Poster 400 3041682

SOLITARY FIBROUS TUMOR - A SINGLE INSTITUTION RETROSPECTIVE STUDY

Ninna Aggerholm-Pedersen¹; Rasmus Blechingberg Friis¹; Thomas Baad-Hansen²; Akmal Safwat¹

¹Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; ²Department of Orthopedic Surgery, Aarhus University Hospital, Aarhus, Denmark

Poster 401 3041744

HIGH-GRADE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA (USRCS): A CLINICAL-PATHOLOGICAL STUDY BY THE ITALIAN SARCOMA GROUP (ISG)

Emanuela Palmerini¹; Piero Picci¹; Rossella Bertulli²; Giacomo Giulio Baldi³; Virginia Ferraresi⁴; Tiziana Venesio⁵; Antonella Brunello⁶; Salvatore Provenzano²; Lorenzo D'Ambrosio⁵; Marco Gambarotti¹; Alessandra Longhi¹; Emanuela Marchesi²; Alessandro Franchi⁹; Elisabetta Setola¹; Angelo Paolo Dei Tos⁷; Marta Sbaraglia⁷; Stefano Ferrari¹; Bruno Vincenzi⁸

¹Istituto Ortopedico Rizzoli, Bologna, BO, Italy; ²Medical Oncology Unit 2 – Adult mesenchymal tumours and rare cancer, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; ³Medical Oncology Department, Hospital of Prato, Prato, Italy; ⁴Istituto Nazionale Tumori “Regina Elena”, Roma, Italy; ⁵Sarcoma Unit, Candiolo Cancer Institute, FPO-IRCCS Candiolo, Candiolo, Italy; ⁶Department of Experimental and Clinical Oncology, Medical Oncology 1 Unit, Istituto Oncologico Veneto - IOV, IRCCS, Padova, Italy; ⁷Azienda ULSS n. 2; Treviso, Italy; ⁸Policlinico Universitario Campus Biomedico, Roma, Italy; ⁹. Department of traslational research, University of Pisa, Pisa, Italy

Poster 402 3008451

DESIGNING A RATIONAL FOLLOW-UP SCHEDULE FOR SOFT TISSUE SARCOMA

David A. Wilson¹; Julia Visgauss¹; David L. Perrin¹; Aaron Gazendam¹; Anthony M. Griffin¹; Peter Ferguson¹; Jay Wunder¹

¹Surgery, University of Toronto, Toronto, ON, Canada

Poster 403 3014026

RADIATION-ASSOCIATED SARCOMA AFTER BREAST CANCER IN FINLAND DURING 1953-2014: A STRONG INCREASE OF ANGIOSARCOMA

Samuli Salminen¹; Mika M. Sampo²; Tom Böhling²; Maija Tarkkanen¹; Carl Blomqvist¹

¹Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; ²Department of Pathology, University of Helsinki and HUSLAB Helsinki University Hospital, Helsinki, Finland

Poster 404 3042577

MULTIDISCIPLINARY TUMOR BOARD RECOMMENDATIONS FOR SARCOMA PATIENTS WITH OLIGOMETASTATIC DISEASE

Christian Galata¹; Elisabeth Wimmer¹; Peter Hohenberger¹; Bernd Kasper²; **Jens Jakob**³

¹Department of Surgery, Division of thoracic surgery and surgical oncology, Medical Faculty Mannheim, University of Heidelberg, Germany, Mannheim, Germany; ²Interdisciplinary Tumor Center, University Medical Center Mannheim, Mannheim, Germany; ³Universitätsmedizin Göttingen Georg-August-Universität, Göttingen, Germany

Poster 405 3007777

ULCERATING SOFT TISSUE SARCOMAS

Brooke M. Crawford¹; Warren Chow²; Sagus Sampath³; Joseph D. Femino¹; Santiago Lozano Calderon⁴; Marilyn Heng⁴

¹Surgery, City of Hope Cancer Center, Duarte, CA, USA; ²Medical Oncology, City of Hope Cancer Center, Duarte, CA, USA; ³Radiation Oncology, City of Hope Cancer Center, Duarte, CA, USA; ⁴Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA

Poster 406 3030992

THE PROGNOSTIC VALUE OF INTERLEUKIN-6 IN PATIENTS WITH SOFT TISSUE SARCOMA

Tomohito Hagi¹; Tomoki Nakamura¹; Koji Kita¹; Kunihiro Asanuma¹; Akihiro Sudo¹

¹Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan

Poster 407 3033650

TRABECTEDIN IN 473 PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS): AN ITALIAN SARCOMA GROUP (ISG), OBSERVATIONAL, MULTICENTER, RETROSPECTIVE STUDY

Emanuela Palmerini¹; Paolo Casali³; Tiziana Venesio²; Virginia Ferraresi⁴; Bruno Vincenzi⁵; Antonella Romanini¹¹; Alessandro Comandone⁶; Giuseppe Badalamenti⁷; Antonio Pizzolorusso⁸; Elisabetta Setola¹; Antonella Brunello⁹; Gabriele Luppi¹⁰; Angela Buonadonna¹²; Tommaso De Pas¹³; Toni Ibrahim¹⁴; Laura Milesi¹⁵; Federica Grosso¹⁶; Maria Abbondanza Pantaleo¹⁷; Francesca Zanelli¹⁸; Emanuela Marchesi¹; Irene Quattrini¹; Alberto Righi¹; Piero Picci¹; Stefano Ferrari¹

¹Istituto Ortopedico Rizzoli, Bologna, BO, Italy; ²IRCC Candiolo, Turin, Italy; ³Istituto Nazionale Tumori, Milan, Italy; ⁴Istituto Regina Elena, Rome, Italy; ⁵Policlinico Campus Biomedico, Roma, Italy; ⁶Humanitas Gradenigo, Torino, Italy; ⁷Policlinico P. Giaccone, Palermo, Italy; ⁸Istituto Nazionale Tumori 'Fondazione Pascale', Napoli, Italy; ⁹Istituto Oncologico Veneto, Padova, Italy; ¹⁰Policlinico di Modena, Modena, Italy; ¹¹Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; ¹²Centro di Riferimento Oncologico CRO, Aviano, Italy; ¹³Istituto Europeo di Oncologia, Milano, Italy; ¹⁴Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy; ¹⁵ASST Papa Giovanni XXIII, Bergamo, Italy; ¹⁶Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy; ¹⁷Policlinico Sant'Orsola Malpighi, Bologna, Italy; ¹⁸IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

Poster 408 3040775

"FASCIA-INFILTRATING SARCOMA": A CATEGORIE OF HIGH RISK OF RECURRENCE AND POOR OUTCOME

Eberhard Stoeckle¹; Audrey Michot¹; Amandine Crombé²; Brice Richez³; Maud Toulmonde⁴; Paul Sargos⁵; Michele Kind²; Veronique Brouste⁶; Antoine Italiano⁴; François Le Loarer⁷

¹Surgery, Institut Bergonié, Bordeaux, France; ²Radiology, Institut Bergonié, Bordeaux, France; ³Anaesthesia, Institut Bergonié, Bordeaux, France; ⁴Medical Oncology, Institut Bergonié, Bordeaux, France; ⁵Radiotherapy, Institut Bergonié, Bordeaux, France; ⁶Clinical and epidemiological research unit, Institut Bergonié, Bordeaux, France; ⁷Pathology, Institut Bergonié, Bordeaux, France

Poster 409 3042580

ESOPHAGEAL GASTROINTESTINAL STROMAL TUMOR VERSUS LEIOMYOSARCOMA: NATIONAL CANCER DATABASE COMPARATIVE STUDY

Basem Azab¹; Francisco Igor Macedo¹; Syed Razi²; Caroline Ripat¹; Omar Picado¹; Dido Franceschi¹; Alan S. Livingstone¹; Danny Yakoub¹

¹Surgical oncology, University of Miami, Miami, FL, USA; ²Cardiothoracic surgery, University of Miami, Miami, FL, USA

Poster 410 WITHDRAWN

Poster 411 3042634

PRIMARY SARCOMA OF LUNG (PSL). A RETROSPECTIVE SERIES.

Jose Duran Moreno⁴; Stefania Kokkali⁴; Vasileios Ramfidis³; Maria Salomidou⁴; Antonia Digklia²; Anna Koumarianou⁵; Periklis Tomos⁶; Nektarios Koufopoulos⁷; Ioannis Vamvakaris⁸; Eleni Psychogiou⁸

²Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; ³3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Sotiria General Hospital, Athens, Greece; ⁴1st Department of Oncology, Saint-Savvas Anticancer Hospital, Athens, Greece; ⁵4th Department of Internal Medicine - Department of Oncology, Attikon University General Hospital, Athens, Greece; ⁶Department of Thoracic surgery, Attikon University General Hospital, Athens, Greece; ⁷Pathology department, Saint-savvas anticancer hospital, Athens, Greece; ⁸First Department of Pathology, Medical School, University of Athens, Athens, Greece

Poster 412 3042713

SCLEROSING EPITHELIOD FIBROSARCOMA OF SOFT TISSUE AND BONE: REPORT OF 12 CASES.

Alessandra Longhi¹; Stefano Bandiera¹; Marco Gambarotti¹; Alberto Righi¹; Angelo Toscano¹; Cristina Ferrari¹; Alessandro Gasbarrini¹; Elisabetta Setola¹; Anna Paioli¹; Marilena Cesari¹; Massimo Abate¹; Davide M. Donati¹

¹Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy

Poster 413 3042830

PREDICTORS OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH PRIMARY SOFT TISSUE SARCOMA

Pramod N. Kamalopathy¹; Adam Z. Kline¹; Dayton D. McMillan¹; Aarti Patel¹; Marilyn Johnson¹; Alexandra Bachinsky¹; Karen De Amorim Bernstein¹; Kevin Raskin¹; Joseph H. Schwab¹; Santiago Lozano Calderon¹

¹Orthopedics, Massachusetts General Hospital, Mount Laurel, NJ, USA

Poster 414 3043002

DYNAMIC PREDICTION FOR PATIENTS WITH HIGH-GRADE EXTREMITY SOFT TISSUE SARCOMA - PERSONALIZED SARCOMA CARE (PERSARC DYNAMIC)

Anja Rueten-Budde²; **Veroniek V. Praag**¹; Michiel van de Sande¹; Marta Fiocco²

¹Orthopedic Surgery, Leiden University Medical Center, Den Haag, Netherlands; ²Mathematical Institute, Leiden University, Leiden, Netherlands

Poster 415 3036211

SPONTANEOUS REGRESSION OF SOFT TISSUE SARCOMA

Michiro Susa¹; Keisuke Horiuchi¹; Masato Saito²; Chiaki Sato¹; Robert Nakayama²; Hideo Morioka³; Kazuhiro Chiba¹

¹Orthopaedics, National Defense Medical College, Tokorozawa, Japan; ²Orthopaedics, Keio University School of Medicine, Tokyo, Japan; ³Orthopaedics, Tokyo Medical Center, Tokyo, Japan

Poster 416 3037922

SOFT TISSUE SARCOMA OF THE EXTREMITY: THE IMPACT OF TREATMENT AT MULTIPLE FACILITIES

Ambria S. Moten¹; Sujana Movva²; Margaret von Mehren²; Sanjay Reddy³; Krisha Howell⁴; Elizabeth Handorf⁵; Jeffrey Farma³

¹Surgery, Temple University Hospital, Philadelphia, PA, USA; ²Dept of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; ³Surgery, Fox Chase Cancer Center, Philadelphia, PA, USA; ⁴Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; ⁵Biostatistics, Fox Chase Cancer Center, Philadelphia, PA, USA

Poster 417 3038292

TREATMENT AND FOLLOW-UP OF 5 PATIENTS WITH INFANTILE MYOFIBROMATIS - A SINGLE CENTER EXPERIENCE

Michal Manisterski¹; Marganit Benish¹; Dror Levin¹; Rina Dvir¹; Hila Rosenfeld-Keidar¹; Sivan Berger-Achituv¹; Yair Peled¹; Osnat Sher²; Yair Gortzak³; Ronit Elhasid¹

¹Pediatric Hemato-Oncology, Tel Aviv Medical Center, Tel Aviv-Yafo, Israel; ²Pathology, Tel Aviv Medical Center, Tel Aviv-Yafo, Israel; ³Orthopedic – Oncology, Tel Aviv Medical Center, Tel Aviv-Yafo, Israel

Poster 418 3042667

INTIMAL SARCOMA: A CLINICOPATHOLOGIC AND IMMUNOHISTOCHEMICAL EXPRESSION IN SEVEN CASES IN THE NATIONAL CANCER INSTITUTE.

Claudia Haydee Sarai Caro Sanchez¹; Dorian Yarih Garcia Ortega¹; Hugo R. Dominguez Malagon¹; Miguel Angel Clara Altamirano¹; Mario Cuellar Hubbe¹; Hector Martinez Said¹; Jorge Martinez Tlahuel¹; Diana Aguilar Leon¹; Guillermo Corredor Alonso¹

¹Skin and Soft Tissue Tumors, National Cancer Institute (Mexico), Tlalpan, Mexico City, Mexico

Poster 419 3003313

MORBIDITY, QUALITY OF LIFE AND PAIN IN RETROPERITONEAL SARCOMA (RPS). RESULTS FROM A PROSPECTIVE STUDY

Marco Fiore¹; Michele Manara¹; Cinzia Brunelli²; Rosalba Miceli³; Dario Callegaro¹; Nicolò N. Rampello¹; Chiara Colombo¹; Stefano Radaelli¹; Augusto Caraceni²; Alessandro Gronchi¹

¹Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ²Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ³Biometrics and Statistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Poster 420 3023377

LOCALIZED MYXOFIBROSARCOMAS: ROLE OF SURGICAL MARGINS AND (NEO)ADJUVANT RADIOTHERAPY

Raoudha Boughzala-Bennadji¹; Eberhard Stoeckle³; Cécile Le Péchoux²; Pierre Méeus⁴; Charles Honoré²; Justine Attal⁵; Florence Duffaud⁶; Gonzague De Pinieux⁷; Emmanuelle Bompas⁸; Juliette Thariat⁹; Agnes Leroux¹⁴; Francois Bertucci¹⁰; Nicolas Isambert¹¹; Corinne Delcambre¹²; Jean-Yves Blay⁴; Marie-Pierre Sunyach⁴; Jean-Michel Coindre³; Paul Sargos³; **Nicolas Penel**¹; Sylvie Bonvalot¹³

¹Medical Oncology, Centre Oscar Lambret, Lille, France; ²Institut Gustave Roussy, Villejuif, France; ³Institut Bergonie, Bordeaux, France; ⁴Centre Leon Berard, Lyon, France; ⁵Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France; ⁶Hôpital de la Timone, Marseille, France; ⁷Hopital Trousseau, Tours, France; ⁸Institut de cancérologie de l'Ouest, Saint-Herblain, France; ⁹Centre Antoine Lacassagne, Nice, France; ¹⁰Institut Paoli-Calmettes, Marseille, France; ¹¹Centre Georges François Leclerc, Dijon, France; ¹²Centre François Baclesse, Caen, France; ¹³Institut Curie, Paris, France; ¹⁴Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France

Poster 421 3026885

MANAGEMENT AFTER UNPLANNED EXCISION IN ADULT EXTREMITY AND SUPERFICIAL TRUNK SOFT TISSUE SARCOMA: ABSTENTION OF SYSTEMATIC RE EXCISION DOES NOT AFFECT OVERALL SURVIVAL, NOR AMPUTATION RATE

*Gauthier Decanter¹; Eberhard Stoeckle²; Charles Honoré³; Pierre Méeus⁴; Jean-Camille Mattei⁵; Pascale Dubray-Longeras⁶; Gwenael Ferron⁷; Sebastien Carrere⁸; Sylvain Causeret⁹; Jean-Marc Guilloit¹⁰; Magali Fau¹¹; Louis-Romée Le Nail¹⁵; Jean-Christophe Machiavello¹²; Jean-Baptiste Delorme¹⁴; Nicolas Regenet¹¹; François Guoin¹⁶; Jean-Yves Blay⁴; Jean-Michel Coindre²; **Nicolas Penel¹**; Sylvie Bonvalot¹³*

¹Medical Oncology, Centre Oscar Lambret, Lille, France; ²Institut Bergonie, Bordeaux, France; ³Institut Gustave Roussy, Villejuif, France; ⁴Centre Leon Berard, Lyon, France; ⁵Hôpital de la Timone, Marseille, France; ⁶Centre Jean Perrin, Clermont Ferrand, France; ⁷Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France; ⁸Institut du Cancer de Montpellier, Montpellier, France; ⁹Centre Georges François Leclerc, Dijon, France; ¹⁰Centre François-Baclesse, Caen, France; ¹¹Institut de Cancérologie de Lorraine, Nancy, France; ¹²Centre Antoine Lacassagne, Nice, France; ¹³Institut Curie, Paris, France; ¹⁴Centre Paul Strauss, Strasbourg, France; ¹⁵CHU, Tours, France; ¹⁶CHU, Nantes, France

Poster 422 3041962

INCREASED SURVIVAL AFTER SURGICAL MANAGEMENT OF HIGH-GRADE AND DEEP-SEATED SOFT TISSUE SARCOMA IN HIGH-VOLUME HOSPITALS: A NATIONWIDE STUDY

Melissa Vos¹; Harriët Blaauwgeers²; Vincent Ho²; Winan J. van Houdt³; Jos van der Hage⁴; Lukas Been⁹; Johannes Bonenkamp⁵; Marc H. Bemelmans⁶; Thijs van Dalen⁷; Dirk Grünhagen⁸; Kees Verhoef⁸

¹Medical Oncology and Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; ²Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, Netherlands; ³Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; ⁴Surgical Oncology, Leiden University Medical Center, Leiden, Netherlands; ⁵Surgical Oncology, Radboud University Medical Center, Nijmegen, Netherlands; ⁶Surgical Oncology, Maastricht University Medical Center+, Maastricht, Netherlands; ⁷Surgical Oncology, University Medical Center Utrecht, Utrecht, Netherlands; ⁸Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; ⁹Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Poster 423 3042165

CHARACTERISTICS OF THE UNPLANNED RESECTION OF A SOFT-TISSUE SARCOMA

Joseph Nelson¹; Nicholas Wallace¹; Caitlin McCarthy¹; Sybil Biermann¹; Geoffrey Siegel¹

¹Orthopaedic Surgery, University of Michigan, Ann Arbor, MI, USA

Poster 424 3042300

OUTCOMES OF SOFT TISSUE SARCOMA RESECTED WITH CLOSE OR POSITIVE MARGINS ON PRIMARY SURGERY

Paul Pou¹; Christian Carrie¹; Gualter Vaz²; Pierre Méeus²; Isabelle Ray-Coquard²; Jean-Yves Blay²; Patrice Peyrat²; Armelle Dufresne²; Mehdi Brahmi²; Marie Karanian²; Marie-Pierre Sunyach¹

¹Radiation Oncology, Centre Léon Bérard, Irigny, France; ²Centre Léon Bérard, Lyon, France

Poster 425 3027922

CLINICAL OUTCOME IN PATIENTS WITH SOFT TISSUE SARCOMA WHO RECEIVED ADDITIONAL EXCISION AFTER UNPLANNED EXCISION: REPORT FROM THE BONE AND SOFT TISSUE TUMOR REGISTRY IN JAPAN

Tomoki Nakamura¹; Akira Kawai²; Tomohito Hagi¹; Koji Kita¹; Kunihiro Asanuma¹; Akihiro Sudo¹

¹Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan; ²National Cancer Center, Tokyo, Japan

Poster 426 3029688

ASSESSMENT OF THE TIME TO TREATMENT INITIATION = 0 COHORT IN SOFT TISSUE SARCOMA PATIENTS AT A TERTIARY CANCER CENTER: ARE WE DEFINING THIS CORRECTLY?

*Joshua M. Lawrenz¹; Jose Vega¹; Jaiben George¹; Gannon L. Curtis¹; Jaymeson Gordon¹; Amanda Maggioletto¹; **Lukas M. Nystrom¹**; Nathan W. Mesko¹*

¹Orthopaedic Surgery, Cleveland Clinic, Cleveland Heights, OH, USA

Poster 427 3030738

PROGNOSTIC RELEVANCE OF SYSTEMIC INFLAMMATORY MARKERS IN SOFT-TISSUE SARCOMA PATIENTS TREATED WITH CURATIVE RESECTION

In Hee Lee¹; Byung Woog Kang¹; Yee Soo Chae¹; Jong Gwang Kim¹; Soo Jung Lee¹

¹Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, Daegu, Korea (the Republic of)

Poster 428 3034536

PREDICTORS OF LYMPH NODE EVALUATION AND MANAGEMENT OF POSITIVE LYMPH NODES IN TRUNCAL/EXTREMITY SOFT TISSUE SARCOMA PATIENTS: THE WHO, THE WHEN AND THE DIFFERENCE IT MAKES

Kaitlyn Dinkins¹; Cecilia G. Ethun¹; Aileen Johnson¹; Thuy B. Tran³; George Poultsides³; Valerie P. Grignol²; J. H. Howard²; Meena Bedi⁴; John Charlson⁵; Jennifer Tseng⁶; Kevin K. Roggin⁶; Konstantinos Chouliaras⁷; Konstantinos Votanopoulos⁷; Darren Cullinan⁸; Ryan C. Fields⁸; David Monson¹; Shervin Oskouei¹; Nickolas Reimer¹; Monica Rizzo¹; Kenneth Cardona¹; Maria C. Russell¹

¹Division of Surgical Oncology, Department of Surgery, Emory University, Atlanta, GA, USA; ²Division of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, OH, USA; ³Department of Surgery, Stanford University, Palo Alto, CA, USA; ⁴Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; ⁵Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; ⁶Department of Surgery, University of Chicago Medicine, Chicago, IL, USA; ⁷Department of Surgery, Wake Forest University, Winston-Salem, NC, USA; ⁸Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA

Poster 429 3042841

NUTRITIONAL PREDICTORS OF WOUND COMPLICATIONS IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE LOWER EXTREMITIES

Adam Z. Kline¹; Pramod N. Kamalopathy¹; Dayton D. McMillan¹; Katharine E. Bruce¹; Aarti Patel¹; Marilyn Johnson¹; Alexandra Bachinsky¹; Karen De Amorim Bernstein²; Kevin Raskin¹; **Santiago Lozano Calderon**¹; Joseph H. Schwab¹
¹Orthopaedics, Massachusetts General Hospital, Boston, MA, USA; ²Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA

Poster 430 3039866

PRIMARY VERSUS STAGED SOFT TISSUE RECONSTRUCTION HAVE SIMILAR WOUND AND ONCOLOGIC OUTCOMES AFTER SOFT TISSUE SARCOMA EXCISION

Joshua M. Lawrenz¹; Danielle C. Marshall¹; Jaiben George¹; Aparna Vijayasekaran²; Jaymeson Gordon¹; Graham S. Schwarz²; **Lukas M. Nystrom**¹; Nathan W. Mesko¹
¹Orthopaedic Surgery, Cleveland Clinic, Cleveland Heights, OH, USA; ²Plastic Surgery, Cleveland Clinic, Cleveland, OH, USA

Poster 431 3025438

SURGICAL ADJUVANT THERAPY USING ACRIDINE ORANGE AFTER INTRA-LESIONAL OR MARGINAL RESECTION IN PATIENTS WITH HIGH-GRADE SOFT TISSUE SARCOMA. A PILOT STUDY.

Tomoki Nakamura¹; Katsuyuki Kusuzaki²; Kunihiro Asanuma¹; Tomohito Hagi¹; Koji Kita¹; Hiroaki Murata³; Takao Matsubara⁴; Akihiro Sudo¹
¹Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan; ²Orthopaedic Surgery, Takai Hospital, Nara, Japan; ³Orthopaedic Surgery, Matsushita Memorial Hospital, Osaka, Japan; ⁴Matsubara Orthopaedics, Tsu, Japan

Poster 432 3029939

LONG-TERM OUTCOME IN PATIENTS WITH COMPLICATED NON-METASTATIC RETROPERITONEAL SOFT TISSUE SARCOMAS REQUIRING UNPLANNED EMERGENCY SURGERY

Alexandru Bărbălan¹; Matthieu Faron¹; Leila Haddag³; Sarah N. Dumont²; Cécile Le Péchoux⁵; Julien Adam⁴; Olivier Mir²; Philippe Terrier⁴; Axel Le Cesne²; Charles Honoré¹
¹Department of Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; ²Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; ³Department of Radiology, Gustave Roussy Cancer Campus, Villejuif, France; ⁴Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France; ⁵Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France

Poster 433 3037277

BENEFIT OF SURGICAL TREATMENT FOR PULMONARY METASTASIS IN SOFT TISSUE SARCOMA PATIENTS

Teruya Kawamoto¹; Toshihiro Akisue²; Ikuo Fujita³; Takuya Fujimoto³; Hitomi Hara¹; Naomasa Fukase¹; Yohei Kawakami¹; Masayuki Morishita³; Toshiyuki Takemori¹; Shuichi Fujiwara¹; Kazumichi Kityama¹; Ryosuke Kuroda¹
¹Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; ²Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan; ³Orthopaedic Surgery, Hyogo Cancer Center, Akashi, Japan

Poster 434 3038338

ALGORITHMS FOR THE SURGICAL MANAGEMENT OF SOFT TISSUE TUMOURS OF THE ABDOMINAL WALL: RETROSPECTIVE SINGLE CENTRE STUDY ON 120 PATIENTS

Isabelle Sourrouille¹; Cecilia Ceribelli¹; Sara Baleri¹; Olivier Mir²; Matthieu Faron¹; Julien Adam³; Sarah N. Dumont²; Axel Le Cesne²; Philippe Terrier³; Charles Honoré¹

¹Oncological Surgery, Gustave Roussy, Paris, France; ²Cancer Medicine, Gustave Roussy, Villejuif, France;

³Pathology, Gustave Roussy, Villejuif, France

Poster 435 3042592

FLUORESCENCE-GUIDED LYMPH VESSEL SEALING TO PREVENT LYMPHOCELE AFTER SARCOMA RESECTION

Jens Jakob²; Andreas Gerken¹; Ioannis Karampinis¹; Peter Hohenberger¹

¹Department of Surgery, Division of thoracic surgery and surgical oncology, Medical Faculty Mannheim, University of Heidelberg, Germany, Mannheim, Germany; ²Universitätsmedizin Göttingen Georg-August-Universität, Göttingen, Germany

Poster 436 3028381

TUMOR NECROSIS FOLLOWING NEOADJUVANT CHEMOTHERAPY FOR SYNOVIAL SARCOMA: A REPORT FROM CHILDREN'S ONCOLOGY GROUP STUDY ARST0332

Rajkumar Venkatramani¹; Douglas Hawkins²; David Parham³; Jennifer Black⁴; Andrea Hayes-Jordan⁵; Suzanne Wolden⁶; Stephen Skapek⁷; Yueh-Yun Chi⁸; Jing Tian⁹; Sheri Spunt¹⁰

¹Pediatrics, Baylor College of Medicine, Houston, TX, USA; ²Seattle Children's Hospital, Seattle, WA, USA; ³Children's Hospital Los Angeles, Los Angeles, CA, USA; ⁴Children's Hospital Colorado, Aurora, CO, USA; ⁵M D Anderson Cancer Center, Houston, TX, USA; ⁶Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁷UT Southwestern/Simmons Cancer Center-Dallas, Dallas, TX, USA; ⁸University of Florida, Gainesville, FL, USA; ⁹COG data center, Gainesville, FL, USA; ¹⁰Lucile Packard Children's Hospital Stanford University, Palo Alto, CA, USA

Poster 437 3012136

COMBINATION PREOPERATIVE CHEMOTHERAPY AND SURGERY FOR LOCALIZED SYNOVIAL SARCOMA: RETROSPECTIVE ANALYSIS OF 117 PATIENTS AT A SINGLE INSTITUTE FOR 26 YEARS.

Takuji Seo¹; Kazuki Sudo¹; Emi Noguchi¹; Akihiko Shimomura¹; Masaki Tanioka¹; Akihiko Yoshida²; Tomoaki Mori³; Eisuke Kobayashi³; Fumihiko Nakatani³; Shintaro Iwata³; Akira Kawai³; Masanaka Sugiyama⁴; Ayumu Arakawa⁴; Tadashi Kumamoto⁴; Chitose Ogawa⁴; Yasuhiro Fujiwara¹; Kan Yonemori¹; Kenji Tamura¹

¹Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; ²Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan; ³Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo, Japan; ⁴Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan

Poster 438 3009765

PAZOPANIB IN ADVANCED SYNOVIAL SARCOMA: THE GUSTAVE ROUSSY EXPERIENCE

Marine Sroussi¹; Sixtine De Percin¹; Miruna Grecea¹; Marc-Antoine Benderra¹; Maud Velez¹; Sarra Akla¹; Naima Lezghed¹; Sarah N. Dumont¹; Cécile Le Péchoux²; Charles Honoré³; Leila Haddag⁴; Matthieu Faron³; Philippe Terrier⁵; Olivier Mir¹; Axel Le Cesne¹

¹Medical Oncology Department, Gustave Roussy Institute, Montrouge, France; ²Radiation Oncology Department, Gustave Roussy Institute, Villejuif, 94800, France; ³Surgery Department, Gustave Roussy Institute, Villejuif, 94800, France; ⁴Radiology Department, Gustave Roussy Institute, Villejuif, 94800, France; ⁵Pathology Department, Gustave Roussy Institute, Villejuif, 94800, France

Poster 439 3028032

SYNERGISM OF P53 ACTIVATORS WITH BCL-2 INHIBITORS IN SYNOVIAL SARCOMA

Toshihiko Nishisho¹; Angela Goytain¹; Xiu Q. Wang¹; Neal M. Poulin¹; Bertha Brodin²; Kevin B. Jones³; Jamie S. Yu¹; Torsten O. Nielsen¹

¹Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada; ²Department of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; ³Department of Orthopaedics, University of Utah School of Medicine, Salt Lake City, UT, USA

Poster 440 3041594

SURVIVAL PREDICTION MODEL OF SYNOVIAL SARCOMA USING ARTIFICIAL NEURAL NETWORKS WITH THE SEER DATABASE

Sung Wook Seo¹; Kyeu Back Kwon¹; Ji Hye Sohn¹; Ji Soo Kim¹

¹Dept of Orthopaedic Surgery, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea (the Republic of)

Poster 441 3035485

DOES CSF1 OVER-EXPRESSION OR REARRANGEMENT INFLUENCE BIOLOGICAL BEHAVIOUR IN TENOSYNOVIAL GIANT CELL TUMOURS OF THE KNEE?

Monique Mastboom¹; Daisy Hoek¹; Judith V. Bovee¹; Michiel A. van de Sande¹; Karoly Szuhai¹

¹Orthopaedics oncology, Leiden University Medical Center, Amsterdam, Noord Holland, Netherlands

Poster 442 3042843

SURGERY IN TENOSYNOVIAL GIANT CELL TUMORS IMPROVES PATIENT REPORTED QUALITY OF LIFE AND JOINT FUNCTION

Floortje Verspoor¹; Monique J.L. Mastboom²; Gerjon Hannink¹; Michiel van de Sande²; H.W.B. Schreuder¹

¹Radboud University Medical Center, Nijmegen, Netherlands; ²Leiden University Medical Center, Leiden, Netherlands

Poster 443 3028098

CHEMOTHERAPY IN THE TREATMENT OF UNDIFFERENTIATED HIGH GRADE PLEOMORPHIC SARCOMA (UPS) OF BONE

John A. Livingston¹; Kristi Posey¹; Wei-Lien Wang²; Alexander J. Lazar²; Cheuk Hong Leungsup³; Heather Linsup³; Valerae Lewis⁴; Patrick Lin⁴; Dejka M. Araujo¹; Ravin Ratan¹; Vinod Ravi¹; Neeta Somaiah¹; Anthony P. Conley¹; Robert Benjamin¹; Shreyaskumar Patel¹

¹Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA; ²Pathology, MD Anderson Cancer Center, Houston, TX, USA; ³Biostatistics, MD Anderson Cancer Center, Houston, TX, USA; ⁴Orthopedic Oncology, MD Anderson Cancer Center, Houston, TX, USA

Poster 444 3042645

HIGH-RISK UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS) TREATED WITH PERIOPERATIVE CHEMOTHERAPY: A SECONDARY ANALYSIS OF A ISG-GEIS RANDOMISED CLINICAL TRIAL (RCT) COMPARING 3 VERSUS 5 CHEMOTHERAPY CYCLES FOR HIGH-RISK SOFT TISSUE SARCOMA (STS)

Sandro Pasquali¹; Chiara Colombo¹; Sara Pizzamiglio¹; Paolo Verderio¹; Dario Callegaro¹; Silvia Stacchiotti¹; Javier Martín-Broto²; Antonio Lopez-Pousasup³; Stefano Ferrari⁴; Andres Povedasup⁵; Antonino De Paoli⁶; Vittorio Quagliuolosup⁷; Josefina Cruz⁸; Alessandro Comandone⁹; Tiziana Venesio¹⁰; Rita De Sanctissup⁷; Elena Palassini¹; Antonio Llomboat-Bosch¹¹; Angelo P. Dei Tos¹²; Paolo Casali¹; Piero Picci⁴; Alessandro Gronchi¹

¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; ²Hospital Universitario Virgen del Rocío, Sevilla, Spain; ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; ⁴Istituto Ortopedico Rizzoli, Bologna, Italy; ⁵Valencian Oncologic Institute, Valencia, Spain; ⁶Centro di Riferimento Oncologico, Aviano, Italy; ⁷Humanitas Cancer Center, Milano, Italy; ⁸University of Canarias Hospital, La Laguna, Spain; ⁹Presidio Sanitario Gradenigo, Spain, Italy; ¹⁰IRCCS Fondazione Piemontese per la Ricerca sul Cancro, Candiolo, Italy; ¹¹Medical School of Valencia, Valencia, Spain; ¹²Treviso General Hospital, Treviso, Italy